Interferon beta antibodies and uses thereof

ABSTRACT

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.

RELATED APPLICATIONS

This application claims the benefit of and priority from U. S.Provisional Patent Applications 62/483,669, filed Apr. 10, 2017,62/339,709, filed May 20, 2016, and 62/329,327, filed Apr. 29, 2016.Each of the foregoing applications is incorporated herein by referencein its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Apr. 28, 2017, isnamed PCFC-1000-101-SL.txt and is 94,206 bytes in size.

PARTIES TO A JOINT RESEARCH STATEMENT

The presently claimed invention was made by or on behalf of the belowlisted parties to a joint research agreement. The joint researchagreement was in effect on or before the date the claimed invention wasmade and the claimed invention was made as a result of activitiesundertaken within the scope of the joint research agreement. The partiesto the joint research agreement are PARTNERS HEALTHCARE and PFIZER INC.

BACKGROUND OF THE INVENTION

The interferon (IFN) family of cytokines was initially discovered bytheir ability to protect cells from viral infections, but it is nowappreciated that this family of evolutionarily conserved cytokines canelicit a broad range of responses. The family is made up of the type I,type II, and type III IFN subfamilies, and the type I IFNs are the mostdiverse of all cytokine families. The human type I IFNs are encoded by13 genes for IFNα subtypes, plus single genes for each of IFNβ, IFNω,IFNκ, and IFNε. IFNβ and the several IFNα isoforms are the best studiedof the type I IFNs. Most IFNα proteins share 78-98% identity, and IFNβshares ˜35% identity with a consensus IFNα sequence. IFNβ is naturallyglycosylated, whereas IFNα isoforms are typically only weaklyglycosylated. All type I IFNs bind to the cell surface class II cytokinereceptor IFNAR (composed of the two chains IFNAR1 and IFNAR2). IFNα hasa half-life in serum of 2-3 hours, but IFNβ is hydrophobic and rarelydetected in serum, and these characteristics are consistent with thenotion that IFNα is effective systemically, whereas IFNβ acts at localsites in an autocrine/paracrine manner.

IFN production can be stimulated by exposure to microbe-derivedpathogen-associated molecular patterns, including microbial nucleicacids, lipids, proteins, and lipoproteins. However, there is increasingevidence that IFN production can also be stimulated by endogenousself-components that are released during disease processes, and this isparticularly relevant in the context of systemic lupus erythematosus(SLE) and other rheumatic diseases such as dermatomyositis (DM). Apathological overproduction of type I IFN expression often characterizesSLE, and IFNα is detectable in sera from a limited number of SLEpatients.

Increasing evidence also points to the importance ofinterferon-regulated gene (IRG) expression in the manifestation of SLEdisease activity/severity, as evidenced by clinical results with theanti-IFNAR antibody anifrolimab. In a placebo-controlled phase 2 study,anifrolimab reduced disease severity across multiple clinical endpoints,while simultaneously inhibiting an IRG signature by approximately 90% atboth doses tested in that study.

In addition to anti-IFN receptor antibody anifrolimab (anti-IFNAR),several anti-IFNα antibodies are under clinical development, such assifalimumab, rontalizumab, and AGS-009. IFNα has been the focus of theseefforts because a large body of evidence (including genetic,immunological, serological, and clinical studies) has associated IFNαwith autoimmune disorders. However, based upon the scientific evidenceto date it is expected that IFNβ will play a role similar to IFNα inautoimmune disorders. To date therapeutic antibodies that specificallytarget IFNβ (and not IFNα), have not been reported. Accordingly, thereis an unmet need for an antibody that specially binds IFNβ for use invarious therapeutic or diagnostic purposes.

SUMMARY OF THE INVENTION

The invention provides antibodies, and antigen-binding fragmentsthereof, that bind Interferon beta (IFNβ), as well as uses therefor, andassociated methods.

Based on the disclosure provided herein, those skilled in the art willrecognize, or be able to ascertain using no more than routineexperimentation, many equivalents to the specific embodiments of theinvention described herein. Such equivalents are intended to beencompassed by the following embodiments (E).

-   E1. An isolated antibody, or antigen-binding fragment thereof, that    specifically binds human interferon β (IFNβ).-   E2. The antibody, or antigen-binding fragment thereof, of embodiment    1, wherein said antibody, or antigen-binding fragment thereof, does    not substantially bind a human IFNα.-   E3. The antibody, or antigen-binding fragment thereof, of embodiment    1, wherein said antibody, or antigen-binding fragment thereof, binds    human IFNβ with a binding affinity (K_(D)) value that is at least    100 fold less, at least 200 fold less, at least 300 fold less, at    least 400 fold less, at least 500 fold less, at least 600 fold less,    at least 700 fold less, at least 800 fold less, at least 900 fold    less, or at least 1000 fold less, than its K_(D) value for a human    IFNα.-   E4. An isolated antibody or antigen-binding fragment thereof, that    specifically binds an epitope in human IFNβ, wherein said epitope    comprises one or more residues from amino acid residues 85-100,    according to the numbering of SEQ ID NO:41.-   E5. An isolated antibody or antigen-binding fragment thereof, of    embodiment 4, wherein said epitope comprises one or more residues    selected from the group consisting of Ala89, Tyr 92, His93, and    His97, according to the numbering of SEQ ID NO:41.-   E6. The antibody, or antigen-binding fragment thereof, of embodiment    4 or 5, wherein said epitope comprises residues Ala89, Tyr 92,    His93, and His97, according to the numbering of SEQ ID NO:41.-   E7. The antibody, or antigen-binding fragment thereof, of any one of    embodiments 4-6, wherein said epitope further comprises one or more    residues selected from the group consisting of Phe8, Leu9, Ser12,    Gln16, Asn86, Asn90, Asp96, and Thr100, according to the numbering    of SEQ ID NO:41.-   E8. The antibody, or antigen-binding fragment thereof, of any one of    embodiments 4-7, wherein said epitope further comprises residues    Phe8, Leu9, Ser12, Gln16, Asn86, Asn90, Asp96, and Thr100, according    to the numbering of SEQ ID NO:41.-   E9. The antibody, or antigen-binding fragment thereof, of any one of    embodiments 4-8, wherein said epitope further comprises one or more    residues selected from the group consisting of Leu5, Leu6, Ser13,    Phe15, and Thr82, according to the numbering of SEQ ID NO:41.-   E10. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-9, wherein said antibody, or antigen-binding    fragment thereof, does not substantially bind mouse IFNβ.-   E11. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-9, wherein said antibody, or antigen-binding    fragment thereof, binds human IFNβ with a binding affinity (K_(D))    value that is at least 100 fold less, at least 200 fold less, at    least 300 fold less, at least 400 fold less, at least 500 fold less,    at least 600 fold less, at least 700 fold less, at least 800 fold    less, at least 900 fold less, or at least 1000 fold less, than its    K_(D) value for mouse IFNβ.-   E12. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-11, wherein said antibody, or antigen-binding    fragment thereof, does not substantially bind rat IFNβ.-   E13. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-11, wherein said antibody, or antigen-binding    fragment thereof, binds human IFNβ with a binding affinity (K_(D))    value that is at least 100 fold less, at least 200 fold less, at    least 300 fold less, at least 400 fold less, at least 500 fold less,    at least 600 fold less, at least 700 fold less, at least 800 fold    less, at least 900 fold less, or at least 1000 fold less, than its    K_(D) value for rat IFNβ.-   E14. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-13, wherein said antibody, or antigen-binding    fragment thereof, binds human IFNβ with a binding affinity (K_(D))    value that is at least at least 50 fold less, at least 100 fold    less, at least 150 fold less, or at least 200 fold less, than its    K_(D) value for rabbit IFNβ.-   E15. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-14, wherein said antibody, or antigen-binding    fragment thereof, also specifically binds to Cynomolgus monkey IFNβ.-   E16. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 3, 11, 13, and 14, wherein said K_(D) value is    measured by surface plasmon resonance (SPR), optionally using a    Biacore T200 instrument.-   E17. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-16, comprising a heavy chain variable region (VH)    that comprises:    -   (a) a VH complementarity determining region one (CDR-H1)        comprising the amino acid sequence of SEQ ID NO: 37,    -   (b) a VH complementarity determining region two (CDR-H2)        comprising the amino acid sequence of SEQ ID NO: 38; and    -   (c) a VH complementarity determining region three (CDR-H3)        comprising the amino acid sequence of SEQ ID NO: 39.-   E18. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-17, comprising the CDR-H1, CDR-H2, and CDR-H3    sequences of SEQ ID NO: 28.-   E19. An isolated antibody, or antigen-binding fragment thereof, that    specifically binds human IFNβ, comprising a VH that comprises:    -   (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:        37,    -   (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:        38; and    -   (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:        39.-   E20. An isolated antibody, or antigen-binding fragment thereof, that    specifically binds human IFNβ, comprising a VH that comprises one or    more paratope residues selected from the group consisting of: Trp33    in CDR-H1, Tyr56 in CDR-H2, Tyr58 in CDR-H2, and Tyr97 in CDR-H3,    according to Kabat numbering.-   E21. The antibody, or antigen-binding fragment thereof, of    embodiment 20, wherein said VH further comprises one or more    paratope residues selected from the group consisting of: Asp54 in    CDR-H2, Gln61 in CDR-H2, Gly98 in CDR-H3, and Leu100 in CDR-H3,    according to Kabat numbering.-   E22. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-21, comprising a VH framework derived from a human    germline VH3, VH1, or VH5 framework sequence.-   E23. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-21, comprising a VH framework sequence derived from    human germline IGHV3-7, IGHV3-23, or IGHV1-69 framework sequence.-   E24. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-21, comprising a VH framework sequence derived from    human germline DP10, DP-88, DP-25, DP-73, IGHV5-10-1*01,    IGHV5-10-1*04, DP-14, DP-75, DP15, DP-8, DP-7, or IGHV7-4-1*02    framework sequence, preferably DP-88, DP-25, DP-73, IGHV5-10-1*01,    or IGFV-10-1*04 framework sequence.-   E25. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-24, comprising a VH that comprises:    -   (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:        37; a CDR-H2 comprising the amino acid sequence of SEQ ID NO:        38; and a CDR-H3 comprising the amino acid sequence of SEQ ID        NO: 39; and    -   (b) a VH framework comprising a sequence that is at least 73%,        at least 75%, at least 79%, at least 89%, at least 90%, at least        92%, at least 93%, or at least 99% identical to the framework        sequence of human germline DP10.-   E26. The antibody, or antigen-binding fragment thereof, of    embodiment 25, wherein said VH framework further comprise four or    fewer, three or fewer, or two or fewer amino acid differences, as    compared to the framework sequence of human germline DP10, at the    following positions (according to Kabat numbering): (A) H2, H47,    H48, H49, H67, H69, H71, H73, H93, and H94; (B) H37, H39, H45, H47,    H91, and H93; and (C) H24, H71, and H94.-   E27. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-26, comprising a VH framework sequence derived from    human germline DP10.-   E28. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-21, comprising a human VH germline consensus    framework sequence.-   E29. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-28, comprising a VH sequence that is at least 91%,    at least 92%, at least 93%, at least 94%, at least 95%, at least    96%, at least 97%, at least 98%, at least 99%, or 100% identical to    SEQ ID NO: 28.-   E30. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-29, comprising a light chain variable region (VL)    that comprises:    -   (a) a VL complementarity determining region one (CDR-L1)        comprising the amino acid sequence of SEQ ID NO: 34,    -   (b) a VL complementarity determining region two (CDR-L2)        comprising the amino acid sequence of SEQ ID NO: 35; and    -   (c) a VL complementarity determining region three (CDR-L3)        comprising the amino acid sequence of SEQ ID NO: 36.-   E31. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-30, comprising the CDR-L1, CDR-L2, and CDR-L3    sequences of SEQ ID NO: 1.-   E32. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-29, comprising a VL that comprises one or more    paratope residues selected from the group consisting of: Tyr32 in    CDR-L1, Ile92 in CDR-L3, and Leu94 in CDR-L3, according to Kabat    numbering.-   E33. The antibody, or antigen-binding fragment thereof, of    embodiment 32, wherein said VL further comprises one or more    paratope residues selected from the group consisting of: Gln27 in    CDR-L1, Asp28 in CDR-L1, Ile29 in CDR-L1, Gly30 in CDR-L1, and Ile93    in CDR-L3, according to Kabat numbering.-   E34. An isolated antibody, or antigen-binding fragment thereof, that    specifically binds human IFNβ, comprising the CDR-H1, CDR-H2, and    CDR-H3 sequences of SEQ ID NO: 28, and the CDR-L1, CDR-L2, and    CDR-L3 sequences of SEQ ID NO: 1.-   E35. An isolated antibody, or antigen-binding fragment thereof, that    specially binds human IFNβ, comprising:    -   (i) a VH that comprises:        -   (a) a CDR-H1 comprising the amino acid sequence of SEQ ID            NO: 37,        -   (b) a CDR-H2 comprising the amino acid sequence of SEQ ID            NO: 38; and        -   (c) a CDR-H3 comprising the amino acid sequence of SEQ ID            NO: 39;    -   and (ii) a VL that comprises:        -   (a) a CDR-L1 comprising the amino acid sequence of SEQ ID            NO: 34,        -   (b) a CDR-L2 comprising the amino acid sequence of SEQ ID            NO: 35; and        -   (c) a CDR-L3 comprising the amino acid sequence of SEQ ID            NO: 36.-   E36. An isolated antibody, or antigen-binding fragment thereof, that    specifically binds human IFNβ, comprising a VL that comprises one or    more paratope residues selected from the group consisting of: Tyr32    in CDR-L1, Ile92 in CDR-L3, and Leu94 in CDR-L3, according to Kabat    numbering.-   E37. The antibody, or antigen-binding fragment thereof, of    embodiment 36, wherein said VL further comprises one or more    paratope residues selected from the group consisting of: Gln27 in    CDR-L1, Asp28 in CDR-L1, Ile29 in CDR-L1, Gly30 in CDR-L1, and Ile93    in CDR-L3, according to Kabat numbering.-   E38. An isolated antibody, or antigen-binding fragment thereof, that    specially binds human IFNβ, comprising (numbering according to    Kabat):    -   (i) a VH that comprises:        -   (a) a CDR-H1 comprising Trp33, and three or fewer amino acid            differences as compared to SEQ ID NO: 37,        -   (b) a CDR-H2 comprising Asp54, Tyr56, Tyr58, and Gln61, and            three or fewer amino acid differences as compared to ID NO:            38; and        -   (c) a CDR-H3 comprising Tyr97, Gly98, and Leu100; and three            or fewer amino acid differences as compared to SEQ ID NO:            39; and    -   (ii) a VL that comprises:        -   (a) a CDR-L1 comprising Gln27, Asp28, Ile29, Gly30, Tyr32;            and three or fewer amino acid differences as compared to SEQ            ID NO: 34,        -   (b) a CDR-L2 comprising a sequence that comprises three or            fewer amino acid differences as compared to SEQ ID NO: 35;            and        -   (c) a CDR-L3 comprising Ile92, Ile93, and Leu94; and three            or fewer amino acid differences as compared to of SEQ ID NO:            36.-   E39. The antibody, or antigen-binding fragment thereof, embodiment    38, wherein said amino acid differences in CDR-H1, CDR-H2, CDR-L1,    CDR-L2, and CDR-L3 are human germline substitutions in which a    non-human CDR residue is replaced with a corresponding human    germline residue.-   E40. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-39, comprising a VL framework derived from a human    germline V_(K) or V_(λ) framework sequence.-   E41. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-39, comprising a VL framework derived from human    germline IGKV1-39 or IGKV3-20 framework sequence.-   E42. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-39, comprising a VL framework derived from human    germline DPK9, DPK5, DPK4, DPK1, IGKV1-5*01, DPK24, DPK21, DPK15,    IGKV1-13*02, IGKV1-17*01, DPK5, IGKV3-11*01, or DPK22 framework    sequence, preferably DPK5, DPK4, DPK1, IGKV1-5*01, DPK24, DPK21, or    DPK15 framework sequence.-   E43. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-42, comprising a VL that comprises:    -   (a) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:        34; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:        35; and a CDR-L3 comprising the amino acid sequence of SEQ ID        NO: 36; and    -   (b) a VL framework comprising a sequence that is at least 66%,        at least 74%, at least 76%, at least 80%, at least 96%, at least        97%, or at least 99% identical to the framework sequence of        human germline DPK9.-   E44. The antibody, or antigen-binding fragment thereof, of    embodiment 43, wherein said VL framework further comprise one amino    acid difference, or no amino acid difference, as compared to the    framework sequence of human germline DPK9, at the following    positions (according to Kabat numbering): (A) L2, L4, L35, L36, L46,    L47, L48, L49, L64, L66, L68, L69, and L71; (B) L36, L38, L44, L46,    and L87; and (C) L2, L48, L64, and L71.-   E45. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-44, comprising a VH framework sequence derived from    human germline DPK9.-   E46. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-39, comprising a human VL germline consensus    framework sequence.-   E47. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-46, comprising a VL sequence that is at least 94%,    at least 95%, at least 96%, at least 97%, at least 98%, at least    99%, or 100% identical to SEQ ID NO:1.-   E48. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-47, comprising a heavy chain constant region (CH)    sequence that is at least 90%, at least 91%, at least 92%, at least    93%, at least 94%, at least 95%, at least 96%, at least 97%, at    least 98%, at least 99%, or 100% identical to SEQ ID NO: 29.-   E49. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-48, comprising a light chain constant region (CL)    sequence that is at least 90%, at least 91%, at least 92%, at least    93%, at least 94%, at least 95%, at least 96%, at least 97%, at    least 98%, at least 99%, or 100% identical to SEQ ID NO: 30.-   E50. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-49, comprising an Fc domain.-   E51. The antibody, or antigen-binding fragment thereof, of    embodiment 50, wherein said Fc domain from an IgA, such as IgA₁ or    IgA₂.-   E52. The antibody, or antigen-binding fragment thereof, of    embodiment 50, wherein said Fc domain is from an IgD.-   E53. The antibody, or antigen-binding fragment thereof, of    embodiment 50, wherein said Fc domain is from an IgE.-   E54. The antibody, or antigen-binding fragment thereof, of    embodiment 50, wherein said Fc domain is from an IgM.-   E55. The antibody, or antigen-binding fragment thereof, of    embodiment 50, wherein said Fc domain is from an IgG.-   E56. The antibody, or antigen-binding fragment thereof, of    embodiment 55, wherein said IgG is IgG₁, IgG₂, IgG₃, or IgG₄.-   E57. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-56, comprising a heavy chain that comprises an    amino acid sequence that is at least 91%, at least 92%, at least    93%, at least 94%, at least 95%, at least 96%, at least 97%, at    least 98%, at least 99%, or 100% identical to SEQ ID NO: 33.-   E58. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-57, comprising a light chain that comprises an    amino acid sequence that is at least 91%, at least 92%, at least    93%, at least 94%, at least 95%, at least 96%, at least 97%, at    least 98%, at least 99%, or 100% identical to SEQ ID NO: 32.-   E59. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-58, comprising the VH sequence encoded by the    insert in the plasmid deposited with the ATCC and having ATCC    Accession No. PTA-122727.-   E60. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-59, comprising the VL sequence encoded by the    insert in the plasmid deposited with the ATCC and having ATCC    Accession No. PTA-122726.-   E61. An isolated antibody, or antigen-binding fragment thereof, that    specifically binds human IFNβ, comprising (a) the CDR-H1, CDR-H2,    and CDR-H3 sequences of SEQ ID NO: 28, and (b)    -   i) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 2;    -   ii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 3;    -   iii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 4;    -   iv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 5;    -   v) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 6;    -   vi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 7;    -   vii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 8;    -   viii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 9;    -   ix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 10;    -   x) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 11;    -   xi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 12;    -   xii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 13;    -   xiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 14;    -   xiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 15;    -   xv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 16;    -   xvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 17;    -   xvii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18;    -   viii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 19;    -   xix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 20;    -   xx) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 21;    -   xxi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 22;    -   xxii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 23;    -   xxiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO:        24;    -   xxiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 25;    -   xxv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 26;        or    -   xxvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 27.-   E62. An isolated antibody, or antigen-binding fragment thereof, that    specifically binds human IFNβ, comprising a VH that comprises the    amino acid sequence of SEQ ID NO:28, and a VL that comprises the    amino acid sequence of any one of SEQ ID NOs. 2-27.-   E63. The antibody, or antigen-binding fragment thereof, of    embodiment 61 or 62, comprising an Fc domain.-   E64. The antibody, or antigen-binding fragment thereof, of    embodiment 63, wherein said Fc domain is from an IgA (e.g., IgA₁ or    IgA₂), IgD, IgE, IgM, or IgG (e.g., IgG₁, IgG₂, IgG₃, or IgG₄).-   E65. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 61-64, comprising a CH that comprises the amino acid    sequence of SEQ ID NO: 29.-   E66. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 61-65, comprising a CL that comprises the amino acid    sequence of SEQ ID NO: 30.-   E67. An antibody, or antigen-binding fragment thereof, that competes    for specific binding to human IFNβ with an antibody, or    antigen-binding fragment thereof, of any one of embodiments 1-66.-   E68. An antibody, or antigen-binding fragment thereof, that competes    for specific binding to human IFNβ with CTI-AF1, or an    antigen-binding fragment of CTI-AF1.-   E69. An antibody, or antigen-binding fragment thereof, that competes    for specific binding to human IFNβ with one or more antibodies    selected from the group consisting of: CTI-AF2, CTI-AF3, CTI-AF4,    CTI-AFS, CTI-AF6, CTI-AF7, CTI-AF8, CTI-AF9, CTI-AF10, CTI-AF11,    CTI-AF12, CTI-AF13, CTI-AF14, CTI-AF15, CTI-AF16, CTI-AF17,    CTI-AF18, CTI-AF19, CTI-AF20, CTI-AF21, CTI-AF22, CTI-AF23,    CTI-AF24, CTI-AF25, CTI-AF26, CTI-AF27, and an antigen-binding    fragment thereof.-   E70. An antibody, or antigen-binding fragment thereof, that    specifically binds human IFNβ, wherein said antibody, or    antigen-binding fragment thereof, binds substantially the same    epitope as CTI-AF1, or an antigen-binding fragment of CTI-AF1.-   E71. An antibody, or antigen-binding fragment thereof, that    specifically binds human IFNβ, wherein said antibody, or    antigen-binding fragment thereof, binds substantial the same epitope    as one or more antibodies, or antigen-binding fragments thereof,    selected from the group consisting of: CTI-AF2, CTI-AF3, CTI-AF4,    CTI-AF5, CTI-AF6, CTI-AF7, CTI-AF8, CTI-AF9, CTI-AF10, CTI-AF11,    CTI-AF12, CTI-AF13, CTI-AF14, CTI-AF15, CTI-AF16, CTI-AF17,    CTI-AF18, CTI-AF19, CTI-AF20, CTI-AF21, CTI-AF22, CTI-AF23,    CTI-AF24, CTI-AF25, CTI-AF26, and CTI-AF27.-   E72. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-71, wherein the antibody, or antigen-binding    fragment, is an Fc fusion protein, a monobody, a maxibody, a    bifunctional antibody, an scFab, an scFv, a peptibody, or an    antigen-binding fragment of any of the foregoing.-   E73. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-72, wherein said antibody, or antigen-binding    fragment thereof, binds human IFNβ with a binding affinity (K_(D))    value no greater than about 5×10⁻⁹ M.-   E74. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-73, wherein said antibody, or antigen-binding    fragment thereof, binds human IFNβ with a binding affinity (K_(D))    value no greater than about 1×10⁻⁹ M.-   E75. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-74, wherein said antibody, or antigen-binding    fragment thereof, binds human IFNβ with a binding affinity (K_(D))    value from about 1×10⁻⁹ M to about 1×10⁻¹⁴ M.-   E76. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-75, wherein said antibody or antigen-binding    fragment (a) inhibits binding of IFNβ and IFNAR; (b) reduces the    expression level of an IFNβ-dependent gene; and/or (c) inhibits IFNβ    induced STAT1 or STAT2 phosphorylation.-   E77. The antibody, or antigen-binding fragment thereof, of    embodiment 76, wherein said antibody, or antigen-binding fragment    thereof, inhibits binding of IFNβ and IFNAR with an IC₅₀ value of    about 5×10⁻⁹ M or less.-   E78. The antibody, or antigen-binding fragment thereof, of    embodiment 76, wherein said antibody, or antigen-binding fragment    thereof, inhibits binding of IFNβ and IFNAR with an IC₅₀ value from    about 1×10⁻⁹ M to about 1×10⁻¹⁴ M.-   E79. An isolated nucleic acid molecule encoding the antibody, or    antigen-binding fragment thereof, of any one of embodiments 1-78.-   E80. An isolated nucleic acid comprising the nucleotide sequence of    SEQ ID NO:166-   E81. An isolated nucleic acid comprising the nucleotide sequence of    SEQ ID NO:167.-   E82. An isolated nucleic acid comprising the nucleotide sequence of    the insert of the plasmid deposited at the ATCC and having Accession    Number PTA-122727.-   E83. An isolated nucleic acid comprising the nucleotide sequence of    the insert of the plasmid deposited at the ATCC and having Accession    Number PTA-122726.-   E84. A vector comprising the nucleic acid molecule of any one of    embodiments 79-83.-   E85. A host cell comprising the nucleic acid molecule of any one of    embodiments 79-83, or the vector of embodiment 84.-   E86. The host cell of embodiment 85, wherein the cell is a mammalian    cell.-   E87. The host cell of embodiment 85 or 83, wherein the host cell is    a CHO cell, a HEK-293 cell, or an Sp2.0 cell.-   E88. A method of producing an antibody, or antigen-binding fragment    thereof, comprising culturing the host cell of any one of    embodiments 85-87, under conditions wherein the antibody, or    antigen-binding fragment thereof, is produced by the host cell.-   E89. The method of embodiment 88, further comprising isolating the    antibody, or antigen-binding fragment thereof.-   E90. An antibody, or antigen-binding fragment thereof, obtained by    the method of embodiment 88 or 89.-   E91. A pharmaceutical composition comprising an antibody, or    antigen-binding fragment thereof, of any one of embodiments 1-78 and    90, and a pharmaceutically acceptable carrier.-   E92. A method of reducing the activity of IFNβ, comprising    administering to a subject in need thereof a therapeutically    effective amount of the antibody, or antigen-binding fragment    thereof, of any one of embodiments 1-78 and 90, or the    pharmaceutical composition of embodiment 91.-   E93. A method of treating a rheumatic disease, comprising    administering to a subject in need thereof a therapeutically    effective amount of the antibody, or antigen-binding fragment    thereof, of any one of embodiments 1-78 and 90, or the    pharmaceutical composition of embodiment 91.-   E94. A method of treating systemic lupus erythematosus (SLE),    comprising administering to a subject in need thereof a    therapeutically effective amount of The antibody, or antigen-binding    fragment thereof, of any one of embodiments 1-78 and 90, or the    pharmaceutical composition of embodiment 91.-   E95. A method of treating dermatomyositis (DM), comprising    administering to a subject in need thereof a therapeutically    effective amount of the antibody, or antigen-binding fragment    thereof, of any one of embodiments 1-78 and 90, or the    pharmaceutical composition of embodiment 91.-   E96. A method of treating an interferonopathy, comprising    administering to a subject in need thereof a therapeutically    effective amount of the antibody, or antigen-binding fragment    thereof, of any one of embodiments 1-78 and 90, or the    pharmaceutical composition of embodiment 91.-   E97. The method of any one of embodiments 92-96, wherein said    subject is a human.-   E98. The method of any one of embodiments 92-97, comprising    administering said antibody or antigen-binding fragment thereof, or    pharmaceutical composition, intravenously.-   E99. The method of any one of embodiments 92-98, comprising    administering said antibody or antigen-binding fragment thereof, or    pharmaceutical composition, subcutaneously.-   E100. The method of any one of embodiments 92-99, wherein said    antibody or antigen-binding fragment thereof, or pharmaceutical    composition, is administered twice a week, once a week, once every    two weeks, once every three weeks, once every four weeks, once every    five weeks, once every six weeks, once every seven weeks, once every    eight weeks, once every nine weeks, once every ten weeks, twice a    month, once a month, once every two months, or once every three    months.-   E101. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-78 and 90, or the pharmaceutical composition of    embodiment 91, for use as a medicament.-   E102. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-78 and 90, or the pharmaceutical composition of    embodiment 91, for use in reducing the activity of IFNβ in a    subject.-   E103. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-78 and 90, or the pharmaceutical composition of    embodiment 91, for use in treating a rheumatic disease in a subject.-   E104. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-78 and 90, or the pharmaceutical composition of    embodiment 91, for use in treating SLE in a subject.-   E105. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-78 and 90, or the pharmaceutical composition of    embodiment 91, for use in treating DM in a subject.-   E106. The antibody, or antigen-binding fragment thereof, of any one    of embodiments 1-78 and 90, or the pharmaceutical composition of    embodiment 91, for use in treating an interferonopathy in a subject.-   E107. The antibody or antigen-binding fragment, or pharmaceutical    composition of any one of embodiments 101-106, wherein said subject    is a human.-   E108. Use of the antibody, or antigen-binding fragment thereof, of    any one of embodiments 1-78 and 90, or the pharmaceutical    composition of embodiment 91, for reducing the activity of IFNβ in a    subject.-   E109. Use of the antibody, or antigen-binding fragment thereof, of    any one of embodiments 1-78 and 90, or the pharmaceutical    composition of embodiment 91, in the manufacture of a medicament for    reducing the activity of IFNβ in a subject.-   E110. Use of the antibody, or antigen-binding fragment thereof, of    any one of embodiments 1-78 and 90, or the pharmaceutical    composition of embodiment 91, for treating a rheumatic disease in a    subject.-   E111. Use of the antibody, or antigen-binding fragment thereof, of    any one of embodiments 1-78 and 90, or the pharmaceutical    composition of embodiment 91, in the manufacture of a medicament for    treating a rheumatic disease in a subject.-   E112. Use of the antibody, or antigen-binding fragment thereof, of    any one embodiments 1-78 and 90, or the pharmaceutical composition    of embodiment 91, for treating SLE in a subject.-   E113. Use of the antibody, or antigen-binding fragment thereof, of    any one of embodiments 1-78 and 90, or the pharmaceutical    composition of embodiment 91, in the manufacture of a medicament for    treating SLE in a subject.-   E114. Use of the antibody, or antigen-binding fragment thereof, of    any one of embodiments 1-78 and 90, or the pharmaceutical    composition of embodiment 91, for treating DM in a subject.-   E115. Use of the antibody, or antigen-binding fragment thereof, of    any one of embodiments 1-78 and 90, or the pharmaceutical    composition of embodiment 91, in the manufacture of a medicament for    treating DM in a subject.-   E116. Use of the antibody, or antigen-binding fragment thereof, of    any one of embodiments 1-78 and 90, or the pharmaceutical    composition of embodiment 91, for treating an interferonopathy in a    subject.-   E117. Use of the antibody, or antigen-binding fragment thereof, of    any one of embodiments 1-78 and 90, or the pharmaceutical    composition of embodiment 91, in the manufacture of a medicament for    treating an interferonopathy in a subject.-   E118. The use of any one of embodiments 108-117, wherein said    subject is a human.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the viscosity of IFNβ antibody in MOD1 buffer.

FIG. 2 is a differential scanning calorimetry (DSC) graph of antibodyCTI-AF1.

FIG. 3 is the Size-Exclusion HPLC (SE-HPLC) analysis of CTI-AF1aggregation, as a result of low-pH hold.

FIGS. 4A-4D show the SE-HPLC analysis of time points from stabilitystudies.

FIGS. 5A-5D show graphs demonstrating that CTI-AF1 is stable over timewhen stored at 40° C. and does not lose the ability to neutralize IFNβ.CTI-AF1 was stored at various temperatures and time periods then theability of the antibody to neutralize IFNβ in an IFN dependentluciferase reporter assay was evaluated. Material stored for 1 week at40° C. (FIG. 5A, T0 equals no time at 40° C.) had no loss ofneutralizing activity; Storage at 40° C. for two or three weeks had noimpact on activity (FIG. 5C). Material that was produced aftertransfection of CHO cells instead of HEK293 cells or containing amutation of amino acid 44 from a phenylalanine to a proline had noimpact on neutralization (FIG. 5B). Finally, material stored for fourweeks at 40° C. or five weeks at room temperature (FIG. 5D) had noimpact on the ability of CTI-AF1 to neutralize IFNβ induced activity.

FIG. 6 depicts data showing identification of mouse anti-human IFNβhybridomas that could block the binding of IFNβ to IFNAR2 by bio-layerinterferometry (BLI) using the ForteBio Octet to measure molecularinteraction. First, mouse anti-human IFNβ Abs were captured on a proteinG sensor from conditioned culture media; next, human IFNβ was bound(indicated by the +hIFN-β arrow), then the Ab:IFNβ complexes wereexposed to the high affinity chain of the human receptor, IFNAR2(indicated by the+IFNAR2 arrow). Non-blocking antibodies show an upwardbump in the curve indicative of additional binding (as indicated by thenon-neutralizer arrow, bottom), whereas neutralizing antibodiesdemonstrated a relatively flat curve (as indicated by neutralizerarrows, top). Several mouse hybridomas demonstrated the ability toneutralize binding of IFNAR2 to IFNβ and were selected for furthercharacterization and eventual humanization.

FIG. 7 depicts data showing determination of CTI-AF1′s K_(D) for humanIFNβ by surface plasmon resonance (SPR). CTI-AF1 was captured on a CM5sensor chip, then, starting at 2.5 nM IFNβ, a 6 point, 2-fold titrationseries of recombinant human IFNβ was flowed over CTI-AF1. The sampleswere run in duplicate and the concentration of IFNβ is indicated to theright of the graph. For each concentration of IFNβ, the thin grey linesdepict the binding of IFNβ in each replicate sample; the heavier greyline represents the average fitted curve calculated by the analysisprogram. The K_(D) of CTI-AF1 for human IFNβ was determined to be about36 μM.

FIGS. 8A-8B demonstrate that CTI-AF1 is a potent neutralizer of IFNβinduced signaling in multiple assays. FIG. 8A shows that HEK293 cellsstably transduced with an IFN stimulated response element (ISRE)luciferase reporter construct were stimulated in the presence of IFNβand titrated amounts of CTI-AF1. A dose-dependent inhibition ofluminescence is seen indicating that IFNβ has been neutralized. Bindingof IFNβ to the interferon receptor (IFNAR) is known to induce thephosphorylation of the STAT1 protein in U937 cells. FIG. 8B shows STAT1phosphorylation analysis. U937 cells were exposed to IFNβ, pre-incubatedwith titrated amounts of CTI-AF1 for 15 minutes, then the level of STAT1phosphorylation was evaluated. The data show that there is adose-dependent inhibition of STAT1 phosphorylation, indicating that IFNβdependent signals have been neutralized by CTI-AF1.

FIG. 9 demonstrates that CTI-AF1 neutralized expression of IFNstimulated gene Mx1 (MxA) in primary human dermal fibroblasts (HDF).There are a number of genes that are known to be expressed in responseto stimulation with IFNs, IFN stimulated genes (ISG). Mx1 (MxA) is wellcharacterized as a type I IFN ISG. Mx1 (MxA) gene expression afterstimulation with recombinant IFNβ was evaluated in primary HDF in thepresence or absence of indicated amounts of CTI-AF1. Cells werestimulated for 5 hours then RNA was isolated. RNA was converted intocDNA and quantitative PCR (qPCR) was performed to determine the level ofMx1 (MxA) expression and B2 M was used as a control. Data are presentedas fold induction; a dose-dependent inhibition of Mx1 (MxA) geneexpression was seen indicating neutralization of IFNβ signaling.

FIGS. 10A-10B demonstrate that CTI-AF1 specifically neutralized IFNβ.U937 cells were stimulated with either IFNβ (FIG. 10A) or IFNα (FIG.10B) for 15 minutes in the presence of neutralizing antibodies to IFNβ(CTI-AF1) or IFNα (sifalimumab, SIF). CTI-AF1 inhibited IFNβ dependentSTAT1 phosphorylation (panel A), but had no impact on IFNα-induced STAT1phosphorylation (panel B). As a control, a neutralizing anti-IFNα (SIF)was used in conjunction with IFNα stimulation to demonstrate IFNαdependent STAT1 phosphorylation could be inhibited.

FIG. 11 demonstrates that CTI-AF1 was a potent inhibitor of endogenousIFNβ secreted by primary human dermal fibroblasts (HDF). HDF werestimulated with polyinosinic:polycytidylic acid (poly I:C) for 24 hoursto induce the expression of IFNβ in the presence of titrated amounts ofCTI-AF1 and then Mx1 (MxA) gene expression was evaluated as described inFIG. 9. A dose-dependent inhibition of Mx1 (MxA) gene expression wasseen with increasing amounts of CTI-AF1 demonstrating the antibodyneutralized endogenously produced IFNβ.

FIGS. 12A-12D depict CTI-AF1 serum PK and IFNβ skin coverage profiles inhuman at 2 mg/kg IV Q4W. Profiles are shown for IFNβ skin:plasma ratioof 10 (FIGS. 12A and 12C) and 100 (FIGS. 12B and 12D). Note that CTI-AF1serum PK is not impacted by IFNβ skin:plasma ratio and IFNβ turnoverhalf-life. The dashed lines in panels C and D represent 95% IFNβcoverage in skin.

FIGS. 13A-13D show the profiles for IFNβ skin:plasma ratio of 10 (FIGS.13A and 13C) and 100 (FIGS. 13B and 13D). Note that serum PK is notimpacted by IFNβ skin:plasma ratio and IFNβ turnover half-life. Thedashed lines in panels C and D represent 95% IFNβ coverage in skin.

FIG. 14 shows the mean serum concentrations of CTI-AF1 in cynomolgusmonkeys from toxicity study.

FIG. 15A shows the sequence and secondary structure of human IFNβ (SEQID NO:41). FIG. 15B shows the sequence alignment of human (SEQ IDNO:41), cynomolgus (SEQ ID NO:44) , mouse (SEQ ID NO:42), rat (SEQ IDNO:43), and rabbit (SEQ ID NO: 45) IFNβ sequences.

FIG. 16A shows the relationship between cutaneous dermatomyositisdisease area and severity index (CDASI) activity and a blood 10-genesignature score. CDASI activity score correlates with an elevated10-gene blood IRG “signature” (Spearman rank correlation r=0.61;p<0.0001). FIG. 16B shows a strong threshold effect observed with aCDASI cutoff of 12 that is associated with IRG signature cutoff of3-fold (P=0.0004, Mann-Whitney test).

FIG. 17 shows serum samples from 25 normal (unaffected) donors, 19 DMdonors with a CDASI of <12, and 38 DM donors with a CDASI of ≥12analyzed for the presence of IFNβ protein using a high-sensitivity ELISAkit (PBL Assay Science) (Wilcoxon test ‘unaffected vs CDASI <12’ p=0.39;Wilcoxon test ‘unaffected vs CDASI p≥12’ p<0.0001).

FIGS. 18A-18B show levels of IFNα or IFNβ mRNA (FIG. 18A) or an IRGsignature in unaffected versus affected skin samples (FIG. 18B) inpaired skin biospies (i.e., unaffected and affected tissue) collectedfrom 5 DM patients and evaluated by a custom Type I IFN TaqMan LowDensity Array (TLDA) (96 assay array). Each data point represents theaverage of 2 independent qPCR reactions per sample; mean±SEM. Panel A:Signed Rank test p-value “unaffected IFNβ vs affected IFNβ”=0.06; SignedRank test p-value “unaffected IFNα vs affected IFNα”=1.0. Panel B:Signed Rank test p-value “unaffected vs affected”=0.002.

FIG. 19 is a graph showing dose-dependent CTI-AF1 inhibition of hybridIFNα/β proteins. Absence (CID1281) or decreased (CID1280) inhibition ofIFN-induced STAT1 phosphorylation indicates that insertion of the IFNαsequence has disrupted the epitope within IFNβ that is recognizedbyCTI-AF1.

FIGS. 20A-20B shows the co-crystal structure of cyno-IFNβ and Fab ofCTI-AF1. Binding epitope residues are depicted in grey in FIG. 20A, andbinding paratope residues are depicted in grey in FIG. 20B.

DETAILED DESCRIPTION OF THE INVENTION 1. ANTI-IFNβ ANTIBODIES

A. Interferon Beta (IFNβ)

Interferon beta (IFNβ), also known as fibroblast IFN, is a glycosylated,secreted, and approximately 22 kDa member of the type I interferonfamily of molecules. The sequence of human IFNβ precursor is shown asSEQ ID NO: 40. A signal peptide (residues 1-21 of SEQ ID NO: 40) of theprecursor is cleaved to produce mature IFNβ (SEQ ID NO: 41), whichshares 47% and 46% amino acid sequence identity with the mouse and ratproteins, respectively.

Alignments of IFNβ from various species are shown in FIG. 15B. Thesignal peptide is underlined in the sequence below.

MTNKCLLQIA LLLCFSTTAL SMSYNLLGFL QRSSNFQCQKLLWQLNGRLE YCLKDRMNFD IPEEIKQLQQ FQKEDAALTIYEMLQNIFAI FRQDSSSTGW NETIVENLLA NVYHQINHLKTVLEEKLEKE DFTRGKLMSS LHLKRYYGRI LHYLKAKEYSHCAWTIVRVE ILRNEYFINR LTGYLRN (Human IFNβ precursor, SEQ ID NO: 40)

The structure of IFNβ contains 5 a-helices, designated A(YNLLGFLQRSSNFQCQKLL; SEQ ID NO:153 or residues 3-21 of SEQ ID NO:41), B(KEDAALTIYEMLQNIFAIF; SEQ ID NO:154 or residues 52-70 of SEQ ID NO:41),C (ETIVENLLANVYHQINHLKTVLEEKL; SEQ ID NO:155 or residues 81-106 of SEQID NO:41), D (SLHLKRYYGRILHYLKA; SEQ ID NO:156 or residues 119-135 ofSEQ ID NO:41), and E (HCAWTIVRVEILRNFYFINRLT; SEQ ID NO:157 or residues140-161 of SEQ ID NO:41). The five a-helices are interconnected by loopsof 2 to 28 residues designated AB, BC, CD, and DE loops (FIG. 15A). Ithas been reported that the A helix, the AB loop, and the E helix areinvolved in binding of IFNβ to its receptor, IFNAR.

B. Anti-IFNβ Antibodies

One potential drawback of an anti-IFNAR antibody (e.g., anifrolimab) isthat both IFNα and IFNβ cytokines bind to IFNAR. Although these twotypes of IFN cytokines elicit similar biological activities to a similardegree, there are significant differences in potency and cell typespecific activities between these two types of IFNs. For example, IFNβelicits a markedly higher anti-proliferative response in some celltypes, such as embryonal carcinoma, melanoma and melanocytes, than doesIFNα. Higher potency of IFNβ in treatment of multiple sclerosis andcertain cancers has also been observed. Blocking the activity of IFNAR,however, does not selectively modulate the activities of IFNβ.Significantly, IFNα is an important cytokine in response to viralinfections, such that blocking its activity may have unwanted effects.Accordingly, an antibody that specially binds IFNβ, but not IFNα, wouldfulfill a significant unmet need for treatment of diseases that areprimarily driven by IFNβ.

In one aspect, the invention provides an isolated antibody, orantigen-binding fragment thereof, that specifically binds human IFNβ.Sequences of exemplary antibodies of the invention are shown in Table11.

As shown in the Examples, in certain embodiments, the antibody of theinvention inhibits the binding of IFNβ to its receptor, and is hencereferred to as a “neutralizing” antibody. Without wishing to be bound byany particular theory, the data indicate that the antibody, orantigen-binding fragment thereof, blocks, or partially blocks, thereceptor binding sites of IFNβ, either by competing for the same oroverlapping residues from IFNAR, or by creating steric hindrance.

For example, residues from helix A, AB loop, and helix E of IFNβ arebelieved to be involved in binding of IFNβ to its receptor. Accordingly,in certain embodiments, the antibody, or antigen-binding fragmentthereof, of the invention binds an epitope comprising one more residuesselected from the group consisting of: residues 3-21 (helix A), 22-51(AB loop); and 140-161 (helix E), according to the numbering of SEQ IDNO: 41.

In certain embodiments, the antibody, or antigen-binding fragmentthereof, bind to human IFNβ with a binding affinity (K_(D)) value thatis at least 100 fold less, than its K_(D) value for a human IFNα undersubstantially the same assay conditions. For example, the ratio of K_(D)for IFNβ versus K_(D) for IFNα can be 1:100 or less, 1:250 or less,1:500 or less, 1:1000 or less, 1: 2500 or less, 1:5000 or less, or1:10,000 or less.

Mutagenesis studies and crystal structure studies also identifiedepitope residues in human IFNβ that are recognized by anti-IFNβantibodies disclosed herein. In particular, among all IFNβ residues thatare within 3.8 A from a heavy atom of the antibody (“potential” epitoperesidues), three different types have been identified: (i) “primary”epitope residues that are characterized as highly buried residues at theof antibody-antigen interface and zero-to-low sequence tolerance to anyother amino acid substitutions at this position; (ii) “secondary”epitope residues that are characterized as residues with medium buriedsurface area at the interface and medium sequence tolerance to aminoacid substitutions at these positions; and (iii) “Optional” epitoperesidues are characterized as residues with low buried surface area atthe interface and high sequence tolerance to amino acid substitutions atthese positions.

Accordingly, in certain embodiments, the antibody, or antigen-bindingfragment thereof, of the invention specifically binds an epitope inhuman IFNβ, wherein said epitope comprises one or more residues selectedfrom the group consisting of Ala89, Tyr 92, His93, and His97, accordingto the numbering of SEQ ID NO:41 (“primary” epitope residues). Incertain embodiments, the epitope further comprises one or more residuesselected from the group consisting of Phe8, Leu9, Ser12, Gln16, Asn86,Asn90, Asp96, and Thr100, according to the numbering of SEQ ID NO:41(“secondary” epitope residues). In certain embodiments, the epitopefurther comprises one or more residues selected from the groupconsisting of Leu5, Leu6, Ser13, Phe15, and Thr82, according to thenumbering of SEQ ID NO:41 (“optional” epitope residues).

In certain embodiments, the antibody, or antigen-binding fragmentthereof, of the invention also specifically binds cynomolgus monkeyIFNβ, in addition to human IFNβ.In certain embodiments, the antibody, orantigen-binding fragment thereof, of the invention specifically binds anepitope in cynomolgus monkey IFNβ, wherein said epitope comprises one ormore residues selected from the group consisting of Ala89, Tyr 92,His93, and His97, according to the numbering of SEQ ID NO:44 (“primary”epitope residues). In certain embodiments, the epitope further comprisesone or more residues selected from the group consisting of Phe8, Leu9,Ser12, Gln16, Asn86, Asn90, Asp96, Thr100 and Tyr67, according to thenumbering of SEQ ID NO:44 (“secondary” epitope residues). In certainembodiments, the epitope further comprises one or more residues selectedfrom the group consisting of Leu5, Leu6, Ser13, Phe15, and Thr82,according to the numbering of SEQ ID NO:44 (“optional” epitoperesidues).

Provided herein are antibody CTI-AF1 and variants thereof. Accordingly,in certain embodiments, the antibody or antigen-binding fragment thereofcomprises the following heavy chain CDR sequences: (i) CDR-H1 comprisingSEQ ID NO: 37, CDR-H2 comprising SEQ ID NO: 38, and CDR-H3 comprisingSEQ ID NO: 39; and/or (ii) the following light chain CDR sequences:CDR-L1 comprising SEQ ID NO: 34, CDR-L2 comprising SEQ ID NO: 35, andCDR-L3 comprising SEQ ID NO: 36.

As demonstrated from the crystal structure studies, not all residues inCDRs contribute to antibody-antigen binding. As shown in Example 7 andTable 14, only limited number of CDR residues are within 3.8 A from aheavy atom of the antigen, and are considered as potential paratoperesidues. Among these potential paratope residues, (i) “primary”paratope residues are those characterized as highly buried residues atthe antibody-antigen interface and low sequence tolerance to any otheramino acid substitutions at this position; and (ii) “secondary” paratoperesidues are characterized as residues with lower buried surface area atthe interface and higher sequence tolerance to amino acid substitutionsat these positions.

Accordingly, in certain embodiments, the antibody, or antigen-bindingfragment thereof, of the invention comprises a VH chain that comprisesone or more paratope residues selected from the group consisting of:Trp33 in CDR-H1, Tyr56 in CDR-H2, Tyr58 in CDR-H2, and Tyr97 in CDR-H3,according to Kabat numbering (“primary” paratope residues). In certainembodiments, the VH further comprises one or more paratope residuesselected from the group consisting of: Asp54 in CDR-H2, Gln61 in CDR-H2,Gly98 in CDR-H3, and Leu100 in CDR-H3, according to Kabat numbering(“secondary” paratope residues). In certain embodiments, the antibody,or antigen-binding fragment thereof, of the invention comprises a VLthat comprises one or more paratope residues selected from the groupconsisting of: Tyr32 in CDR-L1, Ile92 in CDR-L3, and Leu94 in CDR-L3,according to Kabat numbering (“primary” paratope residues). In certainembodiments, the VH further comprises one or more paratope residuesselected from the group consisting of: Gln27 in CDR-L1, Asp28 in CDR-L1,Ile29 in CDR-L1, Gly30 in CDR-L1, and Ile93 in CDR-L3, according toKabat numbering (“secondary” paratope residues). The antibody, orantigen binding fragment thereof, of the invention may also comprise anycombination of the paratope residues disclosed herein.

In certain embodiments, the antibody, or antigen-binding fragmentthereof, described herein comprises the following heavy chain CDRsequences: (i) a CDR-H1 sharing at least 90%, at least 91%, at least92%, at least 93%, at least 94%, or at least 95% identical to SEQ ID NO:37, a CDR-H2 sharing at least 90%, at least 91%, at least 92%, at least93%, at least 94%, or at least 95% identity with SEQ ID NO: 38, and aCDR-H3 sharing at least 90%, at least 91%, at least 92%, at least 93%,at least 94%, or at least 95% identity with SEQ ID NO: 39; and/or (ii)the following light chain CDR sequences: a CDR-L1 sharing at least 90%,at least 91%, at least 92%, at least 93%, at least 94%, or at least 95%identity with SEQ ID NO: 34, a CDR-L2 sharing at least 90%, at least91%, at least 92%, at least 93%, at least 94%, or at least 95% identitywith SEQ ID NO: 35, and a CDR-L3 sharing at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, or at least 95% identity with SEQID NO: 36. In certain embodiments, the amino acid differences, ascompared to SEQ ID NOs. 37, 38, 39, 34, 35, and 36, respectively, arenot one of the primary or secondary paratope residues as shown in Table14.

In certain embodiments, no more than 10, no more than 9, no more than 8,no more than 7, no more than 6, no more than 5, no more than 4, no morethan 3, no more than 3, no more than 2, or no more than one substitutionis made in the sequence of CDR-L1, relative to SEQ ID NO. 34. In certainembodiments, no more than 6, no more than 5, no more than 4, no morethan 3, no more than 3, no more than 2, or no more than one substitutionis made in the sequence of CDR-L2, relative to SEQ ID NO. 35. In certainembodiments, no more than 8, no more than 7, no more than 6, no morethan 5, no more than 4, no more than 3, no more than 3, no more than 2,or no more than one substitution is made in the sequence of CDR-L3,relative to SEQ ID NO. 36. In certain embodiments, no more than 9, nomore than 8, no more than 7, no more than 6, no more than 5, no morethan 4, no more than 3, no more than 3, no more than 2, or no more thanone substitution is made in the sequence of CDR-H1, relative to SEQ IDNO. 37. In certain embodiments, no more than 16, no more than 15, nomore than 14, no more than 13, no more than 12, no more than 11, no morethan 10, no more than 9, no more than 8, no more than 7, no more than 6,no more than 5, no more than 4, no more than 3, no more than 3, no morethan 2, or no more than one substitution is made in the sequence ofCDR-H2, relative to SEQ ID NO. 38. In certain embodiments, no more than9, no more than 8, no more than 7, no more than 6, no more than 5, nomore than 4, no more than 3, no more than 3, no more than 2, or no morethan one substitution is made in the sequence of CDR-H3, relative to SEQID NO. 39. In certain embodiments, the substitution does not changebinding affinity (K_(D)) value by more than 3 orders of magnitude, morethan 2 orders of magnitude, or 1 order of magnitude, as compared withthe K_(D) of the antibody, or antigen-binding fragment thereof, withoutthe substitution. In certain embodiments, the substitution is not one ofthe primary or secondary paratope residues as shown in Table 14.

In certain embodiments, the substitution is a conservative substitutionas provided by Table 1.

TABLE 1 Exemplary Conservative Substitutions Conservative ConservativeResidue substitution Residue substitution Ala Ser Leu Ile, Val Arg LysLys Arg, Gln Asn Gln; His Met Leu, Ile Asp Glu Phe Met, Leu, Tyr Cys SerSer Thr; Gly Gln Asn Thr Ser, Val Glu Asp Trp Tyr Gly Pro Tyr Trp, PheHis Asn, Gln Val Ile, Leu Ile Leu, Val Pro —

In certain embodiments, when an antibody is derived from a non-humanspecies, such as a humanized antibody in which murine CDRs are graftedto a human framework, the substitution is human germline substitution inwhich a non-human CDR residue is replaced with the corresponding humangermline residue. One benefit of such substitution is to increase thehuman amino acid content, and to reduce potential immunogenicity of anantibody derived from a non-human species. For example, if humangermline DPK9 framework is used and the exemplary antibody CTI-AF1, thenthe alignment of the CDR-L1 of CTI-AF1 antibody and human germline DPK9is as follows:

TABLE 2 Position 24 25 26 27 28 29 30 31 32 33 34 Human Germline R A S QS I S S Y L N DPK9 (SEQ ID NO: 46) CTI-AF1 antibody R T S Q D I G N Y LN (SEQ ID NO: 34)

For positions 24, 26, 27, 29, 32, 33, and 34, the human germline residueand the corresponding CTI-AF1 residue are the same, and no substitutionis needed at these positions. For positions 25, 28, 30, and 31 (inbold), the human germline residue and the corresponding CTI-AF1 murineresidue are different. Murine residues of CTI-AF1 at these positions maybe replaced with the corresponding human germline DPK9 residue tofurther increase the human amino acid residue content.

Methods and libraries for introducing human germline residues inantibody CDRs are described in detail in Townsend et al., AugmentedBinary Substitution: Single-pass CDR germlining and stabilization oftherapeutic antibodies, PNAS, vol. 112, 15354-15359 (2015), and UnitedStates Patent Application Number 2017-0073395 Al (published Mar. 16,2017) and are herein incorporated by reference in their entirety.

In certain embodiments, the antibody, or antigen-binding fragmentthereof, described herein comprises a human framework sequence. Forexample, a heavy chain framework sequence can be derived from a humanVH3 germline, a VH1 germline, a VH5 germline, or a VH4 germlinesequence. Preferred human germline heavy chain frameworks are frameworksderived from VH1, VH3, or VH5 germline sequences. For example, VHframeworks from the following well-known germline sequences may be used:IGHV3-23, IGHV3-7, or IGHV1-69, where germline names are based on IMGTgermline definition. Preferred human germline light chain frameworks areframeworks derived from VK or Vλ germline sequences. For example, VLframeworks from the following germlines may be used: IGKV1-39 orIGKV3-20, where germline names are based on IMGT germline definition.Alternatively or in addition, the framework sequence may be a humangermline consensus framework sequence, such as the framework of humanVλ1 consensus sequence, VK1 consensus sequence, VK2 consensus sequence,VK3 consensus sequence, VH3 germline consensus sequence, VH1 germlineconsensus sequence, VH5 germline consensus sequence, or VH4 germlineconsensus sequence.

Sequences of human germline frameworks are available from various publicdatabases, such as V-base, IMGT, NCBI, or Abysis.

In certain embodiments, the human germline VL framework is the frameworkof DPK9 (IMGT name: IGKV1-39), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPK9 germlineresidues as shown in Table 3 (SEQ ID NOs.:46, 47, 48).

TABLE 3 SEQ ID Light Chain  46 DPK9 CDR-L1 RASQSISSYLN  47 DPK9 CDR-L2AASSLQS  48 DPK9 CDR-L3 QQSYSTP  49 DPK12 CDR-L1 KSSQSLLHSDGKTYLY  50DPK12 CDR-L2 EVSNRFS  51 DPK12 CDR-L3 MQSIQLP  52 DPK18 CDR-L1RSSQSLVYSDGNTYLN  53 DPK18 CDR-L2 KVSNRDS  54 DPK18 CDR-L3 MQGTHWP  55DPK24 CDR-L1 KSSQSVLYSSNNKNYLA  56 DPK24 CDR-L2 WASTRES  57 DPK24 CDR-L3QQYYSTP  58 HK102_V1 CDR-L1 RASQSISSWLA  59 HK102_V1 CDR-L2 DASSLES  60HK102_V1 CDR-L3 QQYNSYS  61 DPK1 CDR-L1 QASQDISNYLN  62 DPK1 CDR-L2DASNLET  63 DPK1 CDR-L3 QQYDNLP  64 DPK8 CDR-L1 RASQGISSYLA  65DPK8 CDR-L2 AASTLQS  66 DPK8 CDR-L3 QQLNSYP  67 DPK21 CDR-L1 RASQSVSSNLA 68 DPK21 CDR-L2 GASTRAT  69 DPK21 CDR-L3 QQYNNWP  70 Vg_38K CDR-L1RASQSVSSYLA  71 Vg_38K CDR-L2 DASNRAT  72 Vg_38K CDR-L3 QQRSNWP  73DPK22 CDR-L1 RASQSVSSSYLA  74 DPK22 CDR-L2 GASSRAT  75 DPK22 CDR-L3QQYGSSP  76 DPK15 CDR-L1 RSSQSLLHSNGYNYLD  77 DPK15 CDR-L2 LGSNRAS  78DPK15 CDR-L3 MQALQTP  79 DPL16 CDR-L1 QGDSLRSYYAS  80 DPL16 CDR-L2GKNNRPS  81 DPL16 CDR-L3 NSRDSSGNH  82 DPL8 CDR-L1 TGSSSNIGAGYDVH  83DPL8 CDR-L2 GNSNRPS  84 DPL8 CDR-L3 QSYDSSLSG  85 V1-22 CDR-L1TRSSGSIASNYVQ  86 V1-22 CDR-L2 EDNQRPS  87 V1-22 CDR-L3 QSYDSSN  88Vλ consensus CDR-L1 TGSSSGGSYYVS or  89 TGSSSDVGGSYYVS  90Vλ consensus CDR-L2 ENDSNRPS or  91 EDSNR(S/D)K(Q/G)QKPS  92Vλ consensus CDR-L3 QSWDSSA(N/T) or  93 QSWDSSA(N/T)F(F/V)(G/V)  94Vλ1 consensus CDR-L1 SGSSSNIGNN(A/Y)V(N/H/S) or  95SGSSSNIIGNN(A/Y)V(N/H/S)  96 Vλ1 consensusCDR-L2 GNN(K/N/Q)RPS  97Vλ1 consensusCDR-L3 AAWDDSL(N/S)G  98 Vλ3 consensusCDR-L1CSGD(A/V)LG(K/S)KYAH  99 Vλ3 consensusCDR-L2 KDSERPS 100Vλ3 consensusCDR-L3 QSWDSSG(N/D/T/A) or 101 QSWDSSG(N/D/T/A)H 102Vκ consensus CDR-L1 RASQSLLHSDGISSYLA or 103 RASQGISSYLA 104Vκ consensus CDR-L2 AASSRAS 105 Vκ consensus CDR-L3 QQYNSYP 106Vκ1 consensus CDR-L1 RASQGIS(N/S)YLA 107 Vκ1 consensus CDR-L2 AASSLQS108 Vκ1 consensus CDR-L3 QQYNSYP 109 Vκ2 consensus CDR-L1RSSQSLLHSDGNTYLD or 110 RSSQSLLHSDDGNTYLD 111 Vκ2 consensus CDR-L2(K/T)(V/I)SNR(A/F)S 112 Vκ2 consensus CDR-L3 MQATQFP 113Vκ3 consensus CDR-L1 RASQS(S/V)(S/V)SSYLA 114 Vκ3 consensus CDR-L2GASTRAT 115 Vκ3 consensus CDR-L3 QW(S/N/G/H)NWP

In certain embodiments, the human germline VL framework is the frameworkof DPK12 (IMGT name: IGKV2D-29), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPK12germline residues as shown in Table 3 (SEQ ID NOs.:49, 50, 51).

In certain embodiments, the human germline VL framework is the frameworkof DPK18 (IMGT name: IGKV2-30), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPK18germline residues as shown in Table 3 (SEQ ID NOs.:52, 53, 54).

In certain embodiments, the human germline VL framework is the frameworkof DPK24 (IMGT name: IGKV4-1), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPK24germline residues as shown in Table 3 (SEQ ID NOs.:55, 56, 57).

In certain embodiments, the human germline VL framework is the frameworkof HK102_V1 (IMGT name: IGKV1-5), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding HK102_V1germline residues as shown in Table 3 (SEQ ID NOs.:58, 59, 60).

In certain embodiments, the human germline VL framework is the frameworkof DPK1 (IMGT name: IGKV1-33), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPK1 germlineresidues as shown in Table 3 (SEQ ID NOs.:61, 62, 63).

In certain embodiments, the human germline VL framework is the frameworkof DPK8 (IMGT name: IGKV1-9), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPK8 germlineresidues as shown in Table 3 (SEQ ID NOs.:64, 65, 66).

In certain embodiments, the human germline VL framework is the frameworkof DPK21 (IMGT name: IGKV3-15), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPK21germline residues as shown in Table 3 (SEQ ID NOs.:67, 68, 69).

In certain embodiments, the human germline VL framework is the frameworkof Vg_38K (IMGT name: IGKV3-11), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding Vg_38Kgermline residues as shown in Table 3 (SEQ ID NOs.:70, 71, 72).

In certain embodiments, the human germline VL framework is the frameworkof DPK22 (IMGT name: IGKV3-20), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPK22germline residues as shown in Table 3 (SEQ ID NOs.:73, 74, 75).

In certain embodiments, the human germline VL framework is the frameworkof DPK15 (IMGT name: IGKV2-28), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPK15germline residues as shown in Table 3 (SEQ ID NOs.:76, 77, 78).

In certain embodiments, the human germline VL framework is the frameworkof DPL16 (IMGT name: IGLV3-19), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPL16germline residues as shown in Table 3 (SEQ ID NOs.:79, 80, 81).

In certain embodiments, the human germline VL framework is the frameworkof DPL8 (IMGT name: IGLV1-40), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding DPL8 germlineresidues as shown in Table 3 (SEQ ID NOs.:82, 83, 84).

In certain embodiments, the human germline VL framework is the frameworkof V1-22 (IMGT name: IGLV6-57), and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding V1-22germline residues as shown in Table 3 (SEQ ID NOs.:85, 86, 87).

In certain embodiments, the human germline VL framework is the frameworkof human VA, consensus sequence, and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding VA, germlineconsensus residues as shown in Table 3 (SEQ ID NOs.:88, 89, 90, 91, 92,93). Alternative sequences are provided for the consensus sequence withand without gaps. At positions where there is no consensus, residueswithin parenthesis ( ) are those that are tied for the most frequentresidues present in human antibodies.

In certain embodiments, the human germline VL framework is the frameworkof human Vλ1 consensus sequence, and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding Vλ1 germlineconsensus residues as shown in Table 3 (SEQ ID NOs.:94, 95, 96, 97)Alternative sequences are provided for the consensus sequence with andwithout gaps. At positions where there is no consensus, residues withinparenthesis ( ) are those that are tied for the most frequent residuespresent in human antibodies.

In certain embodiments, the human germline VL framework is the frameworkof human Vλ3 consensus sequence, and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding Vλ3 germlineconsensus residues as shown in Table 3 (SEQ ID NOs.: 98, 99, 100, 101).Alternative sequences are provided for the consensus sequence with andwithout gaps. At positions where there is no consensus, residues withinparenthesis ( ) are those that are tied for the most frequent residuespresent in human antibodies.

In certain embodiments, the human germline VL framework is the frameworkof human Vκ consensus sequence and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding Vκ germlineconsensus residues as shown in Table 3 (SEQ ID NOs.:102, 103, 104, 105).Alternative sequences are provided for the consensus sequence with andwithout gaps.

In certain embodiments, the human germline VL framework is the frameworkof human Vκ1 consensus sequence, and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding Vκ1 germlineconsensus residues as shown in Table 3 (SEQ ID NOs.:106, 107, 108). Atpositions where there is no consensus, residues within parenthesis ( )are those that are tied for the most frequent residues present in humanantibodies.

In certain embodiments, the human germline VL framework is the frameworkof human Vκ2 consensus sequence, and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding Vκ2 germlineconsensus residues as shown in Table 3 (SEQ ID NOs.:109, 110, 111, 112).Alternative sequences are provided for the consensus sequence with andwithout gaps. At positions where there is no consensus, residues withinparenthesis ( ) are those that are tied for the most frequent residuespresent in human antibodies.

In certain embodiments, the human germline VL framework is the frameworkof human VK3 consensus sequence, and one or more residues in CDR-L1,CDR-L2, and CDR-L3 of the antibodies (and fragments) of the inventionmay be substituted with the corresponding germline residues as shown inTable 3 (SEQ ID NOs.:113, 114, 115). At positions where there is noconsensus, residues within parenthesis ( ) are those that are tied forthe most frequent residues present in human antibodies.

In certain embodiments, the human germline VH framework is the frameworkof DP54 (IMGT name: IGHV3-7), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding germline residues asshown in Table 4 SEQ ID NOs.:116, 117).

TABLE 4 SEQ ID Heavy Chain 116 DP54 CDR-H1 GFTFSSYWMS 117 DP54 CDR-H2ANIKQDGSEKYYVDSVKG 118 DP47 CDR-H1 GFTFSSYAMS 119 DP47 CDR-H2AISGSGGSTYYADSVKG 120 DP71 CDR-H1 GGSISSYYWS 121 DP71 CDR-H2GYIYYSGSTNYNPSLKS 122 DP75 CDR-H1 GYTFTGYYMH 123 DP75 CDR-H2GWINPNSGGTNYAQKFQG 124 DP10 CDR-H1 GGTFSSYAIS 125 DP10 CDR-H2GGIIPIFGTANYAQKFQG 126 DP7 CDR-H1 GYTGTSYYMH 127 DP7 CDR-H2GIINPSGGSTSYAQKFQG 128 DP49 CDR-H1 GFTFSSYGMH 129 DP49 CDR-H2AVISYDGSNKYYADSVKG 130 DP51 CDR-H1 GFTFSSYSMN 131 DP51 CDR-H2SYISSSSSTIYYADSVKG 132 DP38 CDR-H1 GFTFSNAWMS 133 DP38 CDR-H2GRIKSKTDGGTTDYAAPVKG 134 DP79 CDR-H1 GGSISSSSYYWG 135 DP79 CDR-H2GSIYYSGSTYYNPSLKS 136 DP78 CDR-H1 GGSISSGDYYWS 137 DP78 CDR-H2GYIYYSGSTYYNPSLKS 138 DP73 CDR-H1 GYSFTSYWIG 139 DP73 CDR-H2GIIYPGDSDTRYSPSFQG 140 VH consensus CDR-H1 GFTFSSYAM(H/S) or 141GFTFSSYAM(H/S)WS 142 VH consensus CDR-H2 GWISPNGGSTYYADSVKG or 143GWISPKANGGSTYYADSVKG 144 VH3 consensus CDR-H1 GFTFSSYAMS 145VH3 consensus CDR-H2 SVISSDG(G/S)STYYADSVKG or 146SVISSKADG(G/S)STYYADSVKG 147 VH5 consensus CDR-H1 GYSFTSYWI(S/G/H) 148VH5 consensus CDR-H2 G(R/I/S)IYPGDSDTRYSPSFQG 149 VH1 consensus CDR-H1GYTFTSY(A/Y)(I/M)H 150 VH1 consensus CDR-H2 GWINP(G/Y)NGNTNYAQKFQ 151VH4 consensus CDR-H1 GGSISSG(N/Y)YYWS 152 VH4 consensus CDR-H2GYIYYSGSTYYNPSLKS

In certain embodiments, the human germline VH framework is the frameworkof DP47 (IMGT name: IGHV3-23), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP47 germlineresidues as shown in Table 4 (SEQ ID NOs.:118, 119).

In certain embodiments, the human germline VH framework is the frameworkof DP71 (IMGT name: IGHV4-59), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP71 germlineresidues as shown in Table 4 (SEQ ID NOs.:120, 121).

In certain embodiments, the human germline VH framework is the frameworkof DP75 (IMGT name: IGHV1-2_02), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP75 germlineresidues as shown in Table 4 (SEQ ID NOs.:122, 123).

In certain embodiments, the human germline VH framework is the frameworkof DP10 (IMGT name: IGHV1-69), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP10 germlineresidues as shown in Table 4 (SEQ ID NOs.:124, 125).

In certain embodiments, the human germline VH framework is the frameworkof DP7 (IMGT name: IGHV1-46), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP7 germlineresidues as shown in Table 4 (SEQ ID NOs.:126, 127).

In certain embodiments, the human germline VH framework is the frameworkof DP49 (IMGT name: IGHV3-30), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP49 germlineresidues as shown in Table 4 (SEQ ID NOs.:128, 129).

In certain embodiments, the human germline VH framework is the frameworkof DP51 (IMGT name: IGHV3-48), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP51 germlineresidues as shown in Table 4 (SEQ ID NOs.:130, 131).

In certain embodiments, the human germline VH framework is the frameworkof DP38 (IMGT name: IGHV3-15), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP38 germlineresidues as shown in Table 4 (SEQ ID NOs.:132, 133).

In certain embodiments, the human germline VH framework is the frameworkof DP79 (IMGT name: IGHV4-39), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP79 germlineresidues as shown in Table 4 (SEQ ID NOs.:134, 135).

In certain embodiments, the human germline VH framework is the frameworkof DP78 (IMGT name: IGHV4-30-4), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP78 germlineresidues as shown in Table 4 (SEQ ID NOs.:136, 137).

In certain embodiments, the human germline VH framework is the frameworkof DP73 (IMGT name: IGHV5-51), and one or more residues in CDR-H1 andCDR-H2 of the antibody, or antigen-binding fragment thereof, of theinvention may be substituted with the corresponding DP73 germlineresidues as shown in Table 4 (SEQ ID NOs.:138, 139).

In certain embodiments, the human germline VH framework is the frameworkof human VH germline consensus sequence, and one or more residues inCDR-H1 and CDR-H2 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding VH germlineconsensus residues as shown in Table 4 (SEQ ID NOs.:140, 141, 142, 143).Alternative sequences are provided for the consensus sequence with andwithout gaps. At positions where there is no consensus, residues withinparenthesis ( ) are those that are tied for the most frequent residuespresent in human antibodies.

In certain embodiments, the human germline VH framework is the frameworkof human VH3 germline consensus sequence, and r one or more residues inCDR-H1 and CDR-H2 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding VH3 germlineconsensus residues as shown in Table 4 (SEQ ID NOs.:144, 145, 146).Alternative sequences are provided for the consensus sequence with andwithout gaps. At positions where there is no consensus, residues withinparenthesis ( ) are those that are tied for the most frequent residuespresent in human antibodies.

In certain embodiments, the human germline VH framework is the frameworkof human VH5 germline consensus sequence, and one or more residues inCDR-H1 and CDR-H2 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding VH5 germlineconsensus residues as shown in Table 4 (SEQ ID NOs.:147, 148). Atpositions where there is no consensus, residues within parenthesis ( )are those that are tied for the most frequent residues present in humanantibodies.

In certain embodiments, the human germline VH framework is the frameworkof human VH1 germline consensus sequence, and one or more residues inCDR-H1 and CDR-H2 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding VH1 germlineconsensus residues as shown in Table 4 (SEQ ID NOs.:149, 150). Atpositions where there is no consensus, residues within parenthesis ( )are those that are tied for the most frequent residues present in humanantibodies.

In certain embodiments, the human germline VH framework is the frameworkof human VH4 germline consensus sequence, and one or more residues inCDR-H1 and CDR-H2 of the antibody, or antigen-binding fragment thereof,of the invention may be substituted with the corresponding VH4 germlineconsensus residues as shown in Table 4 (SEQ ID NOs.:151, 152). Atpositions where there is no consensus, residues within parenthesis ( )are those that are tied for the most frequent residues present in humanantibodies.

In certain embodiments, the antibody, or antigen-binding fragmentthereof, of the invention comprises (numbering according to Kabat):

-   -   (i) a VH that comprises: (a) a CDR-H1 comprising Trp33, and        three or fewer amino acid differences as compared to SEQ ID NO:        37, (b) a CDR-H2 comprising Asp54, Tyr56, Tyr58, and Gln61, and        three or fewer amino acid differences as compared to ID NO: 38;        and (c) a CDR-H3 comprising Tyr97, Gly98, and Leu100; and three        or fewer amino acid differences as compared to SEQ ID NO: 39;        and    -   (ii) a VL that comprises: (a) a CDR-L1 comprising Gln27, Asp28,        Ile29, Gly30, Tyr32; and three or fewer amino acid differences        as compared to SEQ ID NO: 34, (b) a CDR-L2 comprising a sequence        that comprises three or fewer amino acid differences as compared        to SEQ ID NO: 35; and(c) a CDR-L3 comprising Ile92, Ile93, and        Leu94; and three or fewer amino acid differences as compared to        of SEQ ID NO: 36.

In certain embodiments, the amino acid differences in CDR-H1, CDR-H2,CDR-L1, CDR-L2, and CDR-L3 are human germline substitutions in which anon-human CDR residue is replaced with a corresponding human germlineresidue (such as those human germline residues as shown in Tables 3 and4).

In certain embodiments, the antibody or antigen-binding fragment thereofdescribed herein comprises (i) a VH comprising an amino acid sequencethat is at least 50%, at least 60%, at least 70%, at least 75%, at least80%, at least 85%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, or 100% identical to SEQ ID NO: 28, and/or (ii) a VLcomprising an amino acid sequence that is at least 50%, at least 60%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100% identicalto SEQ ID NO: 1. Any combination of these VL and VH sequences is alsoencompassed by the invention.

In certain embodiments, the VH framework is DP10. Other similarframework regions are also predicted to deliver advantageous antibodiesor antibody fragments of the invention comprising CDRs of SEQ ID NOs.37, 38, and 39 include: DP-88, DP-25, DP-73, IGHV5-10-1*01,IGHV5-10-1*04, DP-14, DP-75, DP15, DP-8, DP-7 and IGHV7-4-1*02, whichshare 99%, 93%, 75%, 73%, 73%, 92%, 90%, 90%, 89%, 93%, and 79% sequenceidentity, respectively, with the FW region of DP10, and comprise four orfewer amino acid differences in the common structural features: (A)residues directly underneath CDR (Vernier Zone), H2, H47, H48, and H49,H67, H69, H71, H73, H93, H94; (B) VH/VL chain packing residues: H37,H39, H45, H47, H91, H93; and (C) canonical CDR Structural supportresidues H24, H71, H94 (all Kabat numbering). Particularly preferred areframework regions of DP-88, DP-25, DP-73, IGHV5-10-1*01, andIGFV-10-1*04, sharing 99%, 93%, 75%, 73%, and 73% sequence identity withDP10, respectively, and have two or fewer amino acid differences inthese common structural features.

In certain embodiments, the VL framework is DPK9. Other similarframework regions are also predicted to deliver advantageous antibodiesof the invention comprising CDRs of SEQ ID NOs. 34, 35, and 36 include:DPK5, DPK4, DPK1, IGKV1-5*01, DPK24, DPK21, DPK15, IGKV1-13*02,IGKV1-17*01, DPK8, IGKV3-11*01, and DPK22, which share 99%, 97%, 97%,96%, 80%, 76%, 66%, 97%, 97%, 96%, 76%, and 74% sequence identity,respectively, with the FW region of DPK-9, and comprise one or feweramino acid difference in common structural features: (A) residuesdirectly underneath CDR (Vernier Zone), L2, L4, L35, L36, L46, L47, L48,L49, L64, L66, L68, L69, L71; (B) VH/VL Chain packing Residues: L36,L38, L44, L46, L87; and (C) canonical CDR Structural support residuesL2, L48, L64, L71 (all Kabat numbering). Particularly preferred areframework regions of DPK5, DPK4, DPK1, IGKV1-5*01, DPK24, DPK21, andDPK15, which share 99%, 97%, 97%, 96%, 80%, 76%, and 66% sequenceidentity with DPK9, respectively, and have no amino acid difference inthese common structural features.

In certain embodiments, the antibody or antigen-binding fragment thereofdescribed herein comprises (i) a CDR-H1 comprising SEQ ID NO:37, aCDR-H2 comprising SEQ ID NO:38, a CDR-H3 comprising SEQ ID NO:39, aCDR-L1 comprising SEQ ID NO:34; a CDR-L2 comprising SEQ ID NO:35, and aCDR-L3 comprising SEQ ID NO:36; and (ii) a VL framework comprising asequence that is at least 66%, at least 74%, at least 76%, at least 80%,at least 96%, at least 97%, or at least 99% identical to the frameworksequence of human germline DPK9, and a VH framework comprising asequence that is at least 73%, at least 75%, at least 79%, at least 89%,at least 90%, at least 92%, at least 93%, or at least 99% identical tothe framework sequence of human germline DP10.

In certain embodiments, the antibody or antigen-binding fragment thereofdescribed herein comprises (i) a CH comprising an amino acid sequencethat is at least 50%, at least 60%, at least 70%, at least 75%, at least80%, at least 85%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99%, or 100% identical to SEQ ID NO: 29; and/or (ii) a CLcomprising an amino acid sequence that is at least 50%, at least 60%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100% identicalto SEQ ID NO: 30. Any combination of these CH and CL sequences is alsoencompassed by the invention.

In certain embodiments, the antibody or antigen-binding fragment thereofdescribed herein comprises an Fc domain. The Fc domain can be derivedfrom IgA (e.g., IgA₁ or IgA₂), IgG, IgE, or IgG (e.g., IgG₁, IgG₂, IgG₃,or IgG₄).

In certain embodiments, the antibody or antigen-binding fragment thereofdescribed herein comprises (i) a heavy chain comprising an amino acidsequence that is at least 50%, at least 60%, at least 70%, at least 75%,at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99%, or 100% identical to SEQ ID NO: 33, and/or (ii)a light chain comprising an amino acid sequence that is at least 50%, atleast 60%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%, or100% identical to SEQ ID NO: 32. Any combination of these heavy chainand light chain sequences is also encompassed by the invention.

Additional antibodies (e.g., CTI-AF2 through CTI-AF27), antigen-bindingfragments thereof, and antigen-binding variants thereof, are alsoprovided by the invention. CTI-AF2 to CTI-AF27 share the same VHsequence but have different VL sequences. Accordingly, in certainembodiments, the antibody, or antigen-binding fragment thereof, of theinvention comprises (i) a VH comprising an amino acid sequence that isat least 50%, at least 60%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99%, or 100% identical to SEQ ID NO: 28, and/or (ii) a VLcomprising an amino acid sequence that is at least 50%, at least 60%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100% identicalto any of SEQ ID NOs: 2-27. Any combination of these VL and VH sequencesis also encompassed by the invention.

Also provided by the invention is an antibody, or antigen-bindingfragment thereof, that competes for binding to human IFNβ with any ofthe antibody or antigen-binding fragment thereof described herein, suchas any one of the antibodies listed in Table 11, or antigen-bindingfragments thereof. For example, if the binding of an antibody, or anantigen-binding portion thereof, to human IFNβ reduces the subsequentbinding to human IFNβ by CTI-AF1, the antibody, or an antigen-bindingportion thereof, is deemed as competing with CTI-AF1 for human IFNβbinding.

Also provided by the invention is an antibody, or antigen-bindingfragment thereof, that binds the same epitope of human IFNβ as anyantibody, or antigen-binding fragment thereof, described herein, such asany antibody listed in Table 11, or antigen-binding fragments thereof.For example, an antibody competition assay (and overlapping epitopeanalysis) can be assessed using SPR, as described in detail herein, orany art-recognized competitive binding assay. The SPR binding assaydescribed herein is the preferred, not exclusive method for assessingbinding of the antibody of the invention, and any other test antibodies.

The antibodies, and antigen-binding fragments thereof, of the inventioninclude monoclonal antibodies, polyclonal antibodies, antibody fragments(e.g., Fab, Fab′, F(ab′)₂, Fv, Fc, etc.), chimeric antibodies,bispecific antibodies, heteroconjugate antibodies, single chain (ScFv),mutants thereof, fusion proteins comprising an antibody portion, domainantibodies (dAbs), humanized antibodies, and any other configuration ofthe immunoglobulin molecule that comprises an antigen recognition siteof the required specificity, including glycosylation variants ofantibodies, amino acid sequence variants of antibodies, and covalentlymodified antibodies. The antibodies and antigen-binding fragments may bemurine, rat, human, or any other origin (including chimeric or humanizedantibodies). In some embodiments, the antibody is a monoclonal antibody.In some embodiments, the antibody is a chimeric, humanized or humanantibody. In certain embodiments, the antibody is a fully humanantibody. In certain embodiments, the antibody is a humanized antibody.

The binding affinity of an antibody can be expressed as a K_(D) value,which refers to the dissociation rate of a particular antigen-antibodyinteraction. K_(D) is the ratio of the rate of dissociation, also calledthe “off-rate (k_(off))”, to the association rate, or “on-rate(k_(on))”. Thus, K_(D) equals k_(off)/k_(on) (dissociation/association)and is expressed as a molar concentration (M), and the smaller theK_(D), the stronger the affinity of binding. K_(D) values for antibodiescan be determined using methods well established in the art. Unlessotherwise specified, “binding affinity” refers to monovalentinteractions (intrinsic activity; e.g., binding of an antibody to anantigen through a monovalent interaction).

In certain embodiments, the antibody, or antigen-binding fragmentthereof, of the invention has an affinity (K_(D)) value of not more thanabout 1×10⁻⁷ M, such as not more than about 1×10⁻⁷ M, not more thanabout 9×10⁻⁸ M, not more than about 8×10⁻⁸ M, not more than about 7×10⁻⁸M, not more than about 6×10⁻⁸ M, not more than about 5×10⁻⁸ M, not morethan about 4×10⁻⁸ M, not more than about 3×10⁻⁸ M, not more than about2×10⁻⁸ M, not more than about 1×10⁻⁸ M, not more than about 9×10⁻⁹ M,not more than about 8×10⁻⁹ M, not more than about 7×10⁻⁹ M, not morethan about 6×10⁻⁹ M, not more than about 5×10⁻⁹ M, not more than about4×10⁻⁹ M, not more than about 3×10⁻⁹ M, not more than about 2×10⁻⁹ M,not more than about 1×10⁻⁹ M, not more than about 9×10⁻¹⁰ M, not morethan about 8×10⁻¹⁰ M, not more than about 7×10⁻¹⁰ M, not more than about6×10⁻¹⁰ M, not more than about 5×10⁻¹⁰ M, not more than about 4×10⁻¹⁰ M,not more than about 3×10⁻¹⁰ M, not more than about 2×10⁻¹⁰ M, not morethan about 1×10⁻¹⁰ M, not more than about 9×10⁻¹¹ M, not more than about8×10⁻¹¹ M, not more than about 7×10⁻¹¹ M, not more than about 6×10⁻¹¹ M,not more than about 5×10⁻¹¹ M, not more than about 4×10⁻¹¹ M, not morethan about 3×10⁻¹¹ M, not more than about 2×10⁻¹¹ M, not more than about1×10⁻¹¹ M, not more than about 9×10⁻¹² M not more than about 8×10⁻¹² M,not more than about 7×10⁻¹² M, not more than about 6×10⁻¹² M, not morethan about 5×10⁻¹² M, not more than about 4×10⁻¹² M, not more than about3×10⁻¹² M, not more than about 2×10⁻¹² M, not more than about 1×10⁻¹² M,not more than about 9×10⁻¹³ M, not more than about 8×10⁻¹³ M, not morethan about 7×10⁻¹³ M, not more than about 6×10⁻¹³ M, not more than about5×10⁻¹³ M, not more than about 4×10⁻¹³ M, not more than about 3×10⁻¹³ M,not more than about 2×10⁻¹³ M, not more than about 1×10⁻¹³ M, from about1×10⁻⁷ M to about 1×10⁻¹⁴ M, from about 9×10⁻⁸ M to about 1×10⁻¹⁴ M,from about 8×10⁻⁸ M to about 1×10⁻¹⁴ M, from about 7×10⁻⁸ M to about1×10⁻¹⁴ M, from about 6×10⁻⁸ M to about 1×10⁻¹⁴ M, from about 5×10⁻⁸ Mto about 1×10⁻¹⁴ M, from about 4×10⁻⁸ M to about 1×10⁻¹⁴ M, from about3×10⁻⁸ M to about 1×10⁻¹⁴ M, from about 2×10⁻⁸ M to about 1×10⁻¹⁴ M,from about 1×10⁻⁸ M to about 1×10⁻¹⁴ M, from about 9×10⁻⁹ M to about1×10⁻¹⁴ M, from about 8×10⁻⁹ M to about 1×10⁻¹⁴ M, from about 7×10⁻⁹ Mto about 1×10⁻¹⁴ M, from about 6×10-9 M to about 1×10⁻¹⁴ M, from about5×10⁻⁹ M to about 1×10⁻¹⁴ M, from about 4×10⁻⁹ M to about 1×10⁻¹⁴ M,from about 3×10⁻⁹ M to about 1×10⁻¹⁴ M, from about 2×10⁻⁹ M to about1×10⁻¹⁴ M, from about 1×10⁻⁹ M to about 1×10⁻¹⁴ M, from about 1×10⁻⁷ Mto about 1×10⁻¹³ M, from about 9×10⁻⁸ M to about 1×10⁻¹³ M, from about8×10⁻⁸ M to about 1×10⁻¹³ M, from about 7×10⁻⁸ M to about 1×10⁻¹³ M,from about 6×10⁻⁸ M to about 1×10⁻¹³ M, from about 5×10⁻⁸ M to about1×10⁻¹³ M, from about 4×10⁻⁸ M to about 1×10⁻¹³ M, from about 3×10⁻⁸ Mto about 1×10⁻¹³ M, from about 2×10⁻⁸ M to about 1×10⁻¹³ M, from about1×10⁻⁸ M to about 1×10⁻¹³ M, from about 9×10⁻⁹ M to about 1×10⁻¹³ M,from about 8×10⁻⁹ M to about 1×10⁻¹³ M, from about 7×10⁻⁹ M to about1×10⁻¹³ M, from about 6×10⁻⁹ M to about 1×10⁻¹³ M, from about 5×10⁻⁹ Mto about 1×10⁻¹³ M, from about 4×10⁻⁹ M to about 1×10⁻¹³ M, from about3×10⁻⁹ M to about 1×10⁻¹³ M, from about 2×10⁻⁹ M to about 1×10⁻¹³ M, orfrom about 1×10⁻⁹ M to about 1×10⁻¹³ M.

The value of K_(D) can be determined directly by well-known methods, andcan be computed even for complex mixtures by methods such as those, forexample, set forth in Caceci et al. (1984, Byte 9: 340-362). Forexample, the K_(D) may be established using a double-filternitrocellulose filter binding assay such as that disclosed by Wong &Lohman (1993, Proc. Natl. Acad. Sci. USA 90: 5428-5432). Other standardassays to evaluate the binding ability of ligands such as antibodiestowards target antigens are known in the art, including for example,ELISAs, Western blots, RIAs, and flow cytometry analysis, and otherassays exemplified elsewhere herein.

One exemplary method for measuring binding affinity (K_(D)) value issurface plasmon resonance (SPR), typically using a biosensor system suchas a BIACORE® system. SPR refers to an optical phenomenon that allowsfor the analysis of real-time biospecific interactions by detection ofalterations in protein concentrations within a biosensor matrix, forexample using the BIACORE® system. BIAcore kinetic analysis comprisesanalyzing the binding and dissociation of an antigen from a chip with animmobilized molecule (e.g., a molecule comprising an antigen-bindingdomain), on their surface; or the dissociation of an antibody, orantigen-binding fragment thereof, from a chip with an immobilizedantigen.

In certain embodiments, the SPR measurement is conducted using aBIACORE® T100 or T200 instrument. For example, a standard assaycondition for surface plasmon resonance can be based on antibodyimmobilization of approximately 100-500 Response Units (RU) of IgG onthe SPR chip. Purified target proteins are diluted in buffer to a rangeof final concentrations and injected at a requisite flow rate (e.g.10-100 μl/min) to allow the calculation of Ka. Dissociation is allowedto proceed to establish off-rate, followed by 3 M MgCl₂ (or 20 mM NaOH)for regeneration of the chip surface. Sensorgrams are then analyzedusing a kinetics evaluation software package. In an exemplaryembodiment, the SPR assay is according to the conditions as set forth inExample 1.

In certain embodiments, the binding affinity (K_(D)) value is measuredusing solution-based kinetic exclusion assay (KinExA™). In a particularembodiment, the KinExA measurement is conducted using a KinExA™ 3200instrument (Sapidyne). The Kinetic Exclusion Assay (KinExA™) is ageneral purpose immunoassay platform (basically a flowspectrofluorimeter) that is capable of measuring equilibriumdissociation constants, and association and dissociation rate constantsfor antigen/antibody interactions. Since KinExA™ is performed afterequilibrium has been obtained it is an advantageous technique to use formeasuring the K_(D) of high affinity interactions where the off-rate ofthe interaction may be very slow. The KinExA™ methodology can beconducted generally as described in Drake et al (2004) AnalyticalBiochemistry 328, 35-43.

Another method for determining the K_(D) of an antibody is by usingBio-Layer Interferometry, typically using OCTET® technology (Octet QKesystem, ForteBio).

In general, an anti-IFNβ antibody should bind to IFNβ with highaffinity, in order to effectively block the activities of IFNβ. IFNβbinds IFNAR1 at a K_(D) of about 50 nM, and to IFNAR2 at a K_(D) ofabout 100 μM. Accordingly, it is desirable that the IFNβ antibody havebinding affinities (K_(D)) in nanomolar and picomolar range, such asabout 1×10⁻⁹ M or lower.

Activity Assays

In certain embodiments, the antibody, or antigen-binding fragmentthereof, of the invention is a neutralizing antibody that reduces atleast one activity of IFNβ. Such activity of IFNβ includes, but it notlimited to, binding to IFNAR, increasing expression of an IFNβ-dependentgene, and/or inducing phosphorylation of, e.g., STAT1, and/or STAT2,among other IFNβ activities known in the art. Whether an antibody, orantigen-binding fragment thereof, reduces an activity of IFNβ can beassessed by a number of assays. For example, assays can be used todetermine whether the antibody, or antigen-binding fragment thereof: (a)inhibits the binding of IFNβ to IFNAR; (b) reduces the expression levelof an IFNβ-dependent gene; and/or (c) inhibit IFNβ-inducedphosphorylation, such as phosphorylation of STAT1, and/or STAT2.

In certain embodiments, the antibody, or antigen-binding fragmentthereof, inhibits the binding of IFNβ to IFNAR (e.g., can be assessed bycompetitive binding to IFNβ). For example, an assay may compare (i) thebinding of IFNβ to IFNAR in the presence of the antibody, orantigen-binding fragment thereof, with (ii) the binding of IFNβ to IFNARin the absence of the antibody, or antigen-binding fragment thereof. Thereduction in binding of IFNβ to IFNAR can be at least about 10%, atleast about 20%, at least about 30%, at least about 40%, at least about50%, at least about 60%, at least about 70%, at least about 80%, atleast about 90%, at least about 95%, at least about 96%, at least about97%, at least about 98%, or at least about 99%, in the presence of theanti-IFNβ antibody, or antigen-binding fragment thereof. The expectedbinding of IFNβ to IFNAR in the absence of the antibody, orantigen-binding fragment thereof, can be set as 100%.

In certain embodiments, the antibody, or antigen-binding fragmentthereof, inhibits the binding of IFNβ to IFNAR, with a half maximalinhibitory concentration (IC₅₀) of not more than about 1×10⁻⁷ M, notmore than about 1×10⁻⁸ M, not more than about 1×10⁻⁹ M, not more thanabout 1×10⁻¹⁰ M, not more than about 1×10⁻¹¹ M, not more than about1×10⁻¹² M, not more than about 1×10⁻¹³ M, not more than about 1×10⁻¹⁴ M,not more than about 1×10⁻¹⁵ M, from about 1×10⁻⁷ M to about 5×10⁻¹⁴ M,from about 1×10⁻⁷ M to about 1×10⁻¹⁴ M, from about 1×10⁻⁷ M to about5×10⁻¹³ M, from about 1×10⁻⁷ M to about 1×10⁻¹³ M, from about 1×10⁻⁷ Mto about ×10⁻¹² M, or from about 1×10⁻⁷ M to about 1×10⁻¹² M.

The activities of an antibody, or antigen-binding fragment thereof, ofthe invention can also be assessed by measuring the expression level ofan IFNβ-dependent gene. For example, the gene can be a downstreamcomponent in the IFNβ-mediated signal pathway (such as CMPK2, IFIT1,IF127, IFIH1, IF144, IF144L, IF16, ISG15, LY6E, HERC5, MX1, OAS1, OAS2,OAS3, RSAD2, XAF1, CXCL10, or any combination thereof). Alternatively,the gene can be a reporter gene (e.g., the luciferase reporter gene asused in the examples) where the expression level of the reporter genecorrelates with IFNβ activity (e.g., the reporter gene is operablylinked to an IFNβ-dependent response element). The expression level ofthe downstream gene or reporter gene can be assessed by a variety ofmethods, such as measuring the RNA level, protein level, or activitylevel of a protein. The assay can compare (i) the expression level ofthe IFNβ dependent gene in the presence of the antibody, orantigen-binding fragment thereof, with (ii) the expression level of theIFNβ dependent gene in the absence of the antibody, or antigen-bindingfragment thereof. The reduction in expression level of a downstream geneor reporter gene can be at least about 10%, at least about 20%, at leastabout 30%, at least about 40%, at least about 50%, at least about 60%,at least about 70%, at least about 80%, at least about 90%, at leastabout 95%, at least about 96%, at least about 97%, at least about 98%,or at least about 99%, in the presence of the anti-IFNβ antibody, orantigen-binding fragment thereof. The baseline expression level in theabsence of the antibody, or antigen-binding fragment thereof, can be setas 100%.

In certain embodiments, the antibody, or antigen-binding fragmentthereof, inhibits the expression of an IFNβ-dependent gene, with a halfmaximal inhibitory concentration (IC₅₀) of not more than about 1×10⁻⁷ M,not more than about 1×10⁻⁸ M, not more than about 1×10⁻⁹ M, not morethan about 1×10⁻¹⁰ M, not more than about 1×10⁻¹¹ M, not more than about1×10⁻¹² M, not more than about 1×10⁻¹³ M, not more than about 1×10⁻¹⁴ M,not more than about 1×10⁻¹⁵ M, from about 1×10⁻⁷ M to about 5×10⁻¹⁴ M,from about 1×10⁻⁷ M to about 1×10⁻¹⁴ M, from about 1×10⁻⁷ M to about5×10⁻¹³ M, from about 1×10⁻⁷ M to about 1×10⁻¹³ M, from about 1×10⁻⁷ Mto about 5×10⁻¹² M, or from about 1×10⁻⁷ M to about 1×10⁻¹² M. Incertain embodiments, IC₅₀ of from about 1×10⁻¹⁰ M to about 1×10⁻¹³ M ispreferred. In certain embodiments, IC₅₀ of from about 5×10⁻¹¹ M to about5×10⁻¹² M is preferred.

The inhibitory activity of an antibody, or antigen-binding fragmentthereof, can also be assessed by measuring the level of IFNβ-inducedphosphorylation, such as STAT1 phosphorylation, and/or STAT2phosphorylation level. The assay can compare (i) the phosphorylationlevel of STAT1 and/or STAT2 in the presence of the antibody, orantigen-binding fragment thereof, with (ii) the phosphorylation level ofSTAT1 and/or STAT2 in the absence of the antibody, or antigen-bindingfragment thereof. The reduction in phosphorylation level can be at leastabout 10%, at least about 20%, at least about 30%, at least about 40%,at least about 50%, at least about 60%, at least about 70%, at leastabout 80%, at least about 90%, at least about 95%, at least about 96%,at least about 97%, at least about 98%, or at least about 99%, in thepresence of the anti-IFNβ antibody, or antigen-binding fragment thereof.The baseline STAT1 phosphorylation and/or STAT2 phosphorylation level inthe absence of the antibody, or antigen-binding fragment thereof, can beset as 100%.

In certain embodiments, the antibody, or antigen-binding fragmentthereof, inhibits IFNβ-induced phosphorylation (such as STAT1phosphorylation, and/or STAT2 phosphorylation), with a half maximalinhibitory concentration (IC₅₀) of not more than about 1×10⁻⁷ M, notmore than about 1×10⁻⁸ M, not more than about 1×10⁻⁹ M, not more thanabout 1×10⁻¹⁰ M, not more than about 1×10⁻¹¹ M, not more than about1×10⁻¹² M, not more than about 1×10⁻¹³ M, not more than about 1×10⁻¹⁴ M,not more than about 1×10⁻¹⁵ M, from about 1×10⁻⁷ M to about 5×10⁻¹⁴ M,from about 1×10⁻⁷ M to about 1×10⁻¹⁴ M, from about 1×10⁻⁷ M to about5×10⁻¹³ M, from about 1×10⁻⁷ M to about 1×10⁻¹³ M, from about 1×10⁻⁷ Mto about 5×10⁻¹² M, or from about 1×10⁻⁷ M to about 1×10⁻¹² M. Incertain embodiments, IC₅₀ of from about 1×10⁻¹⁰ M to about 1×10⁻¹³ M ispreferred. In certain embodiments, IC₅₀ of from about 5×10⁻¹¹ M to about5×10⁻¹² M is preferred.

In certain embodiments, the characteristics of the antibody, orantigen-binding fragment thereof, of the invention is further assessedusing other biological activity assays, e.g., in order to evaluate itspotency, pharmacological activity, and potential efficacy as atherapeutic agent. Such assays are known in the art and depend on theintended use for the antibody. Examples include e.g., toxicity assays,immunogenicity assays, stability assays, and/or PK/PD profiling.

C. Nucleic Acids and Methods of Producing Anti-IFNβ Antibodies

The invention also provides polynucleotides encoding any of theantibodies, including antibody portions and modified antibodiesdescribed herein. The invention also provides a method of making any ofthe polynucleotides described herein. Polynucleotides can be made andexpressed by procedures known in the art.

The sequence of a desired antibody, or antigen-binding fragment thereof,and nucleic acid encoding such antibody, or antigen-binding fragmentthereof, can be determined using standard sequencing techniques. Anucleic acid sequence encoding a desired antibody, or antigen-bindingfragment thereof, may be inserted into various vectors (such as cloningand expression vectors) for recombinant production and characterization.A nucleic acid encoding the heavy chain, or an antigen-binding fragmentof the heavy chain, and a nucleic acid encoding the light chain, or anantigen-binding fragment of the light chain, can be cloned into the samevector, or different vectors.

In one aspect, the invention provides polynucleotides encoding the aminoacid sequence of any of the following anti-IFNβ antibodies andantigen-binding portions thereof: CTI-AF1, CTI-AF2, CTI-AF3, CTI-AF4,CTI-AFS, CTI-AF6, CTI-AF7, CTI-AF8, CTI-AF9, CTI-AF10, CTI-AF11,CTI-AF12, CTI-AF13, CTI-AF14, CTI-AF15, CTI-AF16, CTI-AF17, CTI-AF18,CTI-AF19, CTI-AF20, CTI-AF21, CTI-AF22, CTI-AF23, CTI-AF24, CTI-AF25,CTI-AF26, and CTI-AF27.

The invention also provides polynucleotides encoding an antibody, orantigen-binding fragment thereof, that binds substantial the sameepitope as an antibody selected from the group consisting of: CTI-AF1,CTI-AF2, CTI-AF3, CTI-AF4, CTI-AF5, CTI-AF6, CTI-AF7, CTI-AF8, CTI-AF9,CTI-AF10, CTI-AF11, CTI-AF12, CTI-AF13, CTI-AF14, CTI-AF15, CTI-AF16,CTI-AF17, CTI-AF18, CTI-AF19, CTI-AF20, CTI-AF21, CTI-AF22, CTI-AF23,CTI-AF24, CTI-AF25, CTI-AF26, and CTI-AF27.

The invention also provides polynucleotides encoding an antibody, orantigen-binding fragment thereof, that competes for binding to IFNβ withan antibody selected from the group consisting of: CTI-AF1, CTI-AF2,CTI-AF3, CTI-AF4, CTI-AF5, CTI-AF6, CTI-AF7, CTI-AF8, CTI-AF9, CTI-AF10,CTI-AF11, CTI-AF12, CTI-AF13, CTI-AF14, CTI-AF15, CTI-AF16, CTI-AF17,CTI-AF18, CTI-AF19, CTI-AF20, CTI-AF21, CTI-AF22, CTI-AF23, CTI-AF24,CTI-AF25, CTI-AF26, and CTI-AF27.

The invention also provides polynucleotides comprising a sequenceencoding a protein comprising the amino acid sequence selected from thegroup consisting of: (i) SEQ ID NOs:1-27, (ii) SEQ ID NO:28, and (iii)any combination thereof.

The invention also provides polynucleotides comprising the nucleic acidsequence set forth as SEQ ID NOs: 166 or 167.

The invention also provides polynucleotides comprising the nucleic acidsequence of the DNA insert of the plasmid deposited with the ATCC andhaving Accession No. PTA-122727 or the DNA insert of the plasmiddeposited with the ATCC and having Accession No. PTA-122726.

In another aspect, the invention provides polynucleotides and variantsthereof encoding an anti-IFNβ antibody, wherein such variantpolynucleotides share at least 70%, at least 75%, at least 80%, at least85%, at least 87%, at least 89%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, or at least 99% sequence identity to any of thespecific nucleic acid sequences disclosed herein. These amounts are notmeant to be limiting, and increments between the recited percentages arespecifically envisioned as part of the disclosure.

In one embodiment, the VH and VL domains, or antigen-binding portionthereof, or full length HC or LC, are encoded by separatepolynucleotides. Alternatively, both VH and VL, or antigen-bindingportion thereof, or HC and LC, are encoded by a single polynucleotide.

Polynucleotides complementary to any such sequences are also encompassedby the present disclosure. Polynucleotides may be single-stranded(coding or antisense) or double-stranded, and may be DNA (genomic, cDNAor synthetic) or RNA molecules. RNA molecules include HnRNA molecules,which contain introns and correspond to a DNA molecule in a one-to-onemanner, and mRNA molecules, which do not contain introns. Additionalcoding or non-coding sequences may, but need not, be present within apolynucleotide of the present disclosure, and a polynucleotide may, butneed not, be linked to other molecules and/or support materials.

Polynucleotides may comprise a native sequence (i.e., an endogenoussequence that encodes an antibody or a portion thereof) or may comprisea variant of such a sequence. Polynucleotide variants contain one ormore substitutions, additions, deletions and/or insertions such that theimmunoreactivity of the encoded polypeptide is not diminished, relativeto a native immunoreactive molecule. The effect on the immunoreactivityof the encoded polypeptide may generally be assessed as describedherein. In some embodiments, variants exhibit at least about 70%identity, in some embodiments, at least about 80% identity, in someembodiments, at least about 90% identity, and in some embodiments, atleast about 95% identity to a polynucleotide sequence that encodes anative antibody or a portion thereof. These amounts are not meant to belimiting, and increments between the recited percentages arespecifically envisioned as part of the disclosure.

Two polynucleotide or polypeptide sequences are said to be “identical”if the sequence of nucleotides or amino acids in the two sequences isthe same when aligned for maximum correspondence as described below.Comparisons between two sequences are typically performed by comparingthe sequences over a comparison window to identify and compare localregions of sequence similarity. A “comparison window” as used herein,refers to a segment of at least about 20 contiguous positions, usually30 to about 75, or 40 to about 50, in which a sequence may be comparedto a reference sequence of the same number of contiguous positions afterthe two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using theMegAlign® program in the Lasergene® suite of bioinformatics software(DNASTAR®, Inc., Madison, Wis.), using default parameters. This programembodies several alignment schemes described in the followingreferences: Dayhoff, M. O., 1978, A model of evolutionary change inproteins—Matrices for detecting distant relationships. In Dayhoff, M. O.(ed.) Atlas of Protein Sequence and Structure, National BiomedicalResearch Foundation, Washington D.C. Vol. 5, Suppl. 3, pp. 345-358; HeinJ., 1990, Unified Approach to Alignment and Phylogenes pp. 626-645Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, Calif.;Higgins, D. G. and Sharp, P. M., 1989, CABIOS 5:151-153; Myers, E. W.and Muller W., 1988, CABIOS 4:11-17; Robinson, E. D., 1971, Comb. Theor.11:105; Santou, N., Nes, M., 1987, Mol. Biol. Evol. 4:406-425; Sneath,P. H. A. and Sokal, R. R., 1973, Numerical Taxonomy the Principles andPractice of Numerical Taxonomy, Freeman Press, San Francisco, Calif.;Wilbur, W. J. and Lipman, D. J., 1983, Proc. Natl. Acad. Sci. USA80:726-730.

In some embodiments, the “percentage of sequence identity” is determinedby comparing two optimally aligned sequences over a window of comparisonof at least 20 positions, wherein the portion of the polynucleotide orpolypeptide sequence in the comparison window may comprise additions ordeletions (i.e., gaps) of 20 percent or less, usually 5 to 15 percent,or 10 to 12 percent, as compared to the reference sequences (which doesnot comprise additions or deletions) for optimal alignment of the twosequences. The percentage is calculated by determining the number ofpositions at which the identical nucleic acid bases or amino acidresidue occurs in both sequences to yield the number of matchedpositions, dividing the number of matched positions by the total numberof positions in the reference sequence (i.e., the window size) andmultiplying the results by 100 to yield the percentage of sequenceidentity.

Variants may also, or alternatively, be substantially homologous to anative gene, or a portion or complement thereof. Such polynucleotidevariants are capable of hybridizing under moderately stringentconditions to a naturally occurring DNA sequence encoding a nativeantibody (or a complementary sequence).

Suitable “moderately stringent conditions” include prewashing in asolution of 5×SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65° C., 5×SSC, overnight; followed by washing twice at 65° C. for 20minutes with each of 2×, 0.5× and 0.2×SSC containing 0.1% SDS.

As used herein, “highly stringent conditions” or “high stringencyconditions” are those that: (1) employ low ionic strength and hightemperature for washing, for example 0.015 M sodium chloride/0.0015 Msodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ duringhybridization a denaturing agent, such as formamide, for example, 50%(v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1%polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mMsodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50%formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodiumphosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution,sonicated salmon sperm DNA (50 μg/mL), 0.1% SDS, and 10% dextran sulfateat 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodiumcitrate) and 50% formamide at 55° C., followed by a high-stringency washconsisting of 0.1×SSC containing EDTA at 55° C. The skilled artisan willrecognize how to adjust the temperature, ionic strength, etc. asnecessary to accommodate factors such as probe length and the like.

It will be appreciated by those of ordinary skill in the art that, as aresult of the degeneracy of the genetic code, there are many nucleotidesequences that encode a polypeptide as described herein. Some of thesepolynucleotides bear minimal homology to the nucleotide sequence of anynative gene. Nonetheless, polynucleotides that vary due to differencesin codon usage are specifically contemplated by the present disclosure.Further, alleles of the genes comprising the polynucleotide sequencesprovided herein are within the scope of the present disclosure. Allelesare endogenous genes that are altered as a result of one or moremutations, such as deletions, additions and/or substitutions ofnucleotides. The resulting mRNA and protein may, but need not, have analtered structure or function. Alleles may be identified using standardtechniques (such as hybridization, amplification and/or databasesequence comparison).

The polynucleotides of this disclosure can be obtained using chemicalsynthesis, recombinant methods, or PCR. Methods of chemicalpolynucleotide synthesis are well known in the art and need not bedescribed in detail herein. One of skill in the art can use thesequences provided herein and a commercial DNA synthesizer to produce adesired DNA sequence.

For preparing polynucleotides using recombinant methods, apolynucleotide comprising a desired sequence can be inserted into asuitable vector, and the vector in turn can be introduced into asuitable host cell for replication and amplification, as furtherdiscussed herein. Polynucleotides may be inserted into host cells by anymeans known in the art. Cells are transformed by introducing anexogenous polynucleotide by direct uptake, endocytosis, transfection,F-mating or electroporation. Once introduced, the exogenouspolynucleotide can be maintained within the cell as a non-integratedvector (such as a plasmid) or integrated into the host cell genome. Thepolynucleotide so amplified can be isolated from the host cell bymethods well known within the art. See, e.g., Sambrook et al., 1989.

Alternatively, PCR allows reproduction of DNA sequences. PCR technologyis well known in the art and is described in U.S. Pat. Nos. 4,683,195,4,800,159, 4,754,065 and 4,683,202, as well as PCR: The Polymerase ChainReaction, Mullis et al. eds., Birkauswer Press, Boston, 1994.

RNA can be obtained by using the isolated DNA in an appropriate vectorand inserting it into a suitable host cell. When the cell replicates andthe DNA is transcribed into RNA, the RNA can then be isolated usingmethods well known to those of skill in the art, as set forth inSambrook et al., 1989, for example.

Suitable cloning and expression vectors can include a variety ofcomponents, such as promoter, enhancer, and other transcriptionalregulatory sequences. The vector may also be constructed to allow forsubsequent cloning of an antibody variable domain into differentvectors.

Suitable cloning vectors may be constructed according to standardtechniques, or may be selected from a large number of cloning vectorsavailable in the art. While the cloning vector selected may varyaccording to the host cell intended to be used, useful cloning vectorswill generally have the ability to self-replicate, may possess a singletarget for a particular restriction endonuclease, and/or may carry genesfor a marker that can be used in selecting clones containing the vector.Suitable examples include plasmids and bacterial viruses, e.g., pUC18,pUC19, Bluescript (e.g., pBS SK+) and its derivatives, mp18, mp19,pBR322, μMB9, ColE1, pCR1, RP4, phage DNAs, and shuttle vectors such aspSA3 and pAT28. These and many other cloning vectors are available fromcommercial vendors such as BioRad, Strategene, and Invitrogen.

Expression vectors are further provided. Expression vectors generallyare replicable polynucleotide constructs that contain a polynucleotideaccording to the disclosure. It is implied that an expression vectormust be replicable in the host cells either as episomes or as anintegral part of the chromosomal DNA. Suitable expression vectorsinclude but are not limited to plasmids, viral vectors, includingadenoviruses, adeno-associated viruses, retroviruses, cosmids, andexpression vector(s) disclosed in PCT Publication No. WO 87/04462.Vector components may generally include, but are not limited to, one ormore of the following: a signal sequence; an origin of replication; oneor more marker genes; suitable transcriptional controlling elements(such as promoters, enhancers and terminator). For expression (i.e.,translation), one or more translational controlling elements are alsousually required, such as ribosome binding sites, translation initiationsites, and stop codons.

The vectors containing the polynucleotides of interest and/or thepolynucleotides themselves, can be introduced into the host cell by anyof a number of appropriate means, including electroporation,transfection employing calcium chloride, rubidium chloride, calciumphosphate, DEAE-dextran, or other substances; microprojectilebombardment; lipofection; and infection (e.g., where the vector is aninfectious agent such as vaccinia virus). The choice of introducingvectors or polynucleotides will often depend on features of the hostcell.

The antibody, or antigen-binding fragment thereof, may be maderecombinantly using a suitable host cell. A nucleic acid encoding theantibody or antigen-binding fragment thereof can be cloned into anexpression vector, which can then be introduced into a host cell, suchas E. coli cell, a yeast cell, an insect cell, a simian COS cell, aChinese hamster ovary (CHO) cell, or a myeloma cell where the cell doesnot otherwise produce an immunoglobulin protein, to obtain the synthesisof an antibody in the recombinant host cell. Preferred host cellsinclude a CHO cell, a Human embryonic kidney (HEK) 293 cell, or an Sp2.0cell, among many cells well-known in the art.

An antibody fragment can be produced by proteolytic or other degradationof a full-length antibody, by recombinant methods, or by chemicalsynthesis. A polypeptide fragment of an antibody, especially shorterpolypeptides up to about 50 amino acids, can be conveniently made bychemical synthesis. Methods of chemical synthesis for proteins andpeptides are known in the art and are commercially available.

The antibody, or antigen-binding fragment thereof, of the invention maybe affinity matured. For example, an affinity matured antibody can beproduced by procedures known in the art (Marks et al., 1992,Bio/Technology, 10:779-783; Barbas et al., 1994, Proc Nat. Acad. Sci,USA 91:3809-3813; Schier et al., 1995, Gene, 169:147-155; Yelton et al.,1995, J. Immunol., 155:1994-2004; Jackson et al., 1995, J. Immunol.,154(7):3310-9; Hawkins et al., 1992, J. Mol. Biol., 226:889-896; andWO2004/058184).

2. Formulations and Uses

The antibody, or antigen-binding fragment thereof, of the invention canbe formulated as a pharmaceutical composition. The pharmaceuticalcomposition may further comprise a pharmaceutically acceptable carrier,excipient, and/or stabilizer (Remington: The Science and practice ofPharmacy 20th Ed., 2000, Lippincott Williams and Wilkins, Ed. K. E.Hoover), in the form of lyophilized formulation or aqueous solution.Acceptable carriers, excipients, or stabilizers are nontoxic torecipients at the dosages and concentrations, and may comprise bufferssuch as phosphate, citrate, and other organic acids; antioxidantsincluding ascorbic acid and methionine; preservatives (such asoctadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;benzalkonium chloride, benzethonium chloride; phenol, butyl or benzylalcohol; alkyl parabens such as methyl or propyl paraben; catechol;resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecularweight (less than about 10 residues) polypeptides; proteins, such asserum albumin, gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone; amino acids such as glycine, glutamine,asparagine, histidine, arginine, or lysine; monosaccharides,disaccharides, and other carbohydrates including glucose, mannose, ordextrans; chelating agents such as EDTA; sugars such as sucrose,mannitol, trehalose or sorbitol; salt-forming counter-ions such assodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionicsurfactants such as TWEENTM, PLURONICS™ or polyethylene glycol (PEG).Pharmaceutically acceptable excipients are further described herein.

The antibody, or antigen-binding fragment thereof, of the invention canbe used for various therapeutic or diagnostic purposes. For example, theantibody, or antigen-binding fragment thereof, of the invention may beused as an affinity purification agents (e.g., for in vitro purificationof IFNβ), as a diagnostic agent (e.g., for detecting expression of IFNβin specific cells, tissues, or serum).

Exemplary therapeutic uses of the antibody, or antigen-binding fragmentthereof, of the invention include treating a rheumatic disease (such asSLE or DM) or an interferonopathy. The antibody, or antigen-bindingfragment thereof, of the invention may also be used in prophylactictreatment (e.g., administering to a subject who has not exhibited adisease symptom but is susceptible to a rheumatic disease or aninterferonopathy).

For therapeutic applications, the antibody, or antigen-binding fragmentthereof, of the invention can be administered to a mammal, especially ahuman by conventional techniques, such as intravenously (as a bolus orby continuous infusion over a period of time), intramuscularly,intraperitoneally, intra-cerebrospinally, subcutaneously,intra-articularly, intrasynovially, intrathecally, orally, topically, orby inhalation. The antibody, or antigen-binding fragment thereof, of theinvention also is suitably administered by intra-tumoral, peri-tumoral,intra-lesional, or peri-lesional routes.

Accordingly, in one aspect, the invention provides a method of reducingthe activity of IFNβ, comprising administering to a subject (e.g., ahuman) in need thereof a therapeutically effective amount of theantibody, or antigen-binding fragment thereof, of the invention.

In certain embodiments, the subject suffers from or is susceptible to arheumatic disease. In certain embodiments, the rheumatic disease is SLE.In certain embodiments, the rheumatic disease is DM.

In certain embodiments, the subject suffers from or is susceptible to aninterferonopathy.

In certain embodiments, the antibody, or antigen-binding fragmentthereof, of the invention is administered subcutaneously. In certainembodiments, the antibody, or antigen-binding fragment thereof, of theinvention is administered intravenously.

The pharmaceutical compositions may be administered to a subject in needthereof at a frequency that may vary with the severity of the rheumaticdisease or interferonopathy. In the case of prophylactic therapy, thefrequency may vary depending on the subject's susceptibility orpredisposition to a rheumatic disease or an interferonopathy.

The compositions may be administered to patients in need as a bolus orby continuous infusion. For example, a bolus administration of anantibody present as a Fab fragment may be in an amount of from 0.0025 to100 mg/kg body weight, 0.025 to 0.25 mg/kg, 0.010 to 0.10 mg/kg or0.10-0.50 mg/kg. For continuous infusion, an antibody present as an Fabfragment may be administered at 0.001 to 100 mg/kg body weight/minute,0.0125 to 1.25 mg/kg/min, 0.010 to 0.75 mg/kg/min, 0.010 to 1.0mg/kg/min. or 0.10-0.50 mg/kg/min fora period of 1-24 hours, 1-12 hours,2-12 hours, 6-12 hours, 2-8 hours, or 1-2 hours.

For administration of an antibody present as a full-length antibody(with full constant regions), dosage amounts may be from about 1 mg/kgto about 10 mg/kg, from about 2 mg/kg to about 10 mg/kg, from about 3mg/kg to about 10 mg/kg, from about 4 mg/kg to about 10 mg/kg, fromabout 5 mg/kg to about 10 mg/kg, from about 1 mg/kg to about 20 mg/kg,from about 2 mg/kg to about 20 mg/kg, from about 3 mg/kg to about 20mg/kg, from about 4 mg/kg to about 20 mg/kg, from about 5 mg/kg to about20 mg/kg, about 1 mg/kg or more, about 2 mg/kg or more, about 3 mg/kg ormore, about 4 mg/kg or more, about 5 mg/kg or more, about 6 mg/kg ormore, about 7 mg/kg or more, about 8 mg/kg or more, about 9 mg/kg ormore, about 10 mg/kg or more, about 11 mg/kg or more, about 12 mg/kg ormore, about 13 mg/kg or more, about 14 mg/kg or more, about 15 mg/kg ormore, about 16 mg/kg or more, about 17 mg/kg or more, about 19 mg/kg ormore, or about 20 mg/kg or more. The frequency of the administrationwould depend upon the severity of the condition. Frequency could rangefrom three times per week to once every two or three weeks.

Additionally, the compositions may be administered to patients viasubcutaneous injection. For example, a dose of 1 to 100 mg anti-IFNβantibody can be administered to patients via subcutaneous or intravenousinjection administered twice a week, once a week, once every two weeks,once every three weeks, once every four weeks, once every five weeks,once every six weeks, once every seven weeks, once every eight weeks,once every nine weeks, once every ten weeks, twice a month, once amonth, once every two months, or once every three months. For example,antibody CTI-AF1 has an estimated half-life of about 19 days. Thishalf-life supports subcutaneous or intravenous injection at every 2-6weeks, such as once every 2 weeks or once every 4 weeks.

In certain embodiments, the half-life of the anti-IFNβ antibody in humanis about 5 days, about 6 days, about 7 days, about 8 days, about 9 days,about 10 days, about 11 days, about 12 days, about 13 days, about 14days, about 15 days, about 16 days, about 17 days, about 18 days, about19 days, about 20 days, about 21 days, about 22 days, about 23 days,about 24 days, about 25 days, about 26 days, about 27 days, about 28days, about 29 days, about 30 days, from about 5 days to about 40 days,from about 5 days to about 35 days, from about 5 days to about 30 days,from about 5 days to about 25 days, from about 10 days to about 40 days,from about 10 days to about 35 days, from about 10 days to about 30days, from about 10 days to about 25 days, from about 15 days to about40 days, from about 15 days to about 35 days, from about 15 days toabout 30 days, or from about 15 days to about 25 days,

In certain embodiments, the pharmaceutical composition is administeredsubcutaneously or intravenously at every 2-6 weeks, with a dose fromabout 0.1 mg/kg to about 10 mg/kg, from about 0.5 mg/kg to about 10mg/kg, from about 1 mg/kg to about 10 mg/kg, from about 1.5 mg/kg toabout 10 mg/kg, from about 2 mg/kg to about 10 mg/kg, from about 0.1mg/kg to about 8 mg/kg, from about 0.5 mg/kg to about 8 mg/kg, fromabout 1 mg/kg to about 8 mg/kg, from about 1.5 mg/kg to about 8 mg/kg,from about 2 mg/kg to about 8 mg/kg, from about 0.1 mg/kg to about 5mg/kg, from about 0.5 mg/kg to about 5 mg/kg, from about 1 mg/kg toabout 5 mg/kg, from about 1.5 mg/kg to about 5 mg/kg, from about 2 mg/kgto about 5 mg/kg, about 0.5 mg/kg, about 1.0 mg/kg, about 1.5 mg/kg,about 2.0 mg/kg, about 2.5 mg/kg, about 3.0 mg/kg, about 3.5 mg/kg,about 4.0 mg/kg, about 4.5 mg/kg, about 5.0 mg/kg, about 5.5 mg/kg,about 6.0 mg/kg, about 6.5 mg/kg, about 7.0 mg/kg, about 7.5 mg/kg,about 8.0 mg/kg, about 8.5 mg/kg, about 9.0 mg/kg, about 9.5 mg/kg, orabout 10.0 mg/kg.

In certain embodiments, the pharmaceutical composition is administeredsubcutaneously or intravenously at every 2-6 weeks, with a dose of about2.0 mg/kg. In certain embodiments, the pharmaceutical composition isadministered subcutaneous or intravenously every 2-6 weeks, with a doseof from about 2.0 mg/kg to about 10.0 mg/kg.

In one exemplary embodiment, pharmaceutical composition is administeredsubcutaneously every 2 weeks.

The antibody, or antigen-binding fragment thereof, of the invention canbe used as monotherapy or in combination with other therapies to treat arheumatic disease.

3. Definitions

Unless otherwise defined herein, scientific and technical terms used inconnection with the present invention shall have the meanings that arecommonly understood by those of ordinary skill in the art. Further,unless otherwise required by context, singular terms shall includepluralities and plural terms shall include the singular. Generally,nomenclatures used in connection with, and techniques of, cell andtissue culture, molecular biology, immunology, microbiology, geneticsand protein and nucleic acid chemistry and hybridization describedherein are those well-known and commonly used in the art.

An “antigen-binding fragment” of an antibody refers to a fragment of afull-length antibody that retains the ability to specifically bind to anantigen (preferably with substantially the same binding affinity).Examples of an antigen-binding fragment includes (i) a Fab fragment, amonovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) aF(ab′)2 fragment, a bivalent fragment comprising two Fab fragmentslinked by a disulfide bridge at the hinge region; (iii) a Fd fragmentconsisting of the VH and CH1 domains; (iv) a Fv fragment consisting ofthe VL and VH domains of a single arm of an antibody, (v) a dAb fragment(Ward et al., (1989) Nature 341:544-546), which consists of a VH domain;and (vi) an isolated complementarity determining region (CDR),disulfide-linked Fvs (dsFv), and anti-idiotypic (anti-Id) antibody andintrabody. Furthermore, although the two domains of the Fv fragment, VLand VH, are coded for by separate genes, they can be joined, usingrecombinant methods, by a synthetic linker that enables them to be madeas a single protein chain in which the VL and VH regions pair to formmonovalent molecules (known as single chain Fv (scFv)); see e.g., Birdet al. Science 242:423-426 (1988) and Huston et al., Proc. Natl. Acad.Sci. USA 85:5879-5883 (1988)). Other forms of single chain antibodies,such as diabodies, are also encompassed. Diabodies are bivalent,bispecific antibodies in which VH and VL domains are expressed on asingle polypeptide chain, but using a linker that is too short to allowfor pairing between the two domains on the same chain, thereby forcingthe domains to pair with complementary domains of another chain andcreating two antigen-binding sites (see e.g., Holliger et al. Proc.Natl. Acad. Sci. USA 90:6444-6448 (1993); Poljak et al., 1994, Structure2:1121-1123).

An antibody “variable domain” refers to the variable region of theantibody light chain (VL) or the variable region of the antibody heavychain (VH), either alone or in combination. As known in the art, thevariable regions of the heavy and light chains each consist of threecomplementarity determining regions (CDRs), and connected by fourframework regions (FR),and contribute to the formation of theantigen-binding site of antibodies.

Residues in a variable domain are numbered according Kabat, which is anumbering system used for heavy chain variable domains or light chainvariable domains of the compilation of antibodies. See, Kabat et al.,Sequences of Proteins of Immunological Interest, 5th Ed. Public HealthService, National Institutes of Health, Bethesda, Md. (1991)). Usingthis numbering system, the actual linear amino acid sequence may containfewer or additional amino acids corresponding to a shortening of, orinsertion into, a FR or CDR of the variable domain. For example, a heavychain variable domain may include a single amino acid insert (residue52a according to Kabat) after residue 52 of CDR-H2 and inserted residues(e.g. residues 82a, 82b, and 82c, according to Kabat) after heavy chainFR residue 82. The Kabat numbering of residues may be determined for agiven antibody by alignment at regions of homology of the sequence ofthe antibody with a “standard” Kabat numbered sequence. Variousalgorithms for assigning Kabat numbering are available. The algorithmimplemented in the 2012 release of Abysis (www.abysis.org) is usedherein to assign Kabat numbering to variable regions unless otherwisenoted.

Specific amino acid residue positions in an antibody (such as paratoperesidues) are also numbered according to Kabat.

“Complementarity Determining Regions” (CDRs) can be identified accordingto the definitions of the Kabat, Chothia, the accumulation of both Kabatand Chothia, AbM, contact, and/or conformational definitions or anymethod of CDR determination well known in the art. See, e.g., Kabat etal., 1991, Sequences of Proteins of Immunological Interest, 5th ed.(hypervariable regions); Chothia et al., 1989, Nature 342:877-883(structural loop structures). AbM definition of CDRs is a compromisebetween Kabat and Chothia and uses Oxford Molecular's AbM antibodymodeling software (Accelrys®).The “contact” definition of CDRs is basedon observed antigen contacts, set forth in MacCallum et al., 1996, J.Mol. Biol., 262:732-745. The “conformational” definition of CDRs isbased on residues that make enthalpic contributions to antigen binding(see, e.g., Makabe et al., 2008, Journal of Biological Chemistry,283:1156-1166). Still other CDR boundary definitions may not strictlyfollow one of the above approaches, but will nonetheless overlap with atleast a portion of the Kabat CDRs, although they may be shortened orlengthened in light of prediction or experimental findings thatparticular residues or groups of residues or even entire CDRs do notsignificantly impact antigen binding. As used herein, a CDR may refer toCDRs defined by any approach known in the art, including combinations ofapproaches.

In the Examples (see Table 11), the CDRs are defined as follows(numbering according to Kabat; H: heavy chain; L: light chain):

CDR-H1: H26-H35B; CDR-H2: H50-H65; CDR-H3: H95-H102

CDR-L1: L24-L34; CDR-L2: L50-L56; CDR-L3: L89-L97

“Framework” (FR) residues are antibody variable domain residues otherthan the CDR residues. A VH or VL domain framework comprises fourframework sub-regions, FR1, FR2, FR3 and FR4, interspersed with CDRs inthe following structure: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. In the Examples(see Table 11), FR residues include the following (numbering accordingto Kabat; H: heavy chain; L: light chain):

TABLE 5 FR1 FR2 FR3 FR4 Heavy Chain H1-H25 H36-H49 H66-H94 H103-H113Light Chain L1-L23 L35-L49 L57-L88 L98-L107

An “epitope” refers to the area or region of an antigen (Ag) to which anantibody specifically binds, e.g., an area or region comprising aminoacid residues that interact with the antibody (Ab). Epitopes can belinear or non-linear (e.g., conformational).

An antibody, or antigen-binding fragment thereof, binds substantiallythe same epitope as another antibody, or antigen-binding fragmentthereof, when binding of the corresponding antibodies, orantigen-binding fragments thereof, are mutually exclusive. That is,binding of one antibody, or antigen-binding fragment thereof, excludessimultaneous or consecutive binding of the other antibody, orantigen-binding fragment thereof. Epitopes are said to be unique, or notsubstantially the same, if the antigen is able to accommodate binding ofboth corresponding antibodies, or antigen-binding fragments thereof,simultaneously.

The term “paratope” is derived from the above definition of “epitope” byreversing the perspective, and refers to the area or region of anantibody molecule which is involved in binding of an antigen, e.g., anarea or region comprising residues that interacts with the antigen. Aparatope may be linear or conformational (such as discontinuous residuesin CDRs).

The epitope/paratope for a given antibody/antigen binding pair can bedefined and characterized at different levels of detail using a varietyof experimental and computational epitope mapping methods. Theexperimental methods include mutagenesis, X-ray crystallography, NuclearMagnetic Resonance (NMR) spectroscopy, Hydrogen/deuterium exchange MassSpectrometry (HX-MS) and various competition binding methods. As eachmethod relies on a unique principle, the description of an epitope isintimately linked to the method by which it has been determined. Thus,the epitope/paratope for a given antibody/antigen pair will be defineddifferently depending on the mapping method employed.

At its most detailed level, the epitope/paratope for the interactionbetween an antibody (Ab) and antigen (Ag) can be defined by the spatialcoordinates defining the atomic contacts present in the Ag-Abinteraction, as well as information about their relative contributionsto the binding thermodynamics. At one level, an epitope/paratope residuecan be characterized by the spatial coordinates defining the atomiccontacts between the Ag and Ab. In one aspect, the epitope/paratoperesidue can be defined by a specific criterion, e.g., distance betweenatoms in the Ab and the Ag (e.g., a distance of equal to or less thanabout 4 Å (such as 3.8 Å used in the Examples here) from a heavy atom ofthe cognate antibody and a heavy atom of the antigen. In another aspect,an epitope/paratope residue can be characterized as participating in ahydrogen bond interaction with the cognate antibody/antigen, or with awater molecule that is also hydrogen bonded to the cognateantibody/antigen (water-mediated hydrogen bonding). In another aspect,an epitope/paratope residue can be characterized as forming a saltbridge with a residue of the cognate antibody/antigen. In yet anotheraspect, an epitope/paratope residue can be characterized as a residuehaving a non-zero change in buried surface area (BSA) due to interactionwith the cognate antibody/antigen. At a less detailed level,epitope/paratope can be characterized through function, e.g., bycompetition binding with other Abs. The epitope/paratope can also bedefined more generically as comprising amino acid residues for whichsubstitution by another amino acid will alter the characteristics of theinteraction between the Ab and Ag (e.g. alanine scanning).

In the context of an X-ray derived crystal structure defined by spatialcoordinates of a complex between an antibody, e.g., a Fab fragment ortwo Fab fragments, and its antigen, unless otherwise specified, anepitope residue refers to an IFNβ residue (i) having a heavy atom (i.e.,a non-hydrogen atom) that is within a distance of about 4 Å (e.g., 3.8Å) from a heavy atom of the cognate antibody; (ii) participating in ahydrogen bond with a residue of the cognate antibody, or with a watermolecule that is also hydrogen bonded to the cognate antibody(water-mediated hydrogen bonding), (iii) participating in a salt bridgeto a residue of the cognate antibody, and/or (iv) having a non-zerochange in buried surface area (BSA) due to interaction with the cognateantibody. In general, a cutoff is imposed for BSA to avoid inclusion ofresidues that have minimal interactions. Therefore, unless otherwisespecified, epitope residues under category (iv) are selected if it has aBSA of 20 Å² or greater, or is involved in electrostatic interactionswhen the antibody binds to IFNβ. Similarly, in the context of an X-rayderived crystal structure, unless otherwise specified or contradicted bycontext, a paratope residue, refers to an antibody residue (i) having aheavy atom (i.e., a non-hydrogen atom) that is within a distance ofabout 4 Å from a heavy atom of IFNβ, (ii) participating in a hydrogenbond with an IFNβ residue, or with a water molecule that is alsohydrogen bonded to IFNβ (water-mediated hydrogen bonding), (iii)participating in a salt bridge to a residue of IFNβ, and/or (iv) havinga non-zero change in buried surface area due to interaction with IFNβ.Again, unless otherwise specified, paratope residues under category (iv)are selected if it has a BSA of 20 Å² or greater, or is involved inelectrostatic interactions when antibody binds to IFNβ. Residuesidentified by (i) distance or (iv) BSA are often referred to as“contact” residues.

From the fact that descriptions and definitions of epitopes, dependenton the epitope mapping method used, and obtained at different levels ofdetail, it follows that comparison of epitopes for different Abs on thesame Ag can similarly be conducted at different levels of detail. Forexample, epitopes described on the amino acid level, e.g., determinedfrom an X-ray structure, are said to be identical if they contain thesame set of amino acid residues. Epitopes characterized by competitionbinding are said to be overlapping if the binding of the correspondingantibodies are mutually exclusive, i.e., binding of one antibodyexcludes simultaneous or consecutive binding of the other antibody; andepitopes are said to be separate (unique) if the antigen is able toaccommodate binding of both corresponding antibodies simultaneously.

The epitope and paratope for a given antibody/antigen pair may beidentified by routine methods. For example, the general location of anepitope may be determined by assessing the ability of an antibody tobind to different fragments or variant IFNβ polypeptides as more fullydescribed previously elsewhere herein. Specific residues within IFNβthat make contact with specific residues within an antibody may also bedetermined using routine methods, such as those described in theexamples. For example, antibody/antigen complex may be crystallized. Thecrystal structure may be determined and used to identify specific sitesof interaction between the antibody and antigen.

The terms “specifically binds” and “specific binding” are termswell-understood in the art, and methods to determine such specificbinding are also well known in the art. A molecule is said to exhibit“specific binding” if it reacts or associates more frequently, morerapidly, with greater duration and/or with greater affinity with aparticular cell or substance, than it does with alternative cells orsubstances. An antibody, or antigen-binding fragment thereof,“specifically binds” to a target (e.g., IFNβ) if it binds with greateraffinity, avidity, more readily, and/or with greater duration than itbinds other substances.

For example, an antibody, or antigen-binding fragment thereof, thatspecifically binds IFNβ is an antibody that binds its cognate antigen(IFNβ) with greater affinity, avidity, more readily, and/or with greaterduration than it binds other antigens, such as other members of the IFNsuperfamily (e.g., INFα, IFNγ, IFNω), or other unrelated molecules. Forexample, an anti-IFNβ antibody can specifically binds human IFNβ in asample, but does not substantially recognize or bind other molecules inthe sample under a standard binding assay condition. It is alsounderstood that an antibody, or antigen-binding fragment thereof, whichspecifically binds a first target may or may not specifically bind to asecond target. As such, “specific binding” does not necessarily require(although it can include) exclusive binding. Generally, but notnecessarily, reference to “binding” means specific binding.

A variety of assay formats may be used to select an antibody, orantigen-binding fragment thereof, that specifically binds a molecule ofinterest. For example, solid-phase ELISA immunoassay,immunoprecipitation, Biacore™ (GE Healthcare), KinExA,fluorescence-activated cell sorting (FACS), Octet™ (FortéBio, Inc.) andWestern blot analysis are among many assays that may be used to identifyan antibody, or antigen-binding fragment thereof, that specificallybinds an antigen. Typically, a specific binding will be at least twiceof the background signal or noise, more typically at least 10 times ofbackground, at least 50 times of background, at least 100 times ofbackground, at least 500 times of background, at least 1000 of timesbackground, or at least 10,000 times of background.

The specificity of an antibody binding may be assessed by determiningand comparing the K_(D) values of a specific binding between an antibodyand IFNβ, with the K_(D) value of a control antibody that is known notto bind to IFNβ. In general, an antibody is said to “specifically bind”an antigen when the K_(D) is about ×10⁻⁵ M or less.

An antibody, or antigen-binding fragment thereof, “does notsubstantially bind” to an antigen when it does not bind to said antigenwith greater affinity, avidity, more readily, and/or with greaterduration than it binds other antigens. Typically, the binding will be nogreater than twice of the background signal or noise. In general, itbinds the antigen with a K_(D) of 1×10⁻⁴ M or more, 1×10⁻³ M or more,1×10⁻² M or more, or 1×10⁻¹ M or more.

The term “compete”, as used herein with regard to an antibody, meansthat binding of a first antibody, or an antigen-binding portion thereof,to an antigen reduces the subsequent binding of the same antigen by asecond antibody or an antigen-binding portion thereof. In general,binding of a first antibody creates steric hindrance, conformationalchange, or binding to a common epitope (or portion thereof), such thatthe binding of the second antibody to the same antigen is reduced.Standard competitive binding assays may be used to determine whether twoantibodies compete with each other.

One suitable assay for antibody competition involves the use of theBiacore technology, which can measure the extent of interactions usingsurface plasmon resonance (SPR) technology, typically using a biosensorsystem (such as a BIACORE® system). For example, SPR can be used in anin vitro competitive binding inhibition assay to determine the abilityof one antibody to inhibit the binding of a second antibody. Anotherassay for measuring antibody competition uses an ELISA-based approach.Furthermore, a high throughput process for “binning” antibodies basedupon their competition is described in WO2003/48731. Competition ispresent if one antibody, or antigen-binding fragment thereof, reducesthe binding of another antibody, or antigen-binding fragment thereof, toIFNβ. For example, a sequential binding competition assay may be used,with different antibodies being added sequentially. The first antibodymay be added to reach binding that is close to saturation. Then, thesecond antibody is added. If the binding of second antibody to IFNβ isnot detected, or is significantly reduced (e.g., at least about 10%, atleast about 20%, at least about 30%, at least about 40%, at least about50%, at least about 60%, at least about 70%, at least about 80%, or atleast about 90% reduction) as compared to a parallel assay in theabsence of the first antibody (which value can be set as 100%), the twoantibodies are considered as competing with each other. An exemplaryantibody competition assay (and overlapping epitope analysis) by SPR isprovided in Example 1.

A competitive binding assay can also be conducted in which the bindingof the antibody to the antigen is compared to the binding of the targetby another binding partner of that target, such as another antibody or asoluble receptor that otherwise binds the target. The concentration atwhich 50% inhibition occurs is known as the K_(i). Under idealconditions, the K_(i) is equivalent to K_(D). Thus, in general,measurement of K_(i) can conveniently be substituted to provide an upperlimit for K_(D). Binding affinities associated with different molecularinteractions, e.g., comparison of the binding affinity of differentantibodies for a given antigen, may be compared by comparison of theK_(D) values for the individual antibody/antigen complexes. K_(D) valuesfor antibodies or other binding partners can be determined using methodswell established in the art.

An “Fc fusion” protein is a protein wherein one or more polypeptides areoperably linked to an Fc polypeptide. An Fc fusion combines the Fcregion of an immunoglobulin with a fusion partner. The “Fc region” maybe a native sequence Fc region or a variant Fc region. Although theboundaries of the Fc region of an immunoglobulin heavy chain might vary,the human IgG heavy chain Fc region is usually defined to stretch froman amino acid residue at position Cys226, or from Pro230, to thecarboxyl-terminus thereof. The numbering of the residues in the Fcregion is that of the EU index as described in Kabat et al., Sequencesof Proteins of Immunological Interest, 5th Ed. Public Health Service,National Institutes of Health, Bethesda, Md., 1991. The Fc region of animmunoglobulin generally comprises two constant domains, CH₂ and CH₃. Asis known in the art, an Fc region can be present in dimer or monomericform.

The term “therapeutically effective amount” means an amount of ananti-IFNβ antibody, or an antigen-binding fragment thereof, or acombination comprising such antibody, or antigen-binding fragmentthereof, that is of sufficient quantity to achieve the intended purpose,such as decreased binding of IFNβ to IFNAR, the decreasedphosphorylation of STAT1 and/or STAT2, the decreased expression ofIFNβ-dependent gene, or otherwise causing a measurable benefit in vivoto a subject in need. The precise amount will depend upon numerousfactors, including, but not limited to the components and physicalcharacteristics of the therapeutic composition, intended patientpopulation, individual patient considerations, and the like, and can bedetermined by one skilled in the art.

The term “treatment” includes prophylactic and/or therapeutictreatments. If it is administered prior to clinical manifestation of adisease, disorder, or condition, the treatment is consideredprophylactic. Therapeutic treatment includes, e.g., ameliorating orreducing the severity of a disease, disorder, or condition, orshortening the length of the disease, disorder, or condition.Preferably, the disease, disorder, or condition is mediated by orrelated to IFNβ binding to IFNAR.

The term “about”, as used herein, refers to +/−10% of a value.

Biological Deposit

Representative materials of the present invention were deposited in theAmerican Type Culture Collection, 10801 University Boulevard, Manassas,Va. 20110-2209, USA, on Dec. 18, 2015. Vector CTI-AF1-VH, having ATCCAccession No. PTA-122727, comprises a DNA insert encoding the heavychain variable region of antibody CTI-AF1, and vector CTI-AF1-VL, havingATCC Accession No. PTA-122726, comprises a DNA insert encoding the lightchain variable region of antibody CTI-AF1. The deposits were made underthe provisions of the Budapest Treaty on the International Recognitionof the Deposit of Microorganisms for the Purpose of Patent Procedure andRegulations thereunder (Budapest Treaty). This assures maintenance of aviable culture of the deposit for 30 years from the date of deposit. Thedeposit will be made available by ATCC under the terms of the BudapestTreaty, and subject to an agreement between Pfizer Inc. and ATCC, whichassures permanent and unrestricted availability of the progeny of theculture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U. S. or foreignpatent application, whichever comes first, and assures availability ofthe progeny to one determined by the U. S. Commissioner of Patents andTrademarks to be entitled thereto according to 35 U. S.C. Section 122and the Commissioner's rules pursuant thereto (including 37 C.F.R.Section 1.14 with particular reference to 886 OG 638).

The owner of the present application has agreed that if a culture of thematerials on deposit should die or be lost or destroyed when cultivatedunder suitable conditions, the materials will be promptly replaced onnotification with another of the same. Availability of the depositedmaterial is not to be construed as a license to practice the inventionin contravention of the rights granted under the authority of anygovernment in accordance with its patent laws.

EXAMPLES

The invention is further described in detail by reference to thefollowing experimental examples. These examples are provided forpurposes of illustration only, and are not intended to be limitingunless otherwise specified. Thus, the invention should in no way beconstrued as being limited to the following examples, but rather, shouldbe construed to encompass any and all variations which become evident asa result of the teaching provided herein.

Example 1 Generation Of Anti-IFNβ Antibodies

Antibody CTI-AF1 is a humanized IgG1 antibody against the solublecytokine interferon beta (IFNβ). A mouse monoclonal antibody (mouse mAb)against human IFNβ was generated by standard immunizations of femaleBALB/c mice with human IFNβ, and subsequent hybridoma screening.

Two hybridoma clones were selected for humanization based on kineticbinding profile. The clones showed a K_(D) value of about 20 nM and anIC₅₀ of about 20 nM. Hybridoma clones were humanized by using humangermline frameworks sequences from IGKV1-39 (DPK9 light chain variabledomain; Gene Bank Accession No. X59315) and IGHV1-69 (DP10 heavy chainvariable domain; Gene Bank Accession No. L22582).

Multiple rounds of affinity maturation were used to increase theaffinity of the antibody. The sequences of VL region of these antibodiesare shown in Table 11. All antibodies in Table 11 have the same VHsequence. In particular, CTI-AF1 showed a decrease in K_(D) value from25 nM to 29 μM by introducing the following mutations in the light chainvariable domain: S to G mutation in position 30, H to I and T to Imutations at position 92 and 93 respectively, and L to I mutation inposition 96. No mutations were introduced in the heavy chain variabledomain.

The affinities of CTI-AF antibodies to human interferon beta (IFNβ) weredetermined by SPR as follows, using a Biacore T200 instrument.Antibodies were directly immobilized on the surface of a CM5 sensor chipat room temperature, using standard amine-coupling technique.Immobilization levels covered a range from 49 to 375 resonance units(RU). The analyte, recombinant human IFNβ, was then injected in a seriesof dilutions ranging from 10 nM down to 0.078 nM (2-fold dilution), at aflow rate of 30 to 50 μL per minute for an association time ranging from65 to 300 seconds, followed by a dissociation phase of 10 minutes. Eachconcentration was evaluated in duplicate. The analyte was removed byregeneration of the CM5 sensor chip surface between each cycle using 3 MMgCl₂ at pH 3.0 or 10 mM glycine-HCl at pH 1.5, followed by a bufferrinse. This regeneration step removed the bound analyte and returned theresponse signal to baseline. Data from the reference flow cell (withoutanalyte) were subtracted from the antigen binding responses to removesystematic artifacts. The apparent binding affinity was determined witha 1:1 interaction model using Biacore T200 evaluation software version2.0. The equilibrium constant K_(D) was determined as the ratio of thekinetic rate constants, k_(d)/k_(a). Binding was validated by repeatingthe binding experiments over multiple days, using two separateinstruments and different flow cells on the CM5 sensor chip. The resultsare shown in Table 6.

TABLE 6 summaries of biological activities of the antibodies in Table 11Response IC50 (pM) IC50 (pM) K_(D) (M)— rank ISRE pSTAT1 Ab Name biacore(Octet) Neutralization Inhibition CTI-AF1  3.6E−11 1 2 4 CTI-AF2 — — — —CTI-AF3 — — — — CTI-AF4 — 4 — — CTI-AF5 — — — 10 CTI-AF6 — — — — CTI-AF7— — — — CTI-AF8 — 6 460 — CTI-AF9 — 12 75 — CTI-AF10 — 5 — — CTI-AF11 —— — — CTI-AF12 — — — — CTI-AF13 — — — — CTI-AF14 — 7 — 30 CTI-AF15 — 3 —80 CTI-AF16 — 2 14 — CTI-AF17 — — — — CTI-AF18 — — — — CTI-AF19 — — — —CTI-AF20 3.35E−10 8 — 20 CTI-AF21 — 11 — — CTI-AF22 — — — — CTI-AF23 — 9— — CTI-AF24 — — — — CTI-AF25 — — — — CTI-AF26 — — — — CTI-AF27 — 10 —70

Example 2 Biophysical Properties of Anti-IFNβ Antibodies

CTI-AF1 was dialyzed and concentrated to 150 mg/mL in MOD1 buffer with10K MWCO regenerated cellulose membrane. The cynomolgus monkey ETSmaterial was ultrafiltrated/diafiltrated into the same buffer to a finalconcentration of 72 mg/mL with minimal losses of product. Whenformulated in PBS, pH 7.2 at ˜50 mg/mL, CTI-AF1 phase-separated at 2-8°C. and formed a stable milky emulsion. Upon warming up to roomtemperature, the solution becomes clear again. In MOD1 buffer, nophase-separation occurred.

Viscosity was measured at 22° C. using the mVROC viscometer. Injectionswere performed at 100 μL/min using a 100 μL Hamilton syringe. Thedependence of viscosity on concentration is shown in FIG. 1. Even at themaximum concentration the viscosity is still below 10 cP.

Thermal stability was evaluated using MicroCal VP-DSC (Malvern). CTI-AF1was scanned at 1 mg/mL protein in MOD1 buffer at 1 deg/min. As shown inFIG. 2, the first melting transition of this molecule occurs at 69.4°C., which is well above the known required stability threshold forcommercial scale manufacturability.

Low-pH stability was evaluated by titrating protein A pool with citricacid down to pH 2.8, 3.0 and 3.4 and incubating for 5 hours at roomtemperature before neutralizing to pH 7.0. As shown in FIG. 3, theformation of HMMS occurs only at pH 2.8, while at higher pH levels theproduct is stable. This stability will enable inactivation of envelopedviruses at low pH, as required for commercial manufacture.

Freeze/thaw stability was performed at 72 mg/mL in MOD1 buffer byplacing an Eppendorf tube containing 1 mL of product at −80° C. for 10min, followed by thawing at room temperature. No significant aggregationwas observed after 3 cycles of freeze-thaw.

Stability studies were performed at 100 mg/mL in MOD1 buffer for 6 weeksat 2-8° C. (FIG. 4A) and ambient temperature (22° C., FIG. 4C); in MOD1buffer at 5 mg/mL for 4 weeks at 40° C. (FIG. 4B); in 20 mM buffer(glutamic acid pH 4.0, histidine pH 5.8, tris pH 8.0) at 4 mg/mL for 5or 11 days at 37° C. (FIG. 4D). Testing of the time points was performedby SE-HPLC. No significant increase in HMW was detected in any of thestudies. Similarly analysis by CGE did not show any significantdifferences between the time points. Charge heterogeneity was assayed byiCE (Table 7), which showed an increase in acidic species at 37° C.(particularly at pH 8.0) and 40° C., indicating some degree ofdeamidation and/or oxidation. However, no major changes were detected totrigger a liquid chromatography (LS)/mass spectrometry (MS)investigation. Other stability series (2-8° C. and ambient temperature)did not show significant changes in % acidic and % basic species by iCE.

The stability time points from the 40° C. series were tested in thecell-based assay measuring the neutralization of IFNβ activity (FIGS. 5A-D). On day 1, 20,000 HEK293 ISRE-Luc (IFNβ responsive luciferasereporter) cells were plated in 100 μL of DMEM containing 10% fetalbovine serum (FBS) per well in tissue culture treated 96 well plates.Antibody solutions were prepared as 2× stocks starting at a topconcentration of 1 μM in DMEM/10% FBS, and then an 11 point, 10-folddilution series was made with media. A 20× stock of IFNβ (0.625 ng/mL)was prepared in media and added to the antibody titration stocks to afinal 2× concentration. The antibody:IFNβ solutions were incubated for 2hours at 37° C., then 100 μL of the solution was added per well andplates were cultured overnight at 37° C. On day 3, a 150 μg/mL solutionof Beetle Luciferine, potassium salt was prepared and 20 μL/well wasadded and plates were incubated for 15 minutes at 37° C. Luminesence wasread on an EnVision multilabel plate reader. No changes in neutralizingactivity were detected.

CTI-AF1 is compatible with a formulation buffer (20 mM His, 8.5%Sucrose, 0.05 mg/mL EDTA, pH 5.8) and maintains solubility up to 150mg/mL with acceptable viscosity.

TABLE 7 Charge heterogeneity in the stability samples Sample Name plAcidic Main Basic HC_T0 8.74 17.3 79.5 3.2 HC_1wk4C 8.74 17.4 79.7 3HC_2wk4C 8.75 17.5 79.1 3.3 HC_3wk4C 8.74 17.7 78.9 3.4 HC_4wk4C 8.7518.1 78.9 3 HC_5wk4C 8.74 19.1 77.1 3.8 HC_6wk4C 8.74 17.8 79.2 3HC_1wk25C 8.74 17.4 79.3 3.4 HC_2wk25C 8.74 17.9 78.9 3.2 HC_3wk_25C8.73 18.2 78.5 3.4 HC_4wk25C 8.73 19.2 76.9 3.9 HC_5wk25C 8.73 19.8 76.73.5 HC_6wk25C 8.72 20.3 76.4 3.4 40C_1wk 8.71 23.9 70.8 5.2 40C_2wk 8.732.8 60.8 6.4 40C_3wk 8.7 37.4 56.7 5.9 40C_4wk 8.7 42.1 52.1 5.7 pH4_T08.7 18.7 78.5 2.8 pH4_5d 8.7 22 74.9 3.1 pH4_11d 8.69 25.9 67.4 6.7PH5_8_T0 8.74 19.3 77.7 3 pH5_8_5d 8.73 21.3 75.6 3.2 pH5_8_11d 8.7424.4 70.8 4.8 pH8_T0 8.73 21 76.3 2.7 pH8_5d 8.74 27.5 70.1 2.4 pH8_11d8.74 34.1 63.6 2.3

Example 3 Pharmacology Brief Summary

CTI-AF1 is a potent and highly selective humanized IgG1 antibody againstthe soluble cytokine interferon beta (IFNβ). In vitro, CTI-AF1 showedhigh affinity for human IFNβ (K_(D) of 36.7±12.4 μM). The antibodyshowed similar EC₅₀ binding for human and cynomolgus monkey IFNβ(15.28±2.11 μM and 25.04±5.11 μM, respectively). In human cell-basedfunctional assays, CTI-AF1 showed potent neutralization of IFNβ inducedSTAT1 phosphorylation (IC₅₀ 7.7±5.0 to 29.8±6.9 μM) and expression of atype I interferon stimulated luciferase reporter in cultured human cells(ISRE assay; IC₅₀ 28.8±7.6 μM). CTI-AF1 also inhibited the IFNβ-drivenexpression of MxA (Mx1) in gene expression assays (IC₅₀ 29.4±23.5 μM)and was able to inhibit IFNβ endogenously expressed by human dermalfibroblasts, a disease relevant cell type, afterpolyinosinic:polycytidylic acid (poly I:C) stimulation.

Primary Pharmacology, In Vitro

During the initial hybridoma screening, antibodies were selected basedupon their ability to block the binding of IFNβ to IFNAR2, the highaffinity component of the type I IFN receptor (FIG. 6). In subsequentscreenings post humanization and affinity maturation, antibody selectionwas based upon functional neutralization of IFNβ in cell based assays.

SPR was used to determine the K_(D) of CTI-AF1 to human IFNβ; bindingexperiments were performed using a Biacore T200 optical biosensorequipped with research-grade CM5 sensor chip and human IFNβ (Peprotech).Regeneration of the chip was performed using stripping buffer (3 M MgCl₂at pH 3.0 or 10 mM glycine at pH 1.5) followed by a buffer rinse.CTI-AF1 was immobilized on the surface of a CM5 sensor chip at roomtemperature. The capture level covered a range of 50 to 375 resonanceunits (RU). The analyte, human IFNβ, was then injected at a flow rate of30-50 μL per minute for an association time ranging from 65-300 seconds,followed by a dissociation phase of 10 minutes. The kineticcharacterization of the interactions was performed using the traditionalmulti-cycle method, using a series of human IFNβ concentrations from 10nM down to 0.078125 nM in a series of 2-fold dilutions. Eachconcentration was evaluated in duplicate. The analyte was removed byregeneration of the array surface between each cycle using 3 M MgCl₂ atpH 3.0 or 10 mM glycine at pH 1.5, followed by a buffer rinse. Thisregeneration step removed the bound analyte and returned the responsesignal to baseline. Data from the reference flow cell (without analyte)were subtracted from the antigen binding responses to remove systematicartifacts. The apparent binding affinity was determined using a simple1:1 interaction model and the equilibrium constant K_(D) was determinedas the ratio of the kinetic rate constants. The apparent bindingaffinity of CTI-AF1 for human IFNβ was determined to be 36.7±12.4 μM(FIG. 7).

Binding of CTI-AF1 to human IFNβ along with cynomolgus monkey, rabbit,rat and mouse orthologs and three of the nearest type I human homologsand IFNγ (type II) were evaluated in plate-based ELISAs. ELISA plateswere coated overnight at 4° C. with 5 μg/mL of one of the followingcytokines: human IFNβ, cynomolgus monkey IFNβ, rat IFNβ, human IFNα2,IFNγ, human IFNω; mouse IFNβ or human IFNα14(H2) were coated at 1 μg/mL,and rabbit IFNβ was coated at 10 ng/mL. All proteins were diluted incalcium and magnesium-free phosphate buffered saline. Coated plates werewashed with phosphate buffered saline containing 0.05% Tween-20 (PBST)and blocked for 1 hour at room temperature with blocking buffer(PBST+0.5% BSA). Plates were washed again with PBST and primaryantibodies were added to the plate at 30 nM starting concentration,followed by 1:3 dilutions in blocking buffer. For the anti-rabbit IFNβ,1:10 dilutions were performed. Plates were incubated for 1 hour at roomtemperature and then washed with PBST. Binding was detected withspecies-specific peroxidase-linked secondary antibodies andtetramethylbenzidine (TMB1) substrate. The reaction was stopped with0.18 M sulfuric acid (H₂SO₄) and absorbance was read at 450 nm in anEnVision multilabel reader (PerkinElmer). Table 8 shows similarreactivity for human and cynomolgus monkey IFNβ, while reactivity torabbit IFNβ is 200 times lower. There was no detectable binding to rator mouse IFNβ, or to the three nearest human homologs or IFNγ (type II).

TABLE 8 Reactivity of CTI-AFI to IFNβ orthologs and nearest type Ihomologs and IFNγ as measured by ELISA Target Homology (%) CTI-AF1 EC₅₀(pM) Cross-species binding Human IFNβ 100 15.14 Cynomolgus monkey IFNβ95.7 24.67 Rabbit IFNβ 56.1 2948 Rat IFNβ 48.6 No binding Mouse IFNβ47.5 No binding Cross-reactivity Human IFNα2 30.2 No binding HumanIFNα17 38.2 No binding Human IFNω 29.0 No binding Human IFNγ 13.2 Nobinding “No binding”: when the absorbance at 450 nm was < 2× theabsorbance of the blank control wells.

Two in vitro assays were used to demonstrate CTI-AF1 dependentinhibition of IFNβ induced signals. Firstly, HEK293 cells stablytransduced with a human ISRE luciferase reporter were used as a measureof IFNβ dependent gene expression; on day 1, 20,000 HEK293 ISRE-Luc(IFNβ responsive luciferase reporter) cells were plated in 100 μL ofDMEM containing 10% fetal bovine serum (FBS) per well in tissue culturetreated 96 well plates. Antibody solutions were prepared as 2× stocksstarting at a top concentration of 1 μM in DMEM/10% FBS. An 11 point,10-fold dilution series was made with media. A 20× stock of IFNβ (28 nM,final assay concentration was 1.4 nM, the EC₅₀) was prepared in mediaand added to the antibody titration stocks to a final 2× concentration.The antibody:IFNβ solutions were incubated for 2 hours at 37° C., then100 μL was added per well and plates were cultured overnight at 37° C.On day 3, a 150 μg/mL solution of Beetle Luciferine, potassium salt wasprepared and 20 μL/well was added and plates were incubated for 15minutes at 37° C. Luminesence was read on an EnVision multilabel platereader. FIG. 8A shows CTI-AF1 dose-dependent inhibition of IFNβ inducedluciferase activity with an IC₅₀ of 28.8±7.6 μM.

Secondly, CTI-AF1 mediated inhibition of IFNβ induced STAT1phosphorylation was evaluated by phosflow. U937 cells, a human monocyticcell line, were grown in RPMI 1640 containing 10% FBS and 2 mM Glutamax(cRPMI). Antibody stocks were made at 4×, with a top concentration of 4μM (final top concentration was 1 μM) and a 12 point, 10-fold dilutionseries was made in cRPMI; 25 μL was added/well in a u-bottom 96 welltissue culture plate. An equal volume of 4×IFNβ (200 μM, finalconcentration was 50 μM, EC₉₀) was added to the antibody stocks andincubated for 2 hours at 37° C. Control wells included media alone (nostimulation background pSTAT1 expression) and 50 μM IFNβ only (maximumpSTAT1 signal). U937 cells were harvested, centrifuged for 5 min at 1500rpm, room temperature and then resuspended at a concentration of2×10⁶/mL in cRPMI warmed to 37° C.; 50 μL of cell suspension was addedper well and plates placed at 37° C. for 15 minutes. Next, 100 μL ofpre-warmed cytofix buffer was added and plates were placed back at 37°C. for 15 minutes. Plates were removed and centrifuged as describedabove. Media was removed from the plates, cells resuspended and washedin 200 μL of PBS and centrifuged again. Media was removed again, thencells were resuspended in 100 μL of permeabilization buffer IV andincubated at room temperature for 15 minutes. At the end of theincubation, cells were centrifuged and washed as described above. Afterthe PBS wash, cells were resuspended in 100 μL of PBS/5% FBS; 5 μL ofTruStain FcX/well was added and plates were incubated for 10 min at 4°C. Ten microliters of Alexa Fluor 674 (AF647) conjugated anti-phosphoSTAT1 antibody was added per well and incubated for 20 min at 4° C.After incubation, 120 μL of FACS buffer was added per well and plateswere centrifuged as described above. The wash was repeated with 220 μLof FACS buffer and cells were resuspended in 120 uL of FACS buffer. AFortessa cytometer was used to acquire the data and analysis wasperformed using FlowJo software. The geometric mean fluorescenceintensity (Geo MFI) in the AF647 channel was calculated and prismsoftware was used to calculate the IC₅₀. CTI-AF1 is a potent neutralizerof human IFNβ with an IC₅₀ of 29.8±6.9 μM (FIG. 8B).

To evaluate the ability of CTI-AF1 to neutralize recombinant IFNβinduced MxA (Mx1) gene expression normal human dermal fibroblasts (HDF)were plated in a T-150 flask in fibroblast culture medium. To set up theassay, cells were dislodged from the flask using trypsin/EDTA solutionand plated in a 48 well plate with three wells assigned per experimentalcondition. On day 3, the cells were stimulated for 5 hours with culturemedium spiked with 0.15 μM IFNβ that was pre-incubated for 2 hours withor without dilutions of CTI-AF1 ranging from 10 nM to 0.016 nM. Acombination of 0.15 μM IFNβ and 50 nM of isotype control antibody wasused as a negative control for the experiment. After 5 hours, cells wereharvested, RNA was isolated using RNeasy micro kit and cDNA synthesizedusing high capacity cDNA reverse transcription kit. Taqman real time PCRanalyses were performed in a Vii A7 system (Thermo Fisher) using humangene specific primer probes for Mx1 and 82 M. The relativequantification (fold change) was calculated from the resultant C_(t)values using the ΔΔCt method as follows: for each condition, C_(t)values of the endogenous control gene (82 M) were subtracted fromrespective C_(t) values for target gene (Mx1). This was followed bynormalization against the untreated sample to calculate the ΔΔCt values,which were subsequently used to calculate the fold change (2^(−ΔΔCt)).The isotype negative control antibody had no impact on MxA (Mx1)expression; however, in the presence of CTI-AF1, a dose-dependentinhibition of gene transcription was seen with an IC₅₀ of 29.4±23.5 pM(FIG. 9).

The specificity of CTI-AF1 neutralization was evaluated by using thesame pSTAT assay as described earlier for FIG. 8B, however, U937 cellswere stimulated with either a final concentration of 20 pM IFNβ or 50 pMIFNα. The different concentrations of type I IFNs were selected toprovide a similar level of STAT1 phosphorylation as IFNα is a lesspotent activator of IFNAR signaling. A similar 12 point, 10-folddilution series was made with sifalimumab (SIF) as a positive controlfor IFNα neutralization. As can be seen, CTI-AF1 specifically inhibitedIFNβ induced STAT1 phosphorylation, but did not inhibit phosphorylationinduced by IFNα (FIGS. 10 A and B, respectively). A single experimentwas conducted using either IFNω (at 100 μM) or IFNα14 (at 4 pM) andCTI-AF1 had no effect on IFNω or IFNα14 induced STAT1 phosphorylation.

To ensure that CTI-AF1 neutralized endogenously expressed IFNβ, normalhuman dermal fibroblasts were seeded in a 48 well plate with three wellsassigned per experimental condition. On day 3, cells were stimulatedwith or without a combination of 1 μg/mL poly I:C and dilutions ofCTI-AF1 (dose range: 50 pM-100 nM) or 100 nM sifalumumab. After 2.5 and24 hours, cells were harvested, RNA isolated using RNeasy micro kit andcDNA synthesized using high capacity cDNA reverse transcription kit.Taqman real time PCR and fold change calculations were performed asdescribed above (FIG. 9). While the amount of IFNβ induced by poly I:Cstimulation was unknown, a dose-dependent inhibition of MxA (Mx1)expression was seen in the presence of CTI-AF1 (FIG. 11).

Example 4 Translational Pharmacology

The PK/PD relationship for IFNβ in dermatomyositis (DM) has not beendefined. There are no relevant translatable preclinical models availablefor DM and the preclinical efficacious concentration (Ceff) is notunderstood. A type 1 Interferon gene signature will be used clinicallyas a mechanistic biomarker of pharmacology modulation. Type 1 Interferongenes are typically elevated in DM and SLE patients and the meanfold-change of the type 1 Interferon gene signature has been usedpreviously in clinical studies for anti-IFNα (sifalimumab androntalizumab) and anti-IFNAR (anifrolumab) mAbs. However, a quantitativeunderstanding of the gene signature modulation has not been establishedand the relationship between in vivo exposure, target engagement,downstream pharmacology and efficacy over time is not understood. Humanefficacious dose feasibility projections are based on the ability ofCTI-AF1 to neutralize >95% of IFNβ in skin.

An LC\MS\MS assay is used to measure total IFNβ in clinical serum andtissue biopsies, and in combination with CTI-AF1 clinical PK and K_(D),is used to assess and confirm target engagement. Type 1 IFN genesignature in blood and skin, as well as IP-10 (CXCL10), are assessed asmechanistic biomarkers. In a subsequent Proof of Mechanism (PoM)/EarlySignal of Efficacy (ESoE) study in DM patients, cutaneousdermatomyositis disease area and severity index (CDASI) is used as theprimary endpoint (outcome biomarker) in addition to any relevantmechanistic biomarkers.

Pharmacokinetics-Pharmacodynamics Relationship and Human Dose

The pharmacokinetic and pharmacodynamic (PK/PD) relationships betweenantibody drug exposure and IFNβ for CTI-AF1 have been simulated usingreported PK parameters for typical IgG₁ therapeutics, IFNβ-CTI-AF1equilibrium binding constant, IFNβ concentrations in skin and serum, andIFNβ turnover half-life.

A “Site-of-Action” PK/PD model was used to predict the coverage of IFNβin DM patients. An IFNβ coverage of >95% at trough was considerednecessary to achieve efficacy. Skin interstitial concentrations ofCTI-AF1 were assumed to be 30% of serum concentrations. The bindingaffinity of CTI-AF1 to IFNβ determined by SPR (Biacore K_(D)=36.7μM) wasused for PK/PD modeling. Consistent with this, in cell-based functionalassays, CTI-AF1 showed potent neutralization of IFNβ-induced STAT1phosphorylation (IC₅₀ 29.8 μM).

The median IFNβ concentration in DM patient serum was 3 pg/mL (N=26);however, the IFNβ concentration in DM patient skin is not known.Therefore, in the model, the impact of IFNβ skin:plasma ratio wasinvestigated at ratios of 10 and 100. Since this is a sensitiveparameter for the model, these ratios were used as proposed boundaryconditions to demonstrate the impact of the skin:plasma ratio on targetcoverage.

The in vivo half-life of IFNβ turnover was estimated by fitting a3-compartmental model to the human PK data for IFNβ1α, which included 3IV doses. This fitting resulted in two different half-lives for IFNβturnover which are considered most relevant, depending on the phase andcompartments considered ranging from 3 minutes (based on the initialphase) to 126 minutes (based on the effective half-life). To increaseconfidence in this model parameter, an IFNβ assay for cynomolgus monkeyserum was developed for use in cynomolgus monkey.

The IFNβ skin:plasma ratio and the IFNβ turnover rate are sensitiveparameters for the PK/PD model. Thus, the human efficacious dosefeasibility assessment was performed using the ranges described abovefor both IFNβ skin:plasma ratio and IFNβ turnover rate. Exampleassessments for two likely clinical ESoE dose regimens are shown inFIGS. 12 A-D (IV Q4W) and FIGS. 13A-D (SC Q1W). CTI-AF1 solubility of150 mg/mL would enable a clinical dose of 2 mg/kg, as it can bedelivered via a 1 mL injection pen. Hence a dose of 2 mg/kg was used forthe dose feasibility assessments below.

FIGS. 12A-D show that at a dose of 2 mg/kg IV Q4W, irrespective of IFNβskin:plasma ratio, only the 126 min half-life for IFNβ predicts >95%IFNβ coverage in skin. If the half-life of IFNβ was 3 min, >95% IFNβcoverage in skin is predicted to require doses higher than 2 mg/kg.FIGS. 13A-D show that at a dose of 2 mg/kg SC Q1W, irrespective of IFNβskin:plasma ratio, the 126 min half-life for IFNβ predicts >95% IFNβcoverage in skin. If the half-life of IFNβ was 3 min, then only the IFNβskin:plasma ratio of 100 will result in >95% IFNβ coverage in skin at 2mg/kg. By contrast, if IFNβ skin:plasma ratio is 10, achieving >95%coverage will require doses higher than 2 mg/kg.

Human PK/Exposure

Based on the pharmacokinetic profiles of CTI-AF1 in cynomolgus monkey,the pharmacokinetics of CTI-AF1 in human are expected to be similar tothe reported values for a typical IgG₁ therapeutic. The 2-compartmentpharmacokinetic parameter values are summarized in Table 9. Simulatedconcentration-time profiles of CTI-AF1 at projected efficacious doselevels are depicted in the top panels of FIGS. 12A-D and 13A-D.

TABLE 9 Projected Pharmacokinetic Parameters of CTI-AF1 in HumanParameter Definition Projection CL central clearance 0.00258 mL/min/kgV1 central volume 43.7 mL/kg CLD distribution clearance 0.00565mL/min/kg V2 peripheral volume 44.3 mL/kg Ka absorption rate constantfor SC 0.000181/min dosing F_sc SC bioavailability 60% Vdss steady-statevolume of distribution 88 mL/kg T_(1/2) terminal half life 19 days

Nonclinical Pharmacokinetics

IV and SC pharmacokinetics of CTI-AF1 have been assessed in cynomolgusmonkeys using data from a single-dose exploratory toxicity study. Meanserum pharmacokinetic parameter values for cynomolgus monkeys aresummarized in Table 10 and mean serum concentrations of CTI-AF1 areshown in FIG. 14.

TABLE 10 Summary Table of CTI-AF1 Pharmacokinetics in Cynomolgus MonkeysDose Cmax AUCinf CL V_(ss) T_(1/2) F (mg/kg) Route (μg/mL) (μg*hr/mL)(mL/h/kg) (L/kg) (h) (%) 10 SC 97.7 50000 n/a n/a 379 87.3 10 IV 24854900 0.183 0.0823 337 n/a 200 IV 4980 1000000 0.209 0.0747 273 n/a MeanN = 2 monkeys/group, 1 male and 1 female

Example 5 IFNβ as a Target for SLE and DM

There is increasing evidence that IFN production is linked to SLE andother rheumatic diseases, such as DM. Moreover, the perpetuation of theSLE disease process likely involves further production of type I IFNsand a vicious pathogenic cycle.

DM is a rare autoimmune disease (about 20,000 patients in the U. S.)characterized by inflammation of skeletal muscle and skin, and,concomitantly, skeletal muscle weakness and skin rash. DM is typicallyassociated with autoantibodies, and the pathogenesis of the disease mayinvolve sequential binding of these autoantibodies to an endothelialautoantigen, triggering complement activation and vascular inflammation,ultimately leading to perifascicular atrophy.

As shown in FIGS. 16 A-B, data indicated an association of type Iinterferon-regulated gene (IRG) transcript “signature” in DM blood withskin rash activity, as measured by the cutaneous dermatomyositis diseasearea and severity index (CDASI). The highly IFNβ-inducible gene MxA(Mx1) is expressed in DM perifascicular myofibers and capillaries, andblood serum IFNβ—but not IFNα or IFNω—is associated with DM, but notwith other inflammatory myopathies or normal sera. These data supportthe notion that injury to capillaries, myofibers and skin in DM resultsfrom a pathogenic overproduction of IFNβ message and protein. Data havealso demonstrated an association between CDASI scores and serum levelsof IFNβ protein (FIG. 17). Analyses of paired skin biopsies indicate thepresence of both IFNβ mRNA and upregulation of an IRG signature only inaffected tissue (FIGS. 18 A-B). Taken together, these data stronglysuggest that DM is an IFNβ-driven disease.

Given that in many tissue contexts IFNβ production may precede IFNαproduction and initiate a pathogenic elevation of IRG signatureexpression, together with the notion that DM may be a largelyIFNβ-driven disease, it is believed that DM and SLE share manypathogenic features and attributes. Indeed, skin lesions of DM aredifficult if not impossible to distinguish histologically from those ofSLE, and a diagnosis of DM skin lesions typically requires clinicaldetermination of increased CD4+ and CXCR3+ cell types and endothelialexpression of Mx1. Moreover, both DM and SLE are characterized by B cellactivation and autoantibody mediated inflammation and tissuedestruction.

TABLE 11 Sequences of anti-IFN antibodies Sequences Seq Ab(CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 ID Nameunderlined when applicable)) 1 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAFKLLIYSTSRLHSG AF1VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK(CDR-L1, CDR-L2, CDR-L3: SEQ ID NOs 34, 35, and 36, respectively) 2 CTI-VL DIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAFKLLIYSTSRLHSG AF2VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIVLPITFGGGTKVEIK 3 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAFKLLIFSTSRLHSG AF3VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIVLPITFGGGTKVEIK 4 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISSYLNWYQQKPGKAFKLLIYSTSRLHSG AF4VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIVLPITFGGGTKVEIK 5 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAFKLLIYTTSRLRSG AF5VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIVLPITFGGGTKVEIK 6 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIDNFLQWYQQKPGKAFKLLIYSTSRLHSG AF6VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIVLPITFGGGTKVEIK 7 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAFKLLIYSTSKLHSG AF7VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIVLPITFGGGTKVEIK 8 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAFKLLIYSTSRLHSG AF8VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTILPLTFGGGTKVEIK 9 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAFKLLIFSTSRLHSG AF9VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTILPLTFGGGTKVEIK 10 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISSYLNWYQQKPGKAFKLLIYSTSRLHSG AF10VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTILPLTFGGGTKVEIK 11 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAFKLLIYTTSRLRSG AF11VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTILPLTFGGGTKVEIK 12 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIDNFLQWYQQKPGKAFKLLIYSTSRLHSG AF12VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTILPLTFGGGTKVEIK 13 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAFKLLIYSTSKLHSG AF13VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTILPLTFGGGTKVEIK 14 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAFKLLIFSTSRLHSG AF14VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK 15 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISSYLNWYQQKPGKAFKLLIYSTSRLHSG AF15VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK 16 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAFKLLIYTTSRLRSG AF16VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK 17 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIDNFLQWYQQKPGKAFKLLIYSTSRLHSG AF17VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK 18 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAFKLLIYSTSKLHSG AF18VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK 19 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAFKLLIFSTSRLHSG AF19VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIVLPITFGGGTKVEIK 20 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISSYLNWYQQKPGKAFKLLIYTTSRLRSG AF20VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIVLPITFGGGTKVEIK 21 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIDNFLQWYQQKPGKAFKLLIFSTSKLHSG AF21VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIVLPITFGGGTKVEIK 22 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAFKLLIFSTSRLHSG AF22VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTILPLTFGGGTKVEIK 23 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISSYLNWYQQKPGKAFKLLIYTTSRLRSG AF23VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTILPLTFGGGTKVEIK 24 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIDNFLQWYQQKPGKAFKLLIFSTSKLHSG AF24VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTILPLTFGGGTKVEIK 25 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAFKLLIFSTSRLHSG AF25VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK 26 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDISSYLNWYQQKPGKAFKLLIYTTSRLRSG AF26VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK 27 CTI- VLDIQMTQSPSSLSASVGDRVTITCRTSQDIDNFLQWYQQKPGKAFKLLIFSTSKLHSG AF27VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK 28 CTI- VHQVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWMHWVRQAPGQGLEWMGHIDPSDSY AF1TYYNQKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARWDYGNLLFEYWGQGTL to VTVSS ACT-(CDR-H1, CDR-H2, CDR-H3: SEQ ID NOs 37, 38, and 39, AF27 respectively)29 All CH ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL CTI-QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA AFsPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG(K) 30 All CLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT CTI-EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC AFs 32 CTI- LightDIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAFKLLIYSTSRLHSGV AF1 chainPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 33 CTI- HeavyQVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWMHWVRQAPGQGLEWMGHIDPSDSY AF1 chainTYYNQKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARWDYGNLLFEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG(K) 34 CTI- CDR-L1RTSQDIGNYLN AF1 35 CTI- CDR-L2 STSRLHS AF1 36 CTI- CDR-L3 QQGIILPIT AF137 CTI- CDR-H1 GYTFSRYWMH AF1 38 CTI- CDR-H2 HIDPSDSYTYYNQKFKG AF1 39CTI- CDR-H3 WDYGNLLFEY AF1 166 CTI- VHCAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAG AF1 nucleicGTGAGCTGCAAGGCCAGCGGCTACACCTTCAGCCGGTACTGGATGCACTGGGTGCGG acidCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCCACATCGACCCCAGCGACAGCTACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGCGGAGCGAGGACACCGCCGTGTACTACTGCGCCCGGTGGGACTACGGCAACCTGCTGTTCGAGTACTGGGGCCAGGGCACCCTGGTGACCGTCTCGAGC 167 CTI- VLGACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACCGGGTG AF1 nucleicACCATCACCTGCCGGACCAGCCAGGACATCGGCAACTACCTGAACTGGTACCAGCAG acidAAGCCCGGCAAGGCCTTCAAGCTGCTGATCTACAGCACCAGCCGGCTGCACAGCGGCGTGCCCAGCCGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGGGATTATTTTGCCCATTACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG

Example 6 Epitope Mapping

To elucidate the epitope recognized by CTI-AF1, hybrid IFNβ proteinswere made where selected portions of IFNβ sequences were replaced withIFNα sequence. CTI-AF1 specifically neutralizes IFNβ but not IFNα,therefore the inability of CTI-AF1 to neutralize a given hybrid proteinwould indicate loss of the epitope. Hybrid proteins were produced,purified and ability to induce STAT1 phosphorylation was confirmed(Table 12).

TABLE 12 sequences of hybrid IFN proteins Seq Hybrid Sequences IDIFN name (mutated residues underlined) 41 HumanMSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF IFNβQKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKTVLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN158 CID1276 MSYNLLGFLQ RSSN RR C LM L L A QLNGRLEY CLKDRMNFDI PEEIKQLQQFQKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKTVLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN159 CID1277 MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDR HD F G I P Q EIKQLQQFQKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKTVLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN160 CID1280 MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQFQKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIV DK LL T N VYHQINHLKTVLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN161 CID1281 MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQFQKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLA E  VY Q QIN D L EAVLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN162 CID1283 MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQFQKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKTVLEEKLEKED FTRGKLMS I L HL RK YYGRIL HYLKAKEYSH CAWTIVRVEILRNFYFINRL TGYLRN 163 CID1285MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQFQKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKTVLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLK E K K YSH CAWTIVRVEILRNFYFINRL TGYLRN 164 CID1286MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQFQKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKTVLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYS P  CAWTIVRVEILRNFYFINRL TGYLRN 165 CID1287MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQFQKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKTVLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVR A EI LRNF SL I TRL TGYLRN

All purified hybrid proteins were able to induce STAT1 phosphorylation,however, there were differences in the biological activity. Each hybridprotein was used at the EC₈₀ concentration in the followingphospho-STAT1 assay (pSTAT1). U937 cells, a human monocytic cell line,were grown in RPMI 1640 containing 10%FBS (cRPMI). Antibody stocks weremade at 4×, with a top concentration of 4-400 μM (final topconcentration was 1-100 μM) and a 11 point, 10-fold dilution series wasmade in cRPMI; 25 μl was added/well in a u-bottom 96 well tissue cultureplate. An equal volume of 4× hybrid or control IFNβ was added at theappropriate EC₈₀ concentration to the antibody stocks and incubated for2 hours at 37° C. Control wells included media alone (no stimulationbackground pSTAT1 expression) or no addition of antibody (maximum pSTAT1signal). U937 cells were harvested, centrifuged for 5 min at 1500 rpm atroom temperature and then resuspended at a concentration of 2×10⁶/ml incRPMI warmed to 37° C.; 50 μl of cell suspension was added per well andplates placed at 37° C. for 15 minutes. Next 100 μl of pre-warmedcytofix buffer (BD Biosciences, catalog #554655) was added and plateswere placed back at 37° C. for 15 minutes. Plates were removed andcentrifuged as described above. Media was removed from the plates, cellsresuspended and washed in 200 μl of PBS and centrifuged again. Media wasremoved again, cells were resuspended in 100 μl of permeabilizationbuffer IV (BD Biosciences) and incubated at room temperature for 15minutes. At the end of the incubation, cells were centrifuged and washedas described above. After the PBS wash, cells were resuspended in 100 μlof PBS/5% FBS (FACS buffer); 5 μl of TruStain FcX/well (BioLegend) wasadded and plates were incubated for 10 min at 4° C. Ten microliters ofAlexa Fluor 674 (AF647) conjugated anti-phospho STAT1 Ab (BDBiosciences) was added per well and incubated 20 min at 4° C. Afterincubation, 120 μl of FACS buffer was added per well and plates werecentrifuged as described above. The wash was repeated with 220 μl ofFACS buffer and cells were resuspended in 120 ul of FACS buffer; aFortessa cytometer (BD Biosciences) was used to acquire the data andanalysis was performed using FlowJo software (TreeStar). The geometricmean fluorescence intensity (Geo MFI) in the AF647 channel wascalculated and prism software was used to calculate the IC₅₀. Data wasnormalized as the ratio of antibody concentration/IFN concentration andthe percentage of the maximum signal was determined after subtractingthe background.

U937 cells were stimulated with IFNα/IFNβ hybrid proteins for 15 minutesin the presence of CTI-AF1 after which the presence of phosphorylatedSTAT1 was assessed by intracellular flow cytometry. CTI-AF1 did notinhibit CID1280-dependent STAT1 phosphorylation and the potency forCID1281-induced STAT1 phosphorylation neutralization was greatlyreduced. CTI-AF1 neutralized STAT1 phosphorylation of all other hybridIFN proteins with equal potency relative to human IFNβ. See FIG. 19 andTable 13. These data combined indicate that the epitope residuesrecognized by CTI-AF1 are contained within the constructs CID1280 andCID1281, in which the IFNα sequence substitutions span amino acids 85-89and 90-100, respectively (see Table 12).

TABLE 13 IC₅₀ and fold change of CTI-AF1 mediated neutralization of typeI IFN-induced STAT1 phosphorylation IFN protein IC₅₀ (nM) Folddifference from IFNβ Human IFNβ 0.3 CID1276 0.2 0.7 CID1277 0.3 0.9CID1280 47.7 161.8 CID1281 3281.0 11137.1 CID1283 0.4 1.2 CID1285 0.41.4 CID1286 0.4 1.4 CID1287 0.3 1.0

Example 7 Crystal Structure of Anti-IFNβ Antibodies

The co-crystals of the complex between Cynomolgus monkey IFNβ andCTI-AF1 Fab were grown using the following solution as a precipitant:19% PEG 3350, 250 mM sodium Citrate, 100 mM Bis-Tris propane pH 8.5. Thecrystals belong to space group P21 (unit cell parameters a=49.58 Å;b=91.76 Å; c=162.52 Å; b=94.86 deg) and contain two copies of complexper crystal asymmetric unit. The structure has been determined at 3.2 Åresolution using Molecular Replacement method and the refinement wasperformed using autoBUSTER.

CTI-AF1 Fab binds to IFNβ on the side formed by two a-helices, A and C,which define the binding epitope of CTI-AF1 (Table 13)

TABLE 13 Epitope analysis cyno-IFNβ human IFNβ Structure Amino PrimarySecondary Optional Amino Primary Secondary Optional elements Acidsepitope epitope epitope Structural Acids epitope epitope epitope Helix ALeu 5 Leu 5 Helix A Leu 5 Leu 5 Leu 6 Leu 6 Leu 6 Leu 6 Phe 8 Phe 8 Phe8 Phe 8 Leu 9 Leu 9 Leu 9 Leu 9 Ser 12 Ser 12 Ser 12 Ser 12 Ser 13 Ser13 Ser 13 Ser 13 Phe 15 Phe 15 Phe 15 Phe 15 Gln 16 Gln 16 Gln 16 Gln 16Helix C Thr 82 Thr 82 Helix C Thr 82 Thr 82 Asn 86 Asn 86 Asn 86 Asn 86Ala 89 Ala 89 Ala 89 Ala 89 Asn 90 Asn 90 Asn 90 Asn 90 Tyr 92 Tyr 92Tyr 92 Tyr 92 His 93 His 93 His 93 His 93 Asp 96 Asp 96 Asn 96 Asn 96His 97 His 97 His 97 His 97 Thr 100 Thr 100 Thr 100 Thr 100 Helix B Tyr67 Tyr 67 Helix B Phe 67 is not part of the epitope on human IFNβ

All amino acids that are within 3.8 A from of CTI-AF1 were selected as“potential” epitope residues. “Primary” epitope residues arecharacterized as highly buried residues at the of CTI-AF1-IFNβ interfaceand zero-to-low sequence tolerance to any other amino acid substitutionsat this position. “Secondary” epitope residues are characterized asresidues with medium buried surface area at the interface and mediumsequence tolerance to amino acid substitutions at these positions.“Optional” epitope residues are characterized as residues with lowburied surface area at the interface and high sequence tolerance toamino acid substitutions at these positions.

The binding paratope is made up by five CDR-variable regions: CDR-H1,-H2, -H3 and CDR-L1, -L3 (Table 14). The total surface area buried underthe binding interface is 1,920 Å². Analysis of CTI-AF1-IFNβ binding modereveals that the neutralizing effect of CTI-AF1 is achieved throughdirect blockage on the IFNAR1 binding site.

TABLE 14 Paratope analysis Amino Primary Secondary CDRs Acids* Paratopeparatope CDR-H1 Trp 33H Trp 33H CDR-H2 Asp 54H Asp 54H Tyr 56H Tyr 56HTyr 58H Tyr 58H Gln 61H Gln 61H CDR-H3 Tyr 97H Tyr 97H Gly 98H Gly 98HLeu 100H Leu 100H CDR-L1 Gln 27L Gln 27L Asp 28L Asp 28L Ile 29L Ile 29LGly 30L Gly 30L Tyr 32L Tyr 32L CDR-L3 Ile 92L Ile 92L Ile 93L Ile 93LLeu 94L Leu 94L

All amino acids that are within 3.8 β from IFNβ were selected as“potential” binding paratope. “Primary” paratope residues arecharacterized as highly buried residues at the CTI-AF1-IFNβ interfaceand low sequence tolerance to any other amino acid substitutions at thisposition. “Secondary” paratope residues are characterized as residueswith lower buried surface area at the interface and higher sequencetolerance to amino acid substitutions at these positions.

Table 15 summarizes the epitope-paratope interaction pairs. Table 16summarizes epitope and paratope analysis based on BSA.

TABLE 15 Epitope-paratope interaction pairs Human IFNβ epitope residueCTI-AF1 paratope residue(s) Type of interaction 5 Leu 32L Tyr H-bond 6Leu 32L Tyr H-bond 8 Phe 28L Asp, 29L Ile, 30L Gly, 32L Tyr van derWaals 9 Leu 32L Tyr, 92L Ile van der Waals 12 Ser 28L Asp H-bond 92L Ilevan der Waals 13 Ser 92L Ile van der Waals 15 Phe 27L Gln van der Waals16 Gln 27L Gln H-bond 28L Asp, 93L Ile van der Waals 82 Thr 61H Gln vander Waals 86 Asn 58H Tyr, 94L Leu van der Waals 89 Ala 58H Tyr, 94L Leuvan der Waals 90 Asn 93L Ile, van der Waals 94L Leu H-bond 92 Tyr 33HTrp, 56H Tyr van der Waals 93 His 97H Tyr, H-bond 100H Leu, van derWaals 92L Ile H-bond 96 Asp 97H Tyr, van der Waals 33H Trp H-bond 97 His97H Tyr, 98H Gly, 100H Leu van der Waals 100 Thr 97H Tyr H-bond

TABLE 16 Epitope and paratope analysis based on BSA Potential IFNβepitope residues BSA (Å²)  5 Leu 89.8  6 Leu 3.5  8 Phe 72.4  9 Leu 51.812 Ser 30.1 13 Ser 18.9 16 Gln 77.4 82 Thr 40.2 86 Asn 51.8 89 Ala 52.090 Asn 53.1 92 Tyr 75.7 93 His 119.4 Potential paratope Amino BSAresidues Acids* (Å²) CDR-H1 Trp 33H 34.5 CDR-H2 Asp 54H 18.7 Tyr 56H67.6 Tyr 58H 69.9 Gln 61H 52.1 CDR-H3 Tyr 97H 101.7 Gly 98H 31.7 Leu100H 31.3 CDR-L1 Gln 27L 54.4 Asp 28L 39.1 Ile 29L 7.8 Gly 30L 16.8 Tyr32L 91.9 CDR-L3 Ile 92L 80.3 Ile 93L 55.2 Leu 94L 79.7

Example 8 Type I Interferon Expression Profiles

In this example, we studied type I IFN expression profiles of 4 diseaserelevant cell lines in response to toll-like receptor ligandstimulation. Four types of cells were used: PBMCs, a dermal fibroblastcell line, a muscle cell line and a kidney cell line, which werestimulated with a TLR3, TLR4, TLR7/8 and TLR9 agonist in the presenceand absence of anti-IFNβ antibody.

Gene expression levels of Type I IFN and Mx1 in different primary humancell types was measured using quantitative-PCR. Primary cells werecultured in the relevant media as follows: normal human dermalfibroblasts in FGM-2 bulletkit media, normal human mesangial in MsGMbulletkit media, and primary human skeletal muscle derived cells inMyotonic growth medium. Peripheral blood mononuclear cells (PBMC) wereisolated by centrifugation over Ficoll-Paque Plus. Mononuclear cellswere cultured in RPM11640 supplemented with 10% FBS andpenicillin-streptomycin. To measure the type I IFN gene expression,cells were seeded then stimulated with the relevant TLR ligand for 1,2.5, 5, 8 and 24 hours. After culture, cells were harvested, RNA wasisolated and cDNA was synthesized. Expression of the following genes wasassessed by Taqman PCR: IFNβ, Mx1, IFNα1, IFNα2, IFNα4, IFNα5, IFNα6,IFNα7, IFNα8, IFNα14, IFNα16, IFNα17, and B2m. Taqman real time PCR andfold change calculations were performed as described above (FIG. 9).

Table 17A shows that IFNβ is the predominant Type I IFN produced byvarious tissue resident primary human cell types upon Toll like receptor(TLR) ligand stimulation. Dermal fibroblasts, skeletal muscle cells,glomerular mesangial cells and PBMCs from normal human donors werestimulated with poly I:C (TLR3 ligand), LPS (TLR4 ligand), R848 (TLR7/8ligand) and ODN2216 (TLR9 ligand) in a time and dose-dependent manner.Relative expression levels of IFNβ, Mx1, IFNα (1, 2, 4, 5, 6, 7, 8, 14,16, and 17) were measured via quantitative-PCR using B2 M as thecontrol. Relative expression of each gene is indicated as strong (+),weak (+/−) or no expression (−).

CTI-AF1 was shown to be a potent neutralizer of endogenously producedIFNβ from primary human cells stimulated with TLR ligands (poly I:C,LPS, R848 or ODN2216). Cells were stimulated with the various TLRligands in the absence or presence of titrated amounts of CTI-AF1.Expression of Mx1 was measured 24 hours post stimulation, with theexception of PBMCs stimulated with LPS, which was measured at 6 hours.RNA isolation, cDNA synthesis and quantitative PCR were performed asdescribed above (FIG. 9). While the amount of IFNβ induced by any celltype upon TLR stimulation was unknown, a dose-dependent inhibition ofMx1 expression was seen in the presence of CTI-AF1.

Table 17B shows that CTI-AF1 is a potent inhibitor of endogenous IFNβsecreted by primary human cells after poly I:C and LPS stimulation.Cells were stimulated with the indicated TLR ligand and quantitative-PCRwas performed to determine the level of Mx1 expression using B2 M as thecontrol. Dose-dependent inhibition of Mx1 gene expression by CTI-AF1 isindicated by “+” while the absence of CTI-AF1 dependent Mx1 expressioninhibition is indicated by “−”. Conditions where Type I IFN expressionwas insufficient to drive any meaningful increase in Mx1 expression thatcould potentially be neutralized by CTI-AF1 is indicated as NA.

TABLE 17A Gene Dermal Fibroblasts Skeletal Muscle Cells tran- In vitrostimulation script PolyI:C LPS R848 ODN2216 PolyI:C LPS R848 ODN2216IFNβ + + − − + + − − Mx1 + + − − + + − − IFNα1 − − +/− +/− − +/− − −IFNα2 − − − − − − − − IFNα4 − − − − − − − − IFNα5 +/− − − − − − − −IFNα6 − − − − − − − − IFNα7 − − − − − − − − IFNα8 − − − − − − − − IFNα14− − − − − − − − IFNα16 − − − − − − − − IFNα17 − − − − − − − − GeneGlomerular Mesangial Cells PBMCs tran- In vitro stimulation scriptPolyI:C LPS R848 ODN2216 PolyI:C LPS R848 ODN2216 IFNβ + + − − + + + +Mx1 + + − − + + + + IFNα1 − +/− +/− − +/− +/− + + IFNα2 − − − − +/−− + + IFNα4 − − − − +/− − + + IFNα5 − − − − − − + + IFNα6 − − − − +/−− + + IFNα7 − − − − +/− − + + IFNα8 − − − − +/− +/− + + IFNα14 − − − −+/− +/− + + IFNα16 − − − − +/− − + + IFNα17 − − − − − − + + + = strongexpression; +/− = relatively weak expression; − = not detected

TABLE178 Gene Dermal Fibroblasts Skeletal Muscle Cells GlomerularMesangial Cells PBMCs tran- In vitro stimulation script PolyI:C LPS R848ODN2216 PolyI:C LPS R848 ODN2216 PolyI:C LPS R848 ODN2216 PolyI:C LPSR848 ODN2216 Mx1 + + NA NA + + NA NA + + NA NA + + − − + =dose-dependent Inhibition of Mx1 gene expression by CTI-AF1; − = nodose-dependent Inhibition of Mx1 gene expression; NA = not applicable,Insufficient type I IFN expression to drive Mx1 expression

TABLE 18 Sequences of interferon 13 proteins SEQ ID Name Sequence 40Human IFNβ MTNKCLLQIA LLLCFSTTAL SMSYNLLGFL QRSSNFQCQK LLWQLNGRLEprecursor YCLKDRMNFD IPEEIKQLQQ FQKEDAALTI YEMLQNIFAI FRQDSSSTGWNETIVENLLA NVYHQINHLK TVLEEKLEKE DFTRGKLMSS LHLKRYYGRILHYLKAKEYS HCAWTIVRVE ILRNFYFINR LTGYLRN 41 Mature humanMSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF IFNβQKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKTVLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN42 Mature mouse INYKQLQLQE RTNIRKCQEL LEQLNGKINL TYRADFKIPM EMTEKMQKSYIFNβ TAFAIQEMLQ NVFLVFRNNF SSTGWNETIV VRLLDELHQQ TVFLKTVLEEKQEERLTWEM SSTALHLKSY YWRVQRYLKL MKYNSYAWMV VRAEIFRNFL IIRRLTRNFQ N 43Mature rat IDYKQLQFRQ STSIRTCQKL LRQLNGRLNL SYRTDFKIPM EVMHPSQMEK IFNβSYTAFAIQVM LQNVFLVFRS NFSSTGWNET IVESLLDELH QQTELLEIILKEKQEERLTW VTSTTTLGLK SYYWRVQRYL KDKKYNSYAW MVVRAEVFRN FSIILRLNRN FQN 44Mature MSYNLLGFLQ RSSSFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQPQQF CynomolgusQKEDAALTIY EMLQNIYAIF RQDLSSTGWN ETIVENLLAN VYHQIDHLKT monkey IFNβILEEKLEKED FTRGKFVSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFFFINKL TGYLRN45 Mature rabbit MSYNSLQIQL WHGSLTCAKL LLQLNGTTED CLNERINFKV PKEIKEPQQLIFNβ QKEDTTLVIF EMLNNIFDIF RKNFSSTGWN ETLVENLLGE THLQIHHLKSKINKKVTLES IRMNLRLKSY YWRIMDYLET KQYSNCAWKI VQLEIFRNFS FIIMLIDYL

The various features and embodiments of the present invention, referredto in individual sections above apply, as appropriate, to othersections, mutatis mutandis. Consequently features specified in onesection may be combined with features specified in other sections, asappropriate. All references cited herein, including patents, patentapplications, papers, text books, and cited sequence Accession numbers,and the references cited therein are hereby incorporated by reference intheir entirety. In the event that one or more of the incorporatedliterature and similar materials differs from or contradicts thisapplication, including but not limited to defined terms, term usage,described techniques, or the like, this application controls.

1-21. (canceled)
 22. An isolated nucleic acid molecule comprising anucleotide sequence encoding the antibody, or antigen-binding fragmentthereof, specifically binds human IFNβ, wherein the antibody orantigen-binding fragment comprises (a) the CDR-H1, CDR-H2, and CDR-H3sequences of SEQ ID NO: 28, and (b) i) the CDR-L1, CDR-L2, and CDR-L3sequences of SEQ ID NO: 2; ii) the CDR-L1, CDR-L2, and CDR-L3 sequencesof SEQ ID NO: 3; iii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ IDNO: 4; iv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 5; v)the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 6; vi) theCDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 7; vii) the CDR-L1,CDR-L2, and CDR-L3 sequences of SEQ ID NO: 8; viii) the CDR-L1, CDR-L2,and CDR-L3 sequences of SEQ ID NO: 9; ix) the CDR-L1, CDR-L2, and CDR-L3sequences of SEQ ID NO: 10; x) the CDR-L1, CDR-L2, and CDR-L3 sequencesof SEQ ID NO: 11; xi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ IDNO: 12; xii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 13;xiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 14; xiv)the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 15; xv) theCDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 16; xvi) the CDR-L1,CDR-L2, and CDR-L3 sequences of SEQ ID NO: 17; xvii) the CDR-L1, CDR-L2,and CDR-L3 sequences of SEQ ID NO: 18; xviii) the CDR-L1, CDR-L2, andCDR-L3 sequences of SEQ ID NO: 19; xix) the CDR-L1, CDR-L2, and CDR-L3sequences of SEQ ID NO: 20; xx) the CDR-L1, CDR-L2, and CDR-L3 sequencesof SEQ ID NO: 21; xxi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQID NO: 22; xxii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO:23; xxiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 24;xxiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 25; xxv)the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 26; xxvi) theCDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 27; or xxvii) theCDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO:
 1. 23. (canceled) 24.The isolated nucleic acid molecule of claim 22, wherein the antibody, orantigen-binding fragment thereof, comprises: (i) a VH that comprises:(a) a VH CDR -H1 comprising the amino acid sequence of SEQ ID NO: 37,(b) a VH CDR-H2 comprising the amino acid sequence of SEQ ID NO: 38; and(c) a VH CDR-H3 comprising the amino acid sequence of SEQ ID NO: 39; and(ii) a VL that comprises: (a) a VL CDR-L1 comprising the amino acidsequence of SEQ ID NO: 34, (b) a VL CDR-L2 comprising the amino acidsequence of SEQ ID NO: 35; and (c) a VL CDR-L3 comprising the amino acidsequence of SEQ ID NO:
 36. 25. An isolated nucleic acid moleculecomprising: (i) the nucleotide sequence of SEQ ID NO:166; (ii) thenucleotide sequence of SEQ ID NO:167; (iii) the nucleotide sequence ofthe insert of the plasmid deposited at the ATCC and having AccessionNumber PTA-122727; or (iv) the nucleotide sequence of the insert of theplasmid deposited at the ATCC and having Accession Number PTA-122726.26. A vector comprising the nucleic acid molecule of claim
 22. 27. Ahost cell comprising the nucleic acid molecule of claim
 22. 28-35.(canceled)
 36. The isolated nucleic acid molecule of claim 22, whereinthe antibody or antigen-binding fragment comprises one or more of: (i) aheavy chain variable region (VH) that comprises the amino acid sequenceof SEQ ID NO: 28; (ii) a heavy chain constant region (CH) that comprisesthe amino acid sequence of SEQ ID NO: 29; (iii) a light chain variableregion (VL) that comprises the amino acid sequence of SEQ ID NO: 1; (iv)a light chain constant region (CL) that comprises the amino acidsequence of SEQ ID NO: 30; (v) a VH that comprises the amino acidsequence of SEQ ID NO: 28, and a VL that comprises the amino acidsequence of any one of SEQ ID NOs: 2-27; (vi) a heavy chain thatcomprises the amino acid sequence of SEQ ID NO: 33; and (vii) a lightchain that comprises the amino acid sequence of SEQ ID NO:
 32. 37. Theisolated nucleic acid molecule of claim 22, wherein the antibody orantigen-binding fragment comprises a VH that comprises the amino acidsequence of SEQ ID NO: 28 and a VL that comprises the amino acidsequence of SEQ ID NO:
 1. 38. The isolated nucleic acid molecule ofclaim 22, wherein the antibody or antigen-binding fragment comprises aheavy chain that comprises the amino acid sequence of SEQ ID NO: 33 anda light chain that comprises the amino acid sequence of SEQ ID NO: 32.39. The isolated nucleic acid molecule of claim 22, wherein thenucleotide sequence encoding the VH comprises the nucleic acid sequenceof SEQ ID NO:166; and wherein the nucleotide sequence encoding the VLcomprises the nucleic acid sequence of SEQ ID NO:167.
 40. A method ofproducing an antibody, or antigen-binding fragment thereof, comprisingculturing the host cell of claim 27, under conditions wherein theantibody, or antigen-binding fragment thereof, is produced by the hostcell.
 41. A first isolated nucleic acid molecule comprising a nucleotidesequence encoding an immunoglobulin heavy chain, or antigen-bindingfragment thereof, wherein the heavy chain or antigen-binding fragmentcomprises the CDR-H1, CDR-H2, and CDR-H3 sequences of SEQ ID NO: 28, anda second isolated nucleic acid molecule comprising a nucleotide sequenceencoding an immunoglobulin light chain, or antigen-binding fragmentthereof, wherein the light chain or antigen-binding fragment comprises:i) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 2; ii) theCDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 3; iii) the CDR-L1,CDR-L2, and CDR-L3 sequences of SEQ ID NO: 4; iv) the CDR-L1, CDR-L2,and CDR-L3 sequences of SEQ ID NO: 5; v) the CDR-L1, CDR-L2, and CDR-L3sequences of SEQ ID NO: 6; vi) the CDR-L1, CDR-L2, and CDR-L3 sequencesof SEQ ID NO: 7; vii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ IDNO: 8; viii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 9;ix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 10; x) theCDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 11; xi) the CDR-L1,CDR-L2, and CDR-L3 sequences of SEQ ID NO: 12; xii) the CDR-L1, CDR-L2,and CDR-L3 sequences of SEQ ID NO: 13; xiii) the CDR-L1, CDR-L2, andCDR-L3 sequences of SEQ ID NO: 14; xiv) the CDR-L1, CDR-L2, and CDR-L3sequences of SEQ ID NO: 15; xv) the CDR-L1, CDR-L2, and CDR-L3 sequencesof SEQ ID NO: 16; xvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQID NO: 17; xvii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO:18; xviii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 19;xix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 20; xx) theCDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 21; xxi) the CDR-L1,CDR-L2, and CDR-L3 sequences of SEQ ID NO: 22; xxii) the CDR-L1, CDR-L2,and CDR-L3 sequences of SEQ ID NO: 23; xxiii) the CDR-L1, CDR-L2, andCDR-L3 sequences of SEQ ID NO: 24; xxiv) the CDR-L1, CDR-L2, and CDR-L3sequences of SEQ ID NO: 25; xxv) the CDR-L1, CDR-L2, and CDR-L3sequences of SEQ ID NO: 26; xxvi) the CDR-L1, CDR-L2, and CDR-L3sequences of SEQ ID NO: 27; or xxvii) the CDR-L1, CDR-L2, and CDR-L3sequences of SEQ ID NO:
 1. 42. The first and second isolated nucleicacid molecules of claim 41, wherein the heavy chain comprises a heavychain variable region (VH) that comprises the amino acid sequence of SEQID NO: 28; (ii) the heavy chain comprises a heavy chain constant region(CH) that comprises the amino acid sequence of SEQ ID NO: 29; (iii) thelight chain comprises a light chain variable region (VL) that comprisesthe amino acid sequence of SEQ ID NO: 1; (iv) the light chain comprisesa light chain constant region (CL) that comprises the amino acidsequence of SEQ ID NO: 30; (v) the heavy chain or antigen-bindingfragment comprises a heavy chain variable region (VH) that comprises theamino acid sequence of SEQ ID NO: 28, and wherein the light chain orantigen-binding fragment comprises a light chain variable region (VL)that comprises the amino acid sequence of any one of SEQ ID NOs: 2-27;(vi) the heavy chain that comprises the amino acid sequence of SEQ IDNO: 33; (vii) the light chain that comprises the amino acid sequence ofSEQ ID NO: 32; or (viii) a combination of any of (i)-(vii).
 43. Thefirst and second isolated nucleic acid molecules of claim 41, whereinthe heavy chain or antigen-binding fragment comprises: (a) a CDR -H1comprising the amino acid sequence of SEQ ID NO: 37; (b) a CDR-H2comprising the amino acid sequence of SEQ ID NO: 38; (c) a CDR-H3comprising the amino acid sequence of SEQ ID NO: 39; and wherein thelight chain or antigen-binding fragment comprises: (d) a CDR-L1comprising the amino acid sequence of SEQ ID NO: 34; (e) a CDR-L2comprising the amino acid sequence of SEQ ID NO: 35; and (f) a CDR-L3comprising the amino acid sequence of SEQ ID NO:
 36. 44. The first andsecond isolated nucleic acid molecules of claim 41, wherein thenucleotide sequence encoding the VH comprises the nucleic acid sequenceof SEQ ID NO:166; and wherein the nucleotide sequence encoding the VLcomprises the nucleic acid sequence of SEQ ID NO:167.
 45. The first andsecond isolated nucleic acid molecules of claim 41, wherein the heavychain comprises a heavy chain variable region (VH) that comprises theamino acid sequence of SEQ ID NO: 28 and the light chain comprises alight chain variable region (VL) that comprises the amino acid sequenceof SEQ ID NO:
 1. 46. The first and second isolated nucleic acidmolecules of claim 41, wherein the heavy chain comprises the amino acidsequence of SEQ ID NO: 33 and the light chain comprises the amino acidsequence of SEQ ID NO:
 32. 47. A first vector and a second vectorcomprising the first and second nucleic acid molecules, respectively, ofclaim
 41. 48. A host cell comprising the first and second nucleic acidmolecules of claim 41
 49. A method of treating a disease, comprisingadministering to a subject in need thereof a therapeutically effectiveamount of an antibody, or antigen-binding fragment thereof encoded bythe nucleic acid of claim 22; wherein the disease is selected from thegroup consisting of: a rheumatic disease; (ii) dermatomyositis (DM);(iii) systemic lupus erythematosus (SLE); (iv) interferonopathy; and (v)a disease, disorder, or condition mediated by, or related to increasedactivity of IFNβ in a subject in need thereof.